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“No one, unless he is grossly ignorant of what science has done for mankind, 
can entertain any doubt of the incalculable benefits which will hereafter be 
derived from physiology” 
Charles Darwin, 1809 - 1882  
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Abstract 
Hypertension and pregnancy are both accompanied by increases in 
sympathetic nerve activity.  This has been attributed in part, to changes in the 
neurochemistry of the hypothalamic paraventricular nucleus (PVN).  
In hypertension, physiological studies have revealed that decreases in 
GABAergic inhibition and increases in glutamatergic excitation within the PVN 
contribute to this sympathoexcitation.  In late-term pregnancy however, the 
sympathoexcitation appears to be mediated by decreases in GABAergic 
inhibition, with no glutamatergic contribution. 
This study aimed to examine the molecular characteristics of the GABAA and 
NMDA receptor to ascertain whether changes in their subunit expression in the 
PVN could contribute to the sympathoexcitation observed in these physiological 
states.  Whole PVN micropunches subjected to quantitative immunoblotting 
were combined with semi-quantitative analysis of immunohistochemistry to 
ascertain which subunits were altered, and whether the alteration was confined 
to specific parvocellular subnuclei of the PVN.  
The results of this study show that both hypertension and pregnancy are 
accompanied by significant decreases in both the α1 and α5 subunit of the 
GABAA receptor in the PVN.  Furthermore, hypertension is also accompanied 
by a significant increase in the expression of the GluN2A subunit of the NMDA 
receptor, which was associated with increases in the number of GluN2A-
immunoreactive neurones in specific parvocellular subnuclei of the PVN.  
Conversely, pregnancy was associated with a significant increase in GluN2B 
subunit expression which was not associated with changes in cell 
immunoreactivity in any parvocellular subnuclei. 
The results from this study suggest that decreases in α1 and α5 subunits of the 
GABAA receptor may be important in mediating the sympathoexcitation 
observed in both of these physiological states, with the greater level of 
sympathoexcitation observed in hypertension possibly attributed to increases in 
GluN2A-mediated NMDA receptor expression. 
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Chapter 1. Introduction 
Maintenance of cardiovascular homeostasis is a complex neural reflex, required 
to preserve adequate blood flow to organs.  This regulation involves the 
integration of signals from peripheral baroreceptors and results in reflex 
adjustment of the sympathetic nervous system (Heesch, 1999).  Cardiovascular 
diseases such as heart failure and hypertension are multifactoral in nature; but 
a common characteristic is increased sympathetic nerve activity to areas of the 
cardiovascular system, the origins of which are within the brain (Grassi et al., 
2009).  This increased sympathetic outflow is also a characteristic feature of 
pregnancy (Greenwood et al, 2001; Jarvis et al, 2012).  A key site for this 
aberrant control of sympathetic outflow is the hypothalamic paraventricular 
nucleus (PVN; Guyenet, 2006) 
This thesis aims to bring together the current literature regarding the role 
of the PVN and its contribution to normal cardiovascular homeostasis, as well 
as its role in cardiovascular disease.  
 
I. Anatomy of the PVN 
The architecture and anatomy of the PVN have been described extensively in 
various animals including the rat (Swanson & Sawchenko, 1983; Simmons & 
Swanson, 2008), mouse (Kadar et al., 2010), rabbit (Schimchowitsch et al., 
1989), cat (Caverson et al, 1984), sheep (Papadopoulos et al, 1990) platypus 
(Ashwell et al., 2006) and human (Koutcherov et al., 2000).  It is now well 
accepted that in the rat the PVN consists of five anatomically distinct 
parvocellular subnuclei and two magnocellular subnuclei (Swanson & 
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Sawchenko, 1983).  The exact anatomical boundaries of these subnuclei have 
changed depending on the method of detection (e.g. characterisation of efferent 
projections, neurochemical immunoreactivity), however the nomenclature 
ascribed to these five parvocellular subnuclei has remained largely unchanged.  
The five parvocellular subnuclei of the rat PVN are termed the anterior 
parvocellular (PaAP), medial parvocellular (PaMP), dorsal cap (PaDC), ventral 
parvocellular (PaVP) and posterior parvocellular (PaPO – alternatively referred 
to as the lateral parvocellular (PaLP); Figure 1; Swanson et al., 1980; Swanson 
& Sawchenko, 1983; Paxinos & Watson, 1998).  
  
 
 
 
The PVN has long been known to send descending projections from its 
magnocellular neurosecretory regions to the neurohypophysis (Sherlock et al., 
1975).  In addition to this, the PVN is known to send efferent projections to the 
median eminence, locus coeruleus, parabrachial nuclei and dorsal vagal 
complex from its parvocellular regions (Swanson, 1977). 
AM 
AP 
PM 
DC 
MP 
VP 
PO 
MP 
PV PV 
PV 
3V 
3V 
3V 
Figure 1 Schematic representation of the rat PVN showing the anatomically distinct 
subnuclei. Abbreviations: AM = anterior magnocellular, AP = anterior parvocellular, 
PV = periventricular area, DC = dorsal cap, MP = medial parvocellular, VP = ventral 
parvocellular, PM = posterior magnocellular, PO = posterior parvocellular, 3V = 3
rd
 
ventricle. Adapted from Swanson et al, 1980. 
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Importantly, in the rat the PVN is also known to send descending 
projections to other central nuclei involved in autonomic regulation of the 
cardiovascular system (Ranson et al, 1998; Pyner & Coote, 2000).  A significant 
descending projection to the intermediolateral cell column of the spinal cord 
(IML) originates from all parvocellular subnuclei of the PVN, with the majority 
arising from the mid- to caudal levels of the PVN that includes the medial, 
posterior, ventral and dorsal cap regions (Swanson et al., 1980; Oldfield et al., 
2001). This descending projection also closely apposes sympathetic 
preganglionic neurones (SPN) which target both the stellate ganglion (which 
sends sympathetic postganglionic neurones to the heart; Xie et al, 2011) and 
the adrenal medulla (which secretes adrenaline in response to sympathetic 
activation; Ranson et al., 1998; Motawei et al., 1999). Immunohistochemical 
and electrophysiological studies in rats have identified that these descending 
projections utilise either oxytocin or vasopressin as their predominant 
neurotransmitter (Cechetto & Saper, 1988; Yang et al., 2009). 
 Of the cardiovascular command centres, the rostral ventrolateral medulla 
(RVLM) is the most important site in setting vascular tone, and therefore an 
important site in determining blood pressure (Guyenet, 2006; Kumagai et al., 
2012).  The PVN is known to send a dense efferent projection to the RVLM, 
which closely targets spinally projecting neurones emanating from this nucleus 
(Pyner & Coote, 1999; Hardy, 2001). Furthermore, the PVN has also been 
shown to send a branching connection, which targets neurones in both the IML 
and the RVLM (Shafton et al., 1998; Pyner & Coote, 2000).  The distribution of 
these PVN-RVLM projecting neurones is similar to that observed for PVN-IML 
descending projections, with PVN-RVLM neurones being present in all 
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parvocellular subnuclei (Pyner & Coote, 2000), with a more dense distribution in 
the caudal PVN (Figure 2; Pyner & Coote, 2000; Oldfield et al., 2001). 
 
Figure 2 Schematic representation of the location of neurones projecting to the IML and 
RVLM, IML alone or RVLM alone throughout the rostrocaudal extent of the PVN.  
Neurones projecting to both the IML and RVLM were mainly confined to the mid-caudal 
levels (C-D). 3V = 3
rd
 ventricle, Subnuclei abbreviations are as in Figure 1. PaLM = Lateral 
Magnocellular. Coordinates refer to Bregma level (Pyner & Coote, 2000) 
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II. Peripheral Monitoring of Arterial Blood Pressure 
Central control of cardiovascular homeostasis begins with a constant monitoring 
of the peripheral environment, achieved through the activation or inhibition of 
baroreceptors. Baroreceptors are specialised nerve endings that respond to 
stretch (Kougias et al., 2010).  Those which are concerned with blood pressure 
regulation are located in the carotid sinus and the aortic arch (Kougias et al., 
2010).  Their role is to create a negative feedback loop, through which mean 
arterial blood pressure (MAP) is tightly regulated around a “set point”.  These 
cardiovascular baroreceptors are activated by a rise in arterial blood pressure, 
or fall silent if blood pressure falls.  This information is transmitted via cranial 
nerves IX (glossopharyngeal) and X (vagus) to the nucleus tractus solitarii 
(NTS); located within the medulla (Andresen & Kunze, 1994; Kougias et al., 
2010; Kumagai et al., 2012).  Baroreceptors are key components which help to 
maintain mean arterial blood pressure by monitoring of peripheral blood 
pressure that results in reflex changes in sympathetic activity to specific organs, 
chiefly the heart and kidneys (Guyenet, 2006).  
 The most common method of assessing baroreflex function is to 
construct baroreflex curves, marrying alterations in blood pressure with reflex 
alterations in either heart rate or sympathetic nerve activity (Figure 3).  
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Figure 3 Typical heart rate baroreflex curve from un-anaesthetised female sheep. 
Decreases in blood pressure; evoked by i.v. infusion of nitroprusside elicit a reflex 
tachycardia, whereas increases in blood pressure; evoked by i.v. infusion of 
phenylephrine, elicit reflex bradycardia. Open circle represents the “set point” of blood 
pressure (Thomas & Woods, 2004) 
 
Increases in blood pressure, experimentally elicited by intravenous (i.v.) 
infusion of the potent vasoconstrictor phenylephrine in rats (Crandall & Heesch, 
1990; Page et al., 2011), cats (Schmidt & DiMicco, 1984), sheep (Thomas & 
Woods, 2004) and rabbits (Quesnell & Brooks, 1997), results in a reflex 
bradycardia and a renal sympathoinhibition.  Conversely, decreases in blood 
pressure; elicited by i.v. infusion of nitroprusside, results in a reflex tachycardia 
and renal sympathoexcitation (Quesnell & Brooks, 1997; Page et al., 2011).  
The result of which is restoration of blood pressure towards the central “set 
point”. 
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These baroreceptor inputs enter the brain via the NTS (Andresen & 
Kunze, 1994; Kougias et al., 2010).  The NTS is a key site for integration of 
visceral inputs and receives information from gustatory, gastrointestinal and 
respiratory, as well as cardiovascular afferents (Andresen & Kunze, 1994).  
Microinjection of glutamate into the NTS of awake rats produces dose-
dependent pressor and bradycardic responses.  Furthermore, the reflex 
bradycardia induced by i.v. phenylephrine was blocked by prior application of 
the N-methyl-D-aspartate (NMDA) receptor antagonist kynurenic acid, 
suggesting that the NTS is a vital nucleus in mediating the baroreflex, and that 
glutamatergic inputs play a major role in mediating this mechanism (Colombari 
et al., 1994). 
 Neuroanatomical tracing studies in rats have demonstrated that 
cardiovascular areas of the NTS have reciprocal connections with the PVN 
(Kannan et al., 1984; Bailey et al., 2006; Affleck et al., 2012).  Furthermore, 
PVN-RVLM and PVN-spinal cord projecting neurones have been shown to be 
barosensitive.  In vivo measurements of the electrical activity of PVN-RVLM and 
PVN-IML projecting neurones showed that acute increases in blood pressure 
reduces their firing activity, whereas acute decreases in blood pressure 
increases their firing activity (Lovick & Coote, 1988a; Chen & Toney, 2010).  
Recent evidence has shown that NTS-PVN projecting neurones make close 
apposition to both γ-aminobutyric acid (GABA)-ergic and nitrergic interneurones 
surrounding the PVN (Figure 4; Affleck et al., 2012).  It is therefore possible to 
speculate that baroreceptor activation leads to activation of NTS-PVN projecting 
neurones which may in turn activate inhibitory networks within the PVN. 
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Figure 4 Schematic representation of ascending projections from the NTS to the PVN.  
Projections directly target spinally projecting presympathetic neurones as well as 
GABAergic interneurones located around the dorsal and lateral boundaries of the PVN 
and both intra- and extra-PVN nitrergic neurones (Affleck et al., 2012). 
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III. Role of the PVN in Cardiovascular Homeostasis 
As previously described, the PVN sends a dense descending projection from 
parvocellular subnuclei to the IML region of the spinal cord (Hosoya, 1980; 
Swanson et al., 1980; Ranson et al., 1998; Motawei et al., 1999; Pyner & Coote, 
2000).  In a series of experiments examining the electrophysiological properties 
of PVN-IML projecting neurones in rats, it was observed that 97% of neurones 
in this population are quiescent under basal conditions (Lovick & Coote, 1988a).  
Application of glutamate directly onto these neurones only increased the firing 
activity of 41% of neurones, however following unilateral vagotomy; which 
prevents the integration of afferent baroreceptor activity, firing activity was 
increased to 69%, suggesting that at least a proportion of these neurones are 
under tonic baroreceptor-mediated inhibition (Lovick & Coote, 1988a).  
Furthermore, the firing rate of neurones, which did respond to glutamate 
application was significantly attenuated following either a hypertensive or 
hypervolaemic challenge, or augmented following a hypotensive challenge 
(Lovick & Coote, 1988b, a).  The hypervolaemic challenge used in this study did 
not significantly alter blood pressure, suggesting that these neurones are 
capable of responding to fluctuations in blood volume independent of blood 
pressure changes.  This was further evidenced in a series of experiments in 
which a non-hypotensive haemorrhage in rats (withdrawal of 2ml blood) 
resulted in a significant increase in expression of c-fos, a marker of neuronal 
activation, in 12% of PVN-IML projecting neurones, suggesting that these 
neurones are directly activated following hypovolaemic challenges (Badoer et 
al., 1993). 
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In rats, hypervolaemic challenges are known to result in an inhibition of 
renal vascular resistance (Lovick et al., 1993) and renal sympathetic nerve 
activity (Haselton et al., 1994), mediated through activation of atrial volume 
receptors (Karim et al., 1972).  Studies have shown that the PVN is the critical 
central site in mediating this response.  Volume loading in rats resulted in a 
significant increase in the number of c-fos positive neurones in the PVN (Pyner 
et al., 2002).  Furthermore, the renal vasodilatory response to an increase in 
blood volume equivalent to 1% of total body weight was abolished following 
specific lesioning of parvocellular neurones of the PVN in the rat (Lovick et al., 
1993).  To specifically identify whether atrial volume receptors were involved in 
initiating this response, inflation of a balloon at the junction of the superior vena 
cava and right atria in the rat resulted in a significant increase in c-fos positive 
neurones, predominantly located in the medial to posterior regions of the PVN 
(Pyner et al., 2002). 
Taken together, these results suggest a significant role for the PVN in mediating 
the renal response to hypervolaemia.  However, although both spinally 
projecting and RVLM-projecting PVN neurones are barosensitive (Lovick & 
Coote, 1988a; Chen & Toney, 2010), the role of the PVN as an integral 
component in the setting of basal vascular tone appears to be minimal. 
The main evidence for this observation comes from studies in which PVN 
input to sympathetic vasomotor nerves has been removed in rats, either by 
complete transection of the brain caudal to the hypothalamus (Yamori & 
Okamoto, 1969), electrolytic lesion (Herzig et al., 1991) or radiofrequency 
ablation of the PVN (Ernsberger et al., 1985).  In all the studies, removal of the 
PVN failed to significantly alter blood pressure, suggesting the influence of the 
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PVN on blood pressure is minimal.  However, this does not conclusively prove 
that the PVN plays a minor role in controlling blood pressure under normal 
circumstances, since ablation of the RVLM; the major brain site for vasomotor 
control, also fails to significantly alter blood pressure (Cochrane & Nathan, 
1989, 1993).  This suggests that other brain areas may be able to compensate 
for the loss of these brain regions. 
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IV. Neurochemistry of the PVN 
Modulation of sympathetic outflow from the PVN involves the complex 
interaction between inhibitory and excitatory neurotransmitters.  In the rat PVN, 
over 30 neuroactive substances have been identified, including serotonin, 
dopamine, angiotensin, oestrogen, glucagon-like peptide 1, vasopressin, 
oxytocin and neuropeptide Y (Pyner, 2009).  Although detailed studies’ 
examining the distribution of these neuroactive substances is limited, it is clear 
from those that have been studied that their expression throughout the PVN is 
differential.  For example, angiotensin type 1a (AT1A) receptors are distributed 
predominately in the medial and dorsal cap regions (Lenkei et al., 1995) 
whereas oestrogen receptors (ER-β) were localised to the ventral and posterior 
parvocellular subnuclei (Bingham et al., 2006).  Given that different subnuclei of 
the PVN have different efferent projections (Swanson et al., 1980; Oldfield et 
al., 2001), these distinct patterns of distribution mean that neuroactive 
substances can modulate the activity of specific populations of neurones in the 
PVN, thus producing distinct physiological responses. 
 Some of these neuroactive substances appear to be more important than 
others in regulating the sympathetic outflow from the PVN in the rat.  
Descending projections from the PVN to the spinal cord are known to be 
predominantly oxytocinergic or vasopressinergic (Sofroniew, 1980; Yang et al., 
2009).  Within the PVN, γ-aminobutyric acid (GABA) is the most common 
inhibitory neurotransmitter (Decavel & Van den Pol, 1990), with glutamate being 
a predominant excitatory neurotransmitter (Li et al., 2006; Busnardo et al., 
2009). 
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Importantly, modulation of these two neurotransmitter systems also occurs 
within the PVN.  Nitric oxide (NO), acting as a diffuse gaseous molecule (Stern, 
2004), has been shown to stimulate the release of GABA in the PVN in vivo 
(Horn et al., 1994).  Microinjection of the NO donor sodium nitroprusside (SNP) 
or the nitric oxide synthase inhibitor L-NAME produced a significant decrease 
and increase in renal sympathetic nerve activity (RSNA) respectively (Zhang & 
Patel, 1998; Yang & Coote, 2003).  Furthermore, in vivo studies in rats have 
shown that NO in the PVN is released following N-methyl-D-aspartate (NMDA) 
receptor activation, acting in a negative feedback manner to reduce NMDA 
receptor activation (Li et al., 2001). 
The remainder of this chapter will focus on the role of GABA and 
glutamate in the PVN and its role in modulating the sympathetic outflow in 
normal cardiovascular homeostasis, as well as their contribution to the 
exacerbated sympathetic outflow observed in hypertension and late-term 
pregnancy. 
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V. GABA and GABAA Receptors 
Synthesised from the enzymatic decarboxylation of glutamate by glutamic acid 
decarboxylase (GAD; Petroff, 2002), GABA is the most abundant inhibitory 
neurotransmitter in the hypothalamus and the central nervous system (CNS), 
composing around 50% of all cortical and hypothalamic synapses (Decavel & 
Van den Pol, 1990; Macdonald & Olsen, 1994). 
GABA is released from presynaptic terminals of GAD-positive neurones at high 
concentrations (0.3 – 1.0mM. Mody & Pearce, 2004).  Once released, the half-
life of GABA within the synapse is <1ms (Mody & Pearce, 2004).  Recycling of 
GABA predominantly takes place by GABA transporters (GAT), of which four 
have so far been identified (Schousboe et al., 2004).  GABA transporters are 
expressed by astrocytes, and upon uptake GABA is shunted to the Krebs cycle, 
whereupon it is metabolised into glutamine, which is then taken up by 
GABAergic neurones (Brambilla et al., 2003). 
Once GABA has diffused across the synapse it acts at postsynaptic GABAA, 
GABAB or GABAC receptors.  Of these, the GABAA
 receptor is the most 
abundantly expressed (Chebib & Johnston, 1999). 
 The GABAB receptor is a G-protein coupled receptor (GPCR) which acts 
at both pre- and postsynaptic sites (Bettler & Tiao, 2006).   GABAB receptors 
assemble as heteromers composed of the GABAB1 and GABAB2 subunits, with 
molecular diversity arising from the existence of GABAB1a and GABAB1b 
subunits (Bettler & Tiao, 2006). 
Conversely, the GABAC receptor, like the GABAA receptor detailed below, is an 
ionotropic chloride channel (Enz & Cutting, 1998).  It is distinct from the GABAA 
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receptor in that it is insensitive to GABAA receptor modulators such as 
benzodiazepines and barbiturates, is composed uniquely of ρ subunits, and is 
expressed exclusively in the retina (Enz & Cutting, 1998). 
The GABAA receptor is a member of a superfamily of Cys-loop 
transmitter-gated ion channels, which includes the nicotinic acetylcholine 
receptor and the 5HT3 receptor (Macdonald & Olsen, 1994; Johnston, 1996; 
Chebib & Johnston, 1999; Arancibia-Carcamo & Kittler, 2009).  As well as 
GABA, GABAA receptors contain binding sites for many allosteric modulators, 
including ethanol, barbiturates and anaesthetics (Macdonald & Olsen, 1994).  
Upon activation, the GABAA receptor opens a chloride channel, leading to rapid 
hyperpolarisation of the membrane and thereby preventing action potential 
generation (Arancibia-Carcamo & Kittler, 2009). 
Like all members of the Cys-loop gated ion channels, the GABAA receptor is 
composed of five subunits, acquired from a genetic repertoire of 19 so far 
discovered (α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3; Mehta & Ticku, 1999; Sieghart 
et al., 1999).  Each subunit consists of a large extracellular N-terminus domain 
and four transmembrane loops (TM1-4) with a large intracellular domain 
between TM3 and TM4 (Figure 5).  It is widely believed that the TM2 domains, 
of each subunit join in such a way as to form the inner lining of the pore, 
whereas the function of the TM1, TM3 and TM4 domains is to interface with 
lipids.  The intracellular loop between TM3 and TM4 provides the main site for 
protein-protein interactions as well as acting as the main site for protein 
modification through phosphorylation, palmitoylation or ubiquitination (Chebib & 
Johnston, 1999; Sieghart et al., 1999; Arancibia-Carcamo & Kittler, 2009; 
Zheleznova et al., 2009). 
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Figure 5 Schematic representation of a GABAA receptor subunit, showing the large 
extracellular N-terminus, four transmembrane domains and large intracellular loop 
between TM3 and TM4. Abbreviations – TM = Transmembrane (Macdonald & Olsen, 1994) 
 
Although there are theoretically thousands of receptor subunit combinations, 
expression studies have shown that α, β and γ subunits have to combine to 
produce GABAA receptors which pharmacologically resemble native receptors.  
In addition, the δ, ε and π subunits appear to be able to replace the γ subunit, 
producing receptors with distinct physiological and kinetic properties (Sieghart 
et al., 1999).  The preferred combination of subunits within native GABAA 
receptors is two α, two β and one γ subunit (Mehta & Ticku, 1999). 
TM1 TM2 
TM3 TM4 
Intracellular 
Loop 
Intracellular  
Extracellular  
N-terminus  
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Individual GABAA receptor subunits have distinct anatomical distributions 
throughout the brain (Pirker et al., 2000).  Furthermore, both individual subunits 
and receptor subunit conformations confer distinct physiological and 
pharmacological properties, as well as determining the subcellular localisation 
of GABAA receptors (Macdonald & Twyman, 1991; Sun et al., 2004). 
Activation of GABAA receptors requires the binding of two GABA 
molecules to the receptor, and binding of GABA is slow relative to its diffusion 
and clearance rates (Farrant & Nusser, 2005).  Because of this, not all synaptic 
GABAA receptors are opened in response to a single action potential.  This 
allows for a greater depth of modulation at inhibitory post-synaptic sites, with 
the strength of transmission being determined by the number of post-synaptic 
receptors and quantity of GABA released from fusing vesicles.  
Synaptically-mediated inhibition, characterised by fast decay properties 
of the GABA current, is known as “phasic inhibition”.  This typically requires the 
release of high levels of GABA, in the region of 3-5mM and is degraded within 
500μs (Farrant & Nusser, 2005; Cherubini, 2012).  In physiological terms for the 
PVN, phasic inhibition is most likely to occur following physiological stimuli, 
such as that from baroreceptors signalling an increase in blood pressure.  Such 
input is likely to activate NTS-PVN projecting neurones which have been shown 
to closely appose GABAergic interneurones in the PVN (Watkins et al., 2009; 
Affleck et al., 2012), leading to a release of presynaptic GABA. 
As well as phasic inhibition, a significant proportion of neuronal inhibition 
arises from extrasynaptic GABAA receptors located outside of the synaptic cleft, 
mediating so called “tonic inhibition”.  In mouse hippocampal neurones studied 
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in vitro, tonic inhibition has been found to be responsible for generating 75% of 
the total inhibitory charge (Mody & Pearce, 2004; Glykys et al., 2008).  
Effectively, the role of tonic inhibition is to lower the size and duration of the 
excitatory post-synaptic current (EPSC), such that the probability of an action 
potential is reduced (Farrant & Nusser, 2005).  GABAA receptors mediating 
tonic inhibition are typically able to respond to much lower concentrations of 
GABA than their synaptic counterparts.  The concentration of GABA outside of 
the synaptic cleft is estimated to be within the tens of nanomolar, and is 
determined by the activity of GABAergic synapses, as well as the activity of 
sodium and chloride transporters (Farrant & Nusser, 2005). 
Both phasic and tonic inhibition are mediated by receptors with 
physiologically and pharmacologically distinct properties.  Receptors mediating 
tonic inhibition are primarily composed of 5 or  subunits that preferentially 
target the receptor to the extrasynaptic membrane.  Conversely, receptors 
located within the synapse and thus mediating phasic inhibition are primarily 
composed of the 2 subunit typically in combination with the 1 and β2 subunits 
(Benke et al., 1991; Farrant & Nusser, 2005; Glykys et al., 2008).  However, 
electron microscopic analysis of the subcellular location of GABAA receptors is 
yet to find subunits that are exclusively located in either position (Farrant & 
Nusser, 2005). 
Indeed, GABAA receptors containing the α5 subunit have been identified within 
the synapse (Serwanski et al., 2006). To this effect however, in vitro 
electrophysiological studies in the hippocampus of mice genetically bred without 
the α5 subunit of the GABAA receptor  (gabra5
-/- mice) showed no reduction in 
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the response to phasic release of GABA (Glykys & Mody, 2006).  This suggests 
that although the α5 subunit may be present in synapses, it may be present in 
the synapse in conjunction with other subunits that confer physiologically 
distinct properties or that they are located in quiescent or silent synapses. 
Studies investigating the role of the 5 subunit in mediating tonic inhibition have 
found that application of the 5-specific inverse agonist L-655,708 onto 
hippocampal slices significantly increases the spontaneous activity of neurones 
within the CA3 region (Figure 6.; Glykys et al., 2008).  Furthermore, 5 knock-
out mice have significantly higher levels of basal neuronal activity with no 
alteration in phasic inhibition (Glykys & Mody, 2006). 
 
 
Figure 6 Neurones in the CA3 region of hippocampal slices in wild type (WT) mice show 
little spontaneous activity in vitro.  Application of the α5-specific inverse agonist 
L655,708 significantly increases spontaneous gamma wave formation (Glykys et al., 
2008). 
 
 
Within the hypothalamus, in vitro electrophysiological studies in rats have found 
that in the supraoptic nucleus (SON), the α5 subunit contributes to tonic 
inhibition to a much greater extent that the δ subunit (Jo et al., 2011).  
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Furthermore, the α5 subunit has a 400 times greater level of expression than 
the δ subunit (Figure 7; Jo et al., 2011).  Although the SON and PVN are two 
anatomically distinct nuclei, their similar neurochemistry and cellular makeup 
(Swanson & Sawchenko, 1983) suggest that the control of tonic inhibition could 
be controlled in a similar manner. 
 
Figure 7 RT-PCR analysis of α5, γ2 and δ subunit mRNA expression in the SON of SD 
rats.  Minimal expression of the δ subunit was observed (A). Expression of α5 mRNA was 
400% higher than δ subunit (B; Jo et al., 2011) 
  
Within the PVN, 9 of the 19 GABAA receptor subunits have been 
identified using immunohistochemical staining (1, 2, 5, 1, 2, 3, 2, 3 
and ; Pirker et al., 2000).  The contribution each of these subunits makes in 
mediating GABAergic inhibition within the PVN has yet to be elucidated.  
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Regardless of this, the studies detailed below provide compelling evidence that 
GABAergic inhibition is important for the PVN to control cardiovascular 
homeostasis, as well as contributing to the increased neuronal excitability 
observed in both hypertension and pregnancy.   
  
 42 
 
VI. Role of GABA in the PVN for the Normal Control of 
Cardiovascular Homeostasis 
GABA is the most abundant inhibitory neurotransmitter in the CNS (Chebib & 
Johnston, 1999; Pirker et al., 2000) and acts as the primary inhibitory 
neurotransmitter in the hypothalamus, making up over half of all synaptic inputs 
in this area (Decavel & Van den Pol, 1990).  
Anatomically, neurones which are immunoreactive (IR) for GABA, 
revealed by immunofluorescent staining of GABA or the GABA synthesising 
enzyme, GAD67 (Monnerie & Le Roux, 2007), are found to surround the dorsal 
and ventral boundaries of the rat PVN as well as surrounding the lateral 
boundaries of the dorsal cap (Watkins et al., 2009).  Transynaptic tracing of 
descending PVN projections to the adrenal medulla (AM), using Herpes-
Simplex virus conjugated to green fluorescent protein (HSV-GFP) revealed that 
GABA-IR neurones make direct synaptic contact with PVN-IML-AM neurones, 
suggesting these neurones are under direct GABAergic inhibitory control 
(Watkins et al., 2009).  In addition, the relatively sparse number of HSV-GFP 
that co-localised with GABA, in comparison to the large number of GABA-IR 
neurones that were shown to surround the PVN, suggest that other descending 
PVN projections, such as those to the RVLM or NTS, as well as interneurones, 
may be under either direct or indirect GABAergic inhibition.  To this effect, there 
is evidence of GABAergic inhibition of glutamatergic interneurones within the 
PVN (Li et al., 2006).  Furthermore, it was revealed through immunofluorescent 
identification of PVN-IML projecting neurones that this population does not co-
localise with GABA, suggesting that these neurones are unable to influence 
their own activity in an autocrine manner (Watkins et al., 2009). 
 43 
 
It has long been known that manipulation of GABAergic inputs within the 
PVN produces profound effects on the cardiovascular system, influencing 
sympathetic outflow, arterial blood pressure (ABP) and heart rate (HR), 
amongst others (Akine et al., 2003; Li et al., 2006; Li & Pan, 2007b).  Numerous 
studies utilising in vivo preparations have identified that inhibition of autonomic 
outflow from the PVN is governed by both GABAA and GABAB receptors (Li & 
Pan, 2007b). 
Bilateral microinjections of the GABAA receptor agonist muscimol into the PVN 
significantly reduced ABP, HR and RSNA in male Wistar Kyoto (WKY) rats 
(Figure 8 A; Allen, 2002; Akine et al., 2003).  Conversely, disinhibition of the 
PVN by bilateral microinjection of the GABAA receptor antagonists bicuculline or 
gabazine resulted in a significant increase in ABP, HR, plasma adrenaline and 
noradrenaline as well as lumbar sympathetic nerve activity (LSNA) in Sprague-
Dawley (SD) and WKY rats (Figure 8 B; Martin et al., 1991; Li & Pan, 2007b, a) 
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Figure 8 A – Raw trace examples showing decreases in ABP, HR and RSNA following 
bilateral microinjection of 1nmol muscimol into the PVN L & R refer to the time of each 
unilateral injection. (Akine et al, 2003). B – Raw trace examples showing increases in 
LSNA, ABP and HR following bilateral microinjections of increasing concentrations of 
the GABAA receptor antagonist gabazine into the PVN compared with vehicle control. GZ 
= gabazine concentration (nmol/50nl). (Li & Pan, 2007a) 
 
A 
B 
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Coupled with this finding is the observation that unilateral bicuculline 
microinjection into the PVN of virgin female rats increases baroreflex gain and 
shifts the baroreflex curve upwards and to the right, such that alterations in 
blood pressure are met with higher levels of LSNA and HR (Figure 9; Page et 
al., 2011).  
 
Figure 9 Baroreflex curve from virgin female rats. Dashed line shows baroreflex response 
following unilateral bicuculline microinjection into the PVN compared to control (solid 
line).  Bicuculline microinjection increased baroreflex gain and shifted the curve upwards 
and to the right (Page et al., 2011) 
 
Using in vitro rat hypothalamic slice preparations, in which PVN-RVLM 
projecting neurons had been retrogradely labelled with rhodamine-labelled 
microspheres; application of bicuculline significantly increased the number of 
glutamate-mediated EPSCs (Li et al., 2006). In a separate set of experiments in 
which the same population of PVN-RVLM neurones had been labelled, the 
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benzodiazepine diazepam was also shown to significantly increase the decay 
time and amplitude of evoked inhibitory post-synaptic currents (IPSCs) and 
inhibited the spontaneous activity of PVN neurones shown to be responsive to 
bicuculline (Zahner et al., 2007). 
Furthermore, in vivo application of baclofen, an agonist of the GABAB receptor, 
in the PVN resulted in a significant reduction in LSNA, ABP and HR in WKY and 
SD rats, however only at high doses (4.5nmol).  Bilateral microinjection of the 
GABAB antagonist CGP52432 produced no significant effects on LSNA, ABP or 
HR at doses up to 3.0nmol in both WKY and SD rats (Li & Pan, 2007b).  In an in 
vitro hypothalamic slice preparation, application of baclofen significantly 
inhibited the spontaneous firing potential of PVN-spinally projecting neurones 
and decreased their membrane potential (-59.6 ± 1.5 to -64.3 ± 2.5mV. P<0.05; 
Li et al., 2008b). 
These studies suggest that inhibition of sympathetic outflow from the PVN is 
mediated predominantly through the GABAA receptor, and that the GABAB 
receptor has a minimal inhibitory role under normal physiological conditions.  In 
addition, efferent outputs from the PVN are also under tonic inhibitory control 
mediated through both GABAA and GABAB receptors. 
Studies have been undertaken examining the method through which 
disinhibition of the GABAergic system within the PVN results in a 
sympathoexcitatory response. Chen et al (2003) observed that, in agreement 
with previous experiments such as those mentioned above, unilateral 
microinjection of the GABAA receptor antagonist bicuculline into the PVN of 
anaesthetised male SD rats, produced dose-dependent increases in ABP, HR 
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and sympathetic nerve activity.  However, prior injection with either the non-
selective excitatory amino acid antagonist kynurenic acid (Kyn), the NMDA 
receptor antagonist DL-2-amino-5-phosphonovaleric acid (AP-5) or the non-
NMDA receptor antagonist 2,3-dioxo-6-nitro-1,2,3,4- 
tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium (NBQX), significantly 
attenuated the sympathoexcitatory, pressor and tachycardic effects of 
bicuculline injection into the PVN (Figure 10). 
Li et al (2006) confirmed this by showing that prior injection of AP-5 significantly 
attenuated the effects of ipsilateral bicuculline injection, in a dose-dependent 
manner.  Furthermore, this study showed that bicuculline injections into the 
PVN increased the release of glutamate. 
 
These two studies show that the sympathoexcitatory, pressor and tachycardic 
responses to disinhibition of the PVN through GABAA receptor antagonism 
require activation of excitatory amino acid receptors, and that both NMDA and 
non-NMDA receptors are required for this effect. 
 
These studies also noted that microinjection of either AP-5 (Chen et al., 2003; Li 
et al., 2006), Kyn or NBQX (Chen et al., 2003) alone did not alter baseline 
parameters.  Taken together, these results suggest that under normal 
physiological conditions, GABAergic inhibition dominates the neurochemical 
milieu of the PVN, maintaining control of sympathetic outflow and therefore 
control of cardiovascular homeostasis. 
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Figure 10 Increases in renal sympathetic nerve activity, blood pressure and HR following 
application of the GABAA receptor antagonist bicuculline (arrow heads) are significantly 
blunted following pre-treatment with either the NMDA receptor antagonist AP-5 (A) or the 
non-NMDA receptor antagonist NBQX (B; Chen et al., 2003) 
 
Studies have examined the mechanism by which GABA, acting via the 
GABAA receptor mediates inhibitory actions within the PVN (Park et al., 2007).  
Two distinct functional classes of GABAA receptors exist within the CNS; those 
which mediate phasic transmission, and those which respond to low-levels of 
GABA and mediate tonic inhibition. 
In slice preparations of retrograde labelled PVN-RVLM projecting neurones 
from rats, application of 4,5,6,7-tetrahydroisothiazolo-[5,4-c]pyridine-3-ol (THIP), 
a GABAA receptor agonist which preferentially activates extrasynaptic GABAA 
receptors significantly increased the holding potential of these neurones above 
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that of spontaneously evoked inhibitory postsynaptic currents (sIPSCs; Park et 
al, 2007).  Application of GABAA receptor antagonists such as bicuculline and 
pictrotoxin abolished any sIPSC (Park et al., 2007).  The authors of this study 
conclude that PVN-RVLM projecting neurones respond to both phasic and tonic 
GABAergic inhibition and that tonic inhibition is dependent on synaptic spillover 
of GABA (Park et al., 2007). 
 
Through these studies, GABAergic inhibition has been shown to play an 
important role in modulating sympathetic outflow from the PVN, as well as 
contributing to the maintenance of cardiovascular homeostasis.  Under normal 
physiological conditions, this inhibition seems to be mediated primarily through 
the fast ionotropic GABAA receptors, and although activation of GABAB 
receptors has been shown to influence sympathetic outflow from the PVN (Li et 
al., 2008b) they are unlikely to play a major role in contributing to the overall 
inhibitory milieu of this nucleus. Furthermore, GABAergic inhibition of PVN 
autonomic neurones has been shown to be dependent on both phasic 
(synaptic) and tonic (extrasynaptic) receptors (Park et al., 2007).  
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VII. Glutamate Neurotransmission and Receptors 
N-methyl-d-aspartate (NMDA) receptors are glutamate-gated ionotropic 
channels with a high permeability to calcium (Paoletti & Neyton, 2007).  At 
resting membrane potential, the NMDA receptor pore contains a magnesium 
block, the removal of which is voltage dependent (Carvalho et al., 2000).  
NMDA receptors therefore require prior depolarisation to activate.  This is 
achieved through activation of neighbouring α-amino-3-hydro-5-methyl-4- 
isoxazole propionate (AMPA) receptors, which depolarise the membrane 
sufficiently to remove the magnesium block and thus allow for activation of 
NMDA receptors (Carvalho et al., 2000). 
N-methyl-d-aspartate (NMDA) receptors are one of three major ionotropic 
glutamate receptors found in the mammalian CNS (Dingledine et al., 1999).    
NMDA receptors are heterotetrameric receptors, composed from a repertoire of 
three subtypes (GluN1, GluN2A-D, GluN3A-B), with alternative splicing of the 
GluN1 gene rendering eight splice variants termed GluN1-1a/b to GluN1-4a/b 
(Stephenson, 2001; Paoletti & Neyton, 2007).  In native mammalian NMDA 
receptors, the GluN1 subunit is regarded as being an obligatory subunit, 
forming the binding site for the co-agonist glycine.  These typically co-assemble 
with the glutamate-binding GluN2 subunits to form fully functioning receptors 
(Kohr, 2006).  Most native NMDA receptors are composed of two GluN1 
subunits with two of the same subtype of GluN2 subunits (i.e. GluN1/GluN2A), 
however there is evidence that more than one type of GluN2 subunit can 
coassemble in the same receptor (i.e. GluN1/2A/2B), producing unique 
biophysical properties (Chazot et al., 1994). 
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All of the NMDA receptor subunits share common structural membrane 
topology.  GluN1 and GluN2 subunits share around 20% amino acid sequence 
homology, whereas GluN2A and GluN2B subunits share around 70% subunit 
homology (Stephenson, 2001). Each subunit has a common membrane 
structure, comprising a large extracellular N-terminus, three transmembrane 
segments and a cytoplasmic C-terminus (Figure 11). 
 
 
Figure 11 Schematic representation of a NMDA receptor showing potential sites for 
ligand binding.  GluN1 subunits are required for binding of the co-agonist glycine, 
whereas GluN2 subunits bind glutamate (Paoletti & Neyton, 2007). 
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Of the four GluN2A subunits, the GluN2A and GluN2B subunits are the 
most ubiquitously expressed throughout the CNS.  During early development 
GluN2B-containing receptors predominate, switching to GluN2A-containing 
receptors around birth (Monyer et al., 1994).  Both of these subunits confer 
distinct physiological properties on the NMDA receptor.  For example, GluN2A 
receptors display greater currents and faster decay properties than GluN2B 
containing receptors (Figure 12). 
 
 
Figure 12 Decay kinetics of GluN2A and GluN2B containing NMDA receptors in 
transfected HEK cells subjected to 300ms of 100μM glutamate (Monyer et al., 1994). 
 
 
The density of NMDA receptors at the synapse is differentially regulated 
for the GluN2A and GluN2B subunits.  GluN2B subunit incorporation into the 
synapse is constitutive and its mobility into the synapse increases when the 
synapse is quiescent (Gambrill et al., 2011).  Conversely, GluN2A incorporation 
into the synapse requires binding of glutamate to NMDA receptors. Therefore, 
GluN2A synaptic incorporation increases in response to increased synaptic 
activity (Barria & Malinow, 2002; Storey et al., 2011).  Given the developmental 
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profile of high GluN2B vs. low GluN2A expression in early embryos (Monyer et 
al., 1994), the prevailing theory is that the activity-independent GluN2B-
containing receptors first accumulate at synapses.  Once the synapse becomes 
active, these GluN2B subunits are internalised and replaced with GluN2A 
subunits in an activity-dependent fashion (Barria & Malinow, 2002). 
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VIII. Role of Glutamate in the PVN in Normal Cardiovascular 
Homeostasis 
Given the widespread distribution of ionotropic glutamate receptors within the 
PVN (Herman et al., 2000), it is unsurprising the glutamate application exerts a 
potent effect on neuronal excitability and sympathetic outflow emanating from 
this nucleus (Yang et al., 2001; Li et al., 2006; Li et al., 2008a). 
Electron microscopy has shown that glutamatergic inputs synapse onto 
parvocellular neurones within the PVN (van den Pol, 1991).  Further 
immunohistochemical studies have demonstrated that synaptic boutons 
immunopositive for the glutamate vesicular transporter VGLUT2 make close 
apposition to corticotrophin releasing hormone (CRH) positive neurones within 
the medial parvocellular subnuclei (Ziegler et al., 2005). 
The PVN receives a dense glutamatergic input from many hypothalamic 
and extrahypothalamic nuclei.  Brain regions which send an efferent 
glutamatergic projection to the PVN were retrogradely labelled with [3H]D-
aspartate (D-aspartate is an analogue of L-glutamate and is selectively taken up 
by high affinity transporters located on the presynaptic endings of glutamatergic 
neurones (Csaki et al., 2000)).  Many of the regions labelled with [3H]D-
aspartate were within the hypothalamus and included the arcuate nucleus, 
lateral hypothalamic area and dorsomedial nucleus.  Extrahypothalamic 
innervation originated from areas including the amygdala and bed nucleus of 
the stria terminalis (Csaki et al., 2000).  No brainstem areas were labelled with 
[3H]D-aspartate, however recent evidence has shown that ascending projections 
from the NTS that innervate GABAergic neurones within the PVN express small 
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amounts of VGLUT2, suggesting that glutamate may be a neurotransmitter 
involved in this pathway (Affleck et al., 2012). 
Studies have shown that microinjection of NMDA into the PVN of 
normotensive rats dose dependently increases heart rate, blood pressure and 
RSNA, an effect which is blocked by prior application of the NMDA receptor 
antagonist AP-5 (Li et al., 2006).  Interestingly however, application of AP-5 
alone does not produce any significant effect on HR, ABP or RSNA (Li et al., 
2006).  Furthermore, and as previously described (section 1.VI), bicuculline 
induced sympathoexcitation is attenuated following NMDA receptor blockade 
(Chen et al., 2003).  Collectively, these results suggest that glutamate, acting 
through NMDA receptors, does not contribute to the tonic regulation of 
sympathetic outflow in the PVN of normotensive animals.  Moreover, 
glutamatergic inputs appear to be under a dominant tonic inhibition from 
GABAergic terminals. 
 
 The studies outlined so far detail the role of the PVN in the normal 
control of cardiovascular homeostasis and how the modulation of GABAergic 
and glutamatergic inputs results in a carefully orchestrated level of sympathetic 
outflow.  However evidence is accumulating which implicates the PVN as a 
major candidate in contributing to the sympathoexcitation observed in 
cardiovascular disease states; such as hypertension and heart failure, as well 
as in pregnancy.  The remainder of this chapter will examine the literature 
relating to this and how alterations in GABAergic and glutamatergic 
neurotransmission in the PVN have been shown to significantly contribute to 
this sympathoexcitation. 
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IX. Hypertension 
The increased risk of developing cardiovascular and renal disease in patients 
with hypertension was first reported in the early 20th century (Janeway, 1913).  
Recently “The Global Burden of Disease Study 2010” was published in The 
Lancet at the end of 2012.  In this study, hypertension was ranked as a major 
risk factor for serious cardiovascular and circulatory diseases (Lim et al, 2012).  
It is estimated that hypertension alone resulted in between 8.5 – 10 million 
deaths globally in 2010 alone (Lim et al, 2012).  Hypertension is defined as two 
readings of diastolic blood pressure ≥90mmHg, combined with 2 readings of 
systolic blood pressure ≥140mmHg (Carretero & Oparil, 2000). 
 Essential hypertension accounts for around 95% of all hypertensive 
cases, and is defined as hypertension in the absence of any secondary cause 
(i.e. renal disease, aldosteronism; Carretero & Oparil, 2000).  It is now well 
established that essential hypertension has a strong neurogenic component, 
particularly a significant up regulation of sympathetic nerve activity (Grassi et 
al., 2009), however the mechanism behind this sympathoexcitation remains 
poorly understood.  Furthermore, given that two-thirds of patients who take anti-
hypertensive medication fail to meet adequate blood pressure levels 
(Chobanian et al., 2003; Kougias et al., 2010); it is clear that much more work is 
required to fully understand the mechanisms underlying hypertension in order to 
design better therapeutics. 
 Both animal models of hypertension and studies in humans have shed 
considerable light on the mechanism by which neurochemical changes in 
specific brain nuclei contribute to the pathogenesis of hypertension. 
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X. Altered Cardiovascular Control in Extra-Hypothalamic Sites 
Studies in hypertensive humans and rats have identified that baroreflex control 
of heart rate and SNA is attenuated (Judy & Farrell, 1979; Grassi et al., 1998).  
In humans and various animal models of hypertension, the baroreflex curve is 
consistently shifted to the right (Figure 13; Head, 1995; Grassi et al., 1998).  
 
Figure 13 Altered baroreflex control of heart rate in various models of hypertension (B-
D), including humans (A) (Head, 1995). 
 
The cause of this reduced baroreflex gain and resetting is unclear, however the 
reduced gain is most likely the result of both vascular stiffening and cardiac 
hypertrophy, resulting in a reduced distension of the baroreceptors during 
hypertensive challenges (de Andrade et al., 2008; Kougias et al., 2010).  Under 
normal physiological conditions, alterations in ABP result in increased activity of 
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a number of brain sites in the rabbit, including the NTS, RVLM and PVN (Li & 
Dampney, 1994).  Decreased baroreceptor input to the NTS in response to high 
blood pressure in hypertensive animals is likely to therefore result in decreased 
drive to other autonomic centres in the brain.  The caudal ventrolateral medulla 
(CVLM) is one such site known to receive excitatory input from the NTS (Sved 
et al., 2000).  The CVLM projects dense inhibitory processes to the RVLM, 
thereby reducing vasomotor tone in response to baroreceptor activation (Cravo 
& Morrison, 1993). 
Therefore, reduced baroreceptor input resulting from reduced distension of 
peripheral baroreceptors is likely to result in a reduced NTS-CVLM excitatory 
input and a subsequent disinhibition of the RVLM.  In vivo studies in the 
spontaneously hypertensive rat (SHR) and the Goldblatt model of hypertension 
show that a major source of these excitatory inputs in the RVLM are 
glutamatergic (Bergamaschi et al., 1995; Ito et al., 2000), however the origins of 
these glutamatergic inputs to the PVN remains to be fully determined. 
 
One known area of excitatory glutamatergic input into the RVLM is the PVN 
(Stocker et al., 2006).  Significant advancement has been made over the past 
few decades into the role of the PVN in hypertension and the mechanisms by 
which it can sustain the sympathoexcitatory environment observed.  
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XI. Evidence for the Involvement of the PVN in Hypertension 
The hypothalamus has long been believed to contribute to the aetiology of 
essential hypertension.  Early studies showed that transection of the brain 
caudal to the hypothalamus resulted in a significantly greater decrease in blood 
pressure in the SHR compared with normotensive WKY controls (-34 ± 
11mmHg vs. -18 ± 5 mmHg respectively; Yamori & Okamoto, 1969).  
Furthermore, neurones within the posterior hypothalamic area had higher levels 
of spontaneous neuronal firing rates in the adult SHR compared with 
normotensive WKY controls (3.66 ± 0.55 Hz vs. 2.11 ± 0.29 Hz respectively, 
Shonis & Waldrop, 1993). 
These studies provided convincing evidence that the hypothalamus is involved 
in the pathogenesis of essential hypertension in the adult rat.  Furthermore a 
study by Eilam et al (1991), showed that transplantation of hypothalamic tissue 
from embryonic SHR into adult normotensive WKY rats resulted in a 31% 
increase in blood pressure and an 80% increase in heart weight over a period of 
6 weeks. Taken together, these results suggest that hypothalamic control of 
blood pressure contributes significantly to increased vasomotor tone in 
hypertension, and that this may be genetically predetermined in the SHR. 
A study by Ernsberger et al (1985) began to provide evidence that the 
PVN is the main hypothalamic site responsible for the generation of increased 
sympathetic activity in hypertension.  Radiofrequency lesions of the PVN 
prevented the rise in blood pressure in the Dahl salt-sensitive (DSS) rat fed a 
high salt diet.  This rise in blood pressure was not observed in Dahl salt-
resistant rats, or in DSS rats with lesions placed outside the PVN.  A similar 
study employing electrolytic lesions of the PVN in SHR, also found that ablation 
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of the PVN significantly reduced blood pressure in adult SHR with established 
hypertension, but also reduced blood pressure in young, pre-hypertensive SHR 
compared with sham-operated age matched controls (Ciriello et al., 1984).  
These studies add weight to the argument that the PVN does not contribute 
significantly to the control of blood pressure in the normotensive animal; 
however increased neuronal activity within the hypothalamus, specifically the 
PVN dramatically increases blood pressure in the hypertensive state.   
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XII. Role of GABA in the Aetiology of Sympathoexcitation 
Activation of the PVN, either by blockade of inhibitory GABAergic networks or 
by activation of excitatory receptors, has been consistently shown to increase 
MAP in rats and rabbits by increasing sympathetic outflow (Martin et al., 1991; 
Deering & Coote, 2000; Allen, 2002; Chen et al., 2003). Given the role of the 
PVN in regulating sympathetic outflow (Kannan et al., 1989; Kenney et al., 
2003) and the characteristic sympathoexcitation in hypertension in both humans 
and animals (Greenwood et al., 1999; Grassi et al., 2009), studies have long 
focused on the role of the PVN in the development of hypertension. 
 It is known that blockade of the GABAergic system in the PVN of 
normotensive rats produces similar effects to those observed in hypertension 
(i.e. sympathoexcitation, increased ABP; Martin et al., 1991) and that GABA 
plays a dominant role in the PVN under normal physiological conditions 
(Decavel & Van den Pol, 1990).  It is therefore perhaps unsurprising that much 
work has been undertaken to examine the role of GABA in the PVN in the 
aetiology of sympathoexcitation in hypertension. 
 Early studies examining the role of the hypothalamus in hypertension 
identified that the posterior hypothalamus (which encompasses the PVN), 
showed higher levels of spontaneous neuronal activity in the SHR than in age-
matched WKY controls (Shonis & Waldrop, 1993). Since excitatory networks 
are heavily inhibited in the PVN of normotensive rats (Li et al., 2006), the 
increase in neuronal excitability in the hypothalamus of hypertensive rats must 
in part be due to a removal of the inhibitory inputs that are normally present.  
Indeed to this effect, autoradiographic studies of GABAA receptor binding sites 
in the PVN of pre- and established hypertensive SHR (4 weeks and 12 weeks 
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respectively), showed significantly lower binding of [35S]t-
butylbicycleophosphorothionate ([35S]TBPS; a GABAA receptor ligand) to the 
GABAA receptor at both ages compared with age-matched WKY controls 
(Kunkler & Hwang, 1995).  In lieu of this, these results would suggest that the 
ability for GABA to elicit its inhibitory effects within the PVN is blunted, even 
prior to the onset of hypertension. 
However, the physiological effect of GABA activation within the PVN of 
hypertensive rats has produced conflicting results. 
In one series of experiments, bilateral microinjection of the GABAA receptor 
agonist muscimol into the PVN of anaesthetised SHR produced a more 
profound decrease in ABP, HR and LSNA than age matched WKY controls 
(Allen, 2002; Akine et al., 2003). However, in a second set of experiments, 
bilateral microinjection of muscimol into the PVN of SHR produced an 
attenuated decrease in ABP, HR and LSNA at similar concentrations to those 
used in the previous experiment (Li & Pan, 2007b).  Furthermore, the 
sympathoexcitatory, pressor and tachycardic response to disinhibition of the 
PVN with bicuculline has been shown to be both attenuated (Li & Pan, 2007b) 
and augmented (Ito et al., 2002) in SHR compared with WKY controls. 
In vitro analysis of GABAA receptor activity revealed that bicuculline application 
on PVN-RVLM projecting neurones significantly increased the firing rate of all 
labelled, spontaneously active neurones in young (6 weeks) and adult (13 
weeks) WKY and SD rats.  Furthermore, bicuculline application also induced 
spontaneous firing in a subset of quiescent neurones in WKY and SD rats.  
However in the SHR, bicuculline application increased the firing rate of only 
48.9% of labelled neurones, failed to exert an effect on 21.3% of labelled 
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neurones, and surprisingly decreased the firing rate of 29.8% of labelled 
neurones.  In addition, bicuculline application failed to evoke spontaneous firing 
in all but 1 of 12 silent neurones tested (Li & Pan, 2006).  This latter, in vitro 
result reinforces the evidence towards a reduced GABAergic influence in the 
PVN of rats with established hypertension. 
 
Changes in GABAergic inhibition have also been identified in different 
models of hypertension.  In the chronic renal-wrap model of hypertension; in 
which a ligature in the form of a figure-8 loop is tied around a kidney, followed 
by removal of the contralateral kidney, bilateral microinjection of bicuculline into 
the PVN of conscious rats produced an increase in arterial blood pressure that 
was 31% greater than sham operated rats (Haywood et al., 2001).  
Furthermore, GABAA binding sites, measured by autoradiographic labelling with 
[3H] Flunitrazepam, and mRNA expression of the GABAA α1 subunit within the 
PVN were not different between hypertensive and normotensive sham operated 
rats (Haywood et al., 2001). 
However, in acute models of renal-wrap induced hypertension, the 
sympathoexcitatory effects of bilateral microinjection of bicuculline into 
conscious rats was attenuated compared with sham operated controls (Martin & 
Haywood, 1998). 
Analysis of GABA synthesis potential; as identified by immunofluorescent-
identification of the GABA-synthesising enzyme glutamic-acid decarboxylase 
(GAD67) expression, in the PVN of renovascular hypertensive rats; in which 
hypertension is achieved following unilateral occlusion of the renal artery, 
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showed that GAD67 expression was increased in the medial and caudal 
aspects of the PVN (Biancardi et al., 2010).  
The discrepancies observed in these series of experiments are not fully 
understood.  It is possible that different genetic lineages of strains, injection 
techniques, injection sites and anaesthesia could contribute to these 
differences.  Moreover, it is possible that these differential changes in 
GABAergic activity within the PVN are age and disease progression-dependent.  
In the experiments in which GABAergic inhibition appeared blunted, the animals 
were either younger (12-13 weeks) in the case of the SHR, or hypertension was 
in the progressive, rather than established phase (4 days post-surgical renal-
wrap).  This is compared with the experiments showing augmented GABAergic 
inhibition within the PVN, in which the animals were older (14 weeks SHR) or 
chronic renal-wrap had produced established hypertension (≥3 week’s post-
surgery).  Indeed in the renovascular model of hypertension; which showed an 
increase in GAD67 expression in specific PVN subnuclei, this does not 
conclusively relate to an increase in GABAergic tone. Analysis of GABA 
function or post-synaptic GABA receptor densities; which are significant limiting 
factors in the function of GABA, were not measured in this study, nor were 
levels of GAD65 expression, and have not been previously measured in this 
model.  
It is therefore possible to speculate that GABAergic tone is altered in early 
hypertension and is increased as the disease progresses.  Given that blood 
pressure was significantly higher in the younger compared with older SHR 
(142.3 ± 10.3 mmHg vs. 119 ± 7 mmHg respectively; Allen, 2002; Li & Pan, 
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2007b), this is a plausible hypothesis.  Compensatory increases in presynaptic 
GABA release and/or postsynaptic GABAA receptor density could account for 
these differences. However the effects of using differently sourced strains of 
SHR and control rats as a possible cause of this discrepancy, as well as the 
different sites of ABP measurement (carotid vs. femoral), can also not be ruled 
out. 
Indeed recent evidence in a rat model of heart failure points towards differential 
control of sympathoexcitation in early and late phases.  The sympathoexcitation 
observed in the early stages of heart failure was not dependent upon nitrergic 
inputs but was mediated by angiotensin II, whereas this was NO dependent in 
later stages (Pyner et al, 2009; Barrett et al, 2012).  Although this study was not 
directly related to GABAergic control in hypertension, it provides evidence that 
the chronic sympathoexcitation characteristic of cardiovascular disease has the 
potential to be differentially regulated over time. 
 Very recent evidence has been published shedding some light onto one 
mechanism by which GABAergic inhibition within the PVN is reduced in 
hypertension.  GABAA receptor activity is dependent upon intracellular chloride 
concentrations ([Cl-]i), the balance of which is maintained through cation-
chloride co-transporters.  The Na+-K+-2Cl- cotransporter-1 (NKCC1) regulates 
chloride influx across the membrane, whereas the K+-Cl- cotransporter-2 
(KCC2) channel regulates chloride efflux (Payne et al., 2003).  In vitro analysis 
of the GABAA receptor activity of spinally projecting PVN neurones showed a 
significant reduction in activity in the SHR compared with normotensive 
controls, as well as a significant increase in basal firing rate.  However, 
following 2-4 hour incubation with bumetanide, a specific blocker of NKCC1 
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channels, GABAA receptor function was restored and basal firing rate was 
significantly reduced.  Furthermore, expression of the glycosylated isoform of 
NKCC1 was significantly increased in the SHR compared with WKY rats. 
Incubating brain slices from SHR with a blocker of N-glycosylation also 
normalised GABA activity.  In vivo analysis of the contribution of NKCC1 in the 
aetiology of hypertension showed that intracerebroventricular infusion of 
bumetanide in SHR significantly decreased LSNA, ABP and HR as well as 
significantly increasing the response to muscimol (Ye et al., 2012a).  Taken 
together, these results suggest a significant role for the activity of NKCC1, 
particularly the glycosylated isoform, in mediating the decreased GABAergic 
activity within the PVN of hypertensive rats, most likely through disrupting 
transmembrane chloride homeostasis. 
Furthermore, evidence from animals subjected to chronic, unpredictable stress 
were found to show significant reductions in mRNA levels for extrasynaptic 
GABAA receptor subunit (α5 and δ), but not synaptic GABAA receptor subunits 
(α1, α3 and γ2) in parvocellular neurones of the PVN Verkuyl et al., 2004)). 
Although blood pressure levels were not measured in this study, levels of 
corticosterone, which is known to increase blood pressure (Goodwin & Geller, 
2012), were significantly enhanced in the stressed group compared with 
unstressed controls.  It is therefore possible that, rather than a global 
downregulation of all GABAA receptors in the PVN, hypertension and pregnancy 
could be associated with downregulation of specific GABAA receptor subunits. 
As described earlier, the sympathoinhibitory, depressor and bradycardic 
effects of GABAB receptor activation within the PVN only manifest at high 
(4.5nmol) concentrations in normotensive rats (Li & Pan, 2007b). In an in vitro 
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preparation, baclofen application to PVN-spinally projecting neurones produces 
modest, but significant reductions in spontaneous firing potential (Li et al., 
2008b).  However, the effects of bilateral microinjection of baclofen into the PVN 
of SHR were augmented compared with WKY controls.  Furthermore, 
application of baclofen to PVN-spinally projecting, pre-labelled neurones 
produced a more significant decrease in firing activity compared with WKY 
controls (Figure 14; Li & Pan, 2007b; Li et al., 2008b) 
 
Figure 14 Effect of baclofen on firing rate of PVN-spinally projecting neurones. A: 
Application of 100μM baclofen evoked an outward current in 54% of recorded neurones 
in WKY rats and 85% in SHR.  The evoked current was significantly greater in the SHR 
compared with age-matched WKY controls. B: This response was blocked by prior 
administration of the GPCR blocker GDPβS in both WKY and SHR (Li et al, 2008). 
 
In a hypothalamic brain slice preparation, bath application of the GABAB 
receptor antagonist CGP-55845 produced no significant changes in the firing 
activity of PVN-RVLM projecting neurones in 6- or 13- week old WKY, 6 – or 13-
week old SD or 6-week old SHR at either low (1μM) or high (5μM) 
concentrations.  Conversely, application of 1μM CGP-55845 to hypothalamic 
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brain slices from 13-week old SHR produced significant increases in the on-
going firing activity of 75% of PVN-RVLM neurones measured.  Application of 
CGP-55845 also induced spontaneous firing in 75% of silent PVN-RVLM 
neurones measured in the 13-wk old SHR (Li & Pan, 2006). 
The results of these studies clearly show that GABAB receptors play little role in 
mediating tonic inhibition of PVN-RVLM neurones in normotensive rats.  
However, the effects of GABAB receptor activation or inhibition in the PVN of 
13-week old SHR are significantly increased. 
The reason for the increased GABAB receptor-mediated inhibition in the PVN of 
the SHR is not fully understood.  Since a decrease in the activity of GABAA 
receptors in the PVN was noted in these studies (Li & Pan, 2006, 2007b; Li et 
al., 2008b), it is possible that increased GABAB receptor activity is 
compensatory. 
The GABAB receptor exists as both a pre- and postsynaptic receptor (Li 
& Pan, 2010). As a presynaptic receptor, GABAB receptors inhibit 
neurotransmitter release and have been shown to inhibit the release of 
glutamate and GABA in the basolateral amygdala (Yamada et al., 1999).  It is 
therefore possible that activation of GABAB receptors in the PVN could act to 
inhibit presynaptic GABA release, and that an increase in GABAB activity in the 
SHR could act to inhibit GABA release to a greater effect than in normotensive 
controls, thereby contributing to the reduced GABAA-receptor mediated 
inhibition. To this effect, reduced concentrations of endogenous GABA have 
been reported in the hypothalamus of 10 week and 17 week old SHR (Hambley 
et al., 1984). 
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 The work described above encompasses the range of studies that have 
been undertaken examining the role of GABA in the PVN of hypertensive rats. 
Concluding a specific role for GABA in the PVN in the aetiology of hypertension 
remains difficult and it is therefore clear that more work needs to be undertaken 
to fully elucidate the changes that occur in the inhibitory environment. 
One way of examining the potential contribution that PVN-GABA plays in the 
development of hypertension is to examine its role in heart failure (HF).  Heart 
failure shares with hypertension a characteristic sympathoexcitation in both 
animals (Zhang et al., 2002) and humans (Charkoudian & Rabbitts, 2009; 
Floras, 2009).  In addition, not only has PVN activity been shown to be 
significantly increased in HF, as shown by Fos expression; a marker of neuronal 
activity  (Vahid-Ansari & Leenen, 1998), but the firing rate of PVN-RVLM 
projecting neurones has also been shown to be significantly increased in HF 
(Han et al., 2010), as is also observed in hypertension (Li & Pan, 2006). 
 
 Experiments examining the physiological effect of GABA activation and 
blockade, similar to those mentioned above in the hypertensive rat have been 
undertaken in rats with HF.  The sympathoexcitatory effects following unilateral 
microinjection of bicuculline into the PVN of rats that had undergone left 
coronary artery ligation, resulting in a characteristic heart failure profile 
(hypertrophic heart, infarct, sympathoexcitation and increased left ventricular 
end diastolic pressure), were found to be significantly blunted compared with 
sham operated rats (Zhang et al., 2002; Wang et al., 2009). Furthermore, the 
sympathoinhibitory, depressor and bradycardic effect of muscimol injection into 
the PVN were also significantly blunted in HF rats (Zhang et al., 2002; Wang et 
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al., 2009).  Moreover, mRNA expression of the α1 subunit of the GABAA 
receptor is significantly reduced in the PVN of rats with HF compared with sham 
operated rats (Wang et al., 2009). This conclusion of a reduced GABAergic 
inhibition in the PVN of HF rats is in agreement with in vitro work examining the 
firing properties of PVN-RVLM projecting neurones in HF rats.  The 
spontaneous activity of PVN-RVLM projecting neurones was significantly 
greater in HF rats compared with sham operated rats (Han et al., 2010). 
Furthermore there were also significantly fewer spontaneous inhibitory post-
synaptic currents (sIPSCs) in these neurones, which were a result of reduced 
pre-synaptic GABA release (Han et al., 2010).  Bicuculline-evoked increases in 
the firing rate of PVN-RVLM projecting neurones were also decreased in HF, 
where bicuculline failed to evoke a response in any of the labelled neurones 
tested, compared to 80% in sham operated controls (Han et al., 2010).  These 
results were distinct from PVN-IML projecting neurones, which displayed a 
normal firing pattern and sIPSC rate (Han et al., 2010).   
 
In addition; and in contrast to that which is observed in hypertension, the activity 
of GABAB receptors is also blunted in the PVN of rats with HF, since application 
of the GABAB receptor agonist baclofen produces blunted decreases in RSNA, 
HR and ABP (Wang et al., 2009). 
 
These results provide interesting insight into the role of PVN-GABA in the 
aetiology of sympathoexcitation in rats with chronic heart failure.  Given that 
both hypertension and HF display significant increases in sympathetic activity 
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emanating, at least in part, from the PVN, HF provides an interesting model for 
the potential mechanisms that are taking place in hypertension.   
However caution does need to be observed when extrapolating data observed 
in HF to that in hypertension.  Although both conditions do elicit 
sympathoexcitation and increased PVN activity, some differences in this activity 
do exist.  For example, in rats with HF, there is an increase in activity of PVN-
RVLM projecting neurones only (Han et al., 2010), whereas in hypertensive 
rats, the firing rate of PVN-RVLM and PVN-IML projecting neurones is 
increased (Li & Pan, 2006; Li et al., 2008b).  Moreover, rats with HF show no 
significant change in blood pressure compared with sham controls (Zhang et al., 
2002), which could indicate towards a differential control of sympathetic 
outflows in these two conditions. 
 
 Regardless of the effects of GABA in the PVN of HF rats, the current 
understanding of the role of PVN-GABA in hypertension remains poorly 
understood.  The results obtained from studies in HF can and should be used 
as a framework to examine potentially similar changes in hypertension. 
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XIII. Role of Glutamate in the Aetiology of 
Sympathoexcitation 
It is known that under normal physiological circumstances, GABAergic inhibition 
plays a dominant role in regulating sympathetic outflow in the rat PVN.  To this 
effect, application of the NMDA receptor antagonist AP-5 into the PVN produces 
no effect on blood pressure (Chen et al., 2003).  However, although the role of 
GABA in the PVN of hypertensive rats is contested, results largely suggest that 
GABAergic inhibition is blunted.  Given that the PVN is known to widely express 
both NMDA and non-NMDA receptors (Herman et al., 2000), it is possible that 
this would lead to disinhibition and the ability for glutamatergic excitation to 
predominate. 
 As previously described, microinjection of AP-5 into the PVN of 
normotensive rats produces no significant change in blood pressure, heart rate 
or both RSNA and LSNA (Chen et al., 2003; Li & Pan, 2007a).  This is most 
likely due to the high level of GABAergic inhibition observed in the PVN.  
However, bilateral microinjection of AP-5 into the PVN of 13 week old SHR 
produced a significant reduction in ABP, HR and LSNA (27.6 ± 2.8 mmHg, 14.8 
± 5.6 bpm, 24.1 ± 8% respectively compared with age matched WKY; Li & Pan, 
2007a). In addition, bilateral application of the selective non-NMDA receptor 
antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) into the PVN produced 
no significant effects in the normotensive rat, however produced significant 
reductions in ABP, HR and LSNA in the SHR (20.6 ± 2.5 mmHg, 16.5 ± 8.2bpm, 
23.6 ± 1.9% respectively; Li & Pan, 2006).  These observations suggest that the 
sympathoexcitation emanating from the PVN in hypertensive rats is due, at 
least in part to activation of both NMDA and non-NMDA receptors. Furthermore, 
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given that the reductions in these parameters to both NMDA and non-NMDA 
receptor blockade are similar in magnitude, it is possible to suggest that both of 
these receptor subtypes contribute equally.  This is further evidenced by the 
bilateral application of Kyn into the PVN.  Microinjection of Kyn into the PVN of 
normotensive WKY rats produced no significant cardiovascular effect, whereas 
when applied to the PVN of the SHR ABP, HR and LSNA were reduced by 40.9 
± 3.9mmHg, 30.1 ± 3.6bpm and 32.3 ± 1.8% respectively (Li & Pan, 2006). 
 The role of glutamate in contributing to the increased activity of the PVN 
in other models of hypertension has also been investigated.  The Dahl Salt 
Sensitive (DSS) rat is a genetic model of salt sensitive-hypertension.  The 
degree of hypertension that this rat model exerts is dependent on dietary salt 
intake, with even normal salt intake producing mild hypertension (Pinto et al., 
1998).  This differs from the SHR, which produces hypertension regardless of 
salt intake.  The Dahl Salt Resistant (DSR) rat is produced by substituting 
chromosome 13 for that of the salt resistant Brown Norway rat (Gabor & 
Leenen, 2012).  Dahl Salt Sensitive rats fed a normal salt diet (0.1% NaCl) had 
a resting ABP of 109 ± 3mmHg compared with 106 ± 4mmHg for the DSR rat 
fed on the same diet.  When fed high salt diets (8% NaCl), DSS rats recorded a 
ABP of 153 ± 8mmHg compared with 112 ± 3mmHg in the DSR rats (Gabor & 
Leenen, 2012).  Bilateral infusion of Kyn into the PVN of DSS rats fed normal 
salt diets produced no alteration in ABP or HR.  However, when infused into the 
PVN of DSS fed high salt diets, Kyn produced significant decreases in both 
ABP and HR (Gabor & Leenen, 2012).  Given that these results mirror those 
observed in the SHR, it would appear that glutamatergic inputs are an important 
component of multiple models of hypertension. 
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These results can be replicated in a hypothalamic in vitro preparation.  
Application of AP-5, CNQX or Kyn failed to elicit any effect on the firing rate or 
membrane potential of PVN-IML projecting neurones in WKY rats.  Conversely, 
AP-5, CNQX and Kyn all elicited a significant decrease in the firing rate of PVN-
IML projecting neurones in 11-13 week old SHR (Li et al., 2008a).  Puff 
application of NMDA onto these neurones also elicited significantly greater 
inward currents in SHR compared to WKY, whereas inward currents elicited by 
puff application of AMPA were similar in SHR and WKY (Li et al., 2008a).  
These results not only show that the increased response to both NMDA and 
non-NMDA stimulation in vivo is, at least in part due to stimulation of 
presympathetic neurones targeting the spinal cord, but also the activity of post-
synaptic NMDA receptors is somehow increased on these neurones, whereas 
the activity of AMPA receptors remains the same.   
 What remains unclear from the studies discussed previously is whether 
the increased influence of the glutamatergic network in the PVN of hypertensive 
rats is due to an increase in the activity of postsynaptic glutamate receptors, a 
withdrawal of the inhibition, which normally prevents activation of these 
receptors, or a combination of the two. 
To evidence this latter part, microinjection of either the GABAA receptor 
antagonist gabazine or bicuculline into the PVN produces a significant increase 
in ABP, HR and SNA in both normotensive and SHR (Chen et al., 2003; Li & 
Pan, 2007a).  However, the cardiovascular and sympathoexcitatory effects of 
GABAA receptor antagonism were blocked by prior antagonism of glutamatergic 
receptors with Kyn (Chen et al., 2003; Li & Pan, 2007a).  These results suggest 
that withdrawal of GABAergic inhibition results in the activation of glutamatergic 
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inputs within the PVN.  Given that evidence suggests GABAergic inputs are 
reduced in the PVN of hypertensive rats (Li & Pan, 2007b), it is possible to 
suggest that this withdrawal would result in the activation of glutamate 
receptors. 
Furthermore, recent evidence also suggests that the expression of postsynaptic 
NMDA receptors is up-regulated in the PVN of hypertensive rats.  Analysis of 
whole PVN protein and mRNA expression of the GluN2A and GluN2B subunits 
of the NMDA receptor show an increase in expression in the SHR compared 
with age-matched WKY controls (Ye et al., 2012b).  In addition, casein kinase 2 
(CK2) phosphorylation of GluN2B subunits, phosphorylation of which results in 
internalisation of the GluN2B subunit and a selective enhancement of synaptic 
GluN2A subunits (Sanz-Clemente et al., 2010), was increased in the PVN of 
SHRs compared with WKY controls (Ye et al., 2012b). 
The evidence therefore appears to suggest that the increased influence of 
glutamatergic inputs in the PVN of hypertensive rats results from both reduced 
GABAergic inhibition of glutamatergic networks, as well as an increase in the 
expression of postsynaptic NMDA receptors. 
  
 As with PVN-GABA, much work has been undertaken examining the role 
of glutamate in the sympathoexcitatory actions of heart failure. 
Experiments have shown that microinjection of NMDA into the PVN of rats with 
HF show an augmented pressor and sympathoexcitatory response than sham 
operated controls (Li et al., 2003).  Conversely, blockade of NMDA receptors 
with AP-5 produced significant decreases in ABP and RSNA in HF, but not in 
sham operated controls (Li et al., 2003).  Furthermore, expression of the GluN1 
 76 
 
subunit of the NMDA receptor was also increased in the PVN of HF rats (Li et 
al., 2003).  This data points toward a heightened activity of NMDA receptor 
activity within the PVN of rats with HF, and generally correlates with the data 
observed from hypertensive animals and discussed previously.  In addition, it 
has been shown that chronic blockade of AT1 receptors within the PVN of rats 
with HF reverses the augmented response to NMDA microinjection and 
normalises the GluN1 expression (Kleiber et al., 2010). 
  
 The influence of glutamate in the PVN on the sympathoexcitation and 
cardiovascular characteristics observed in hypertension has been extensively 
studied, and the results appear to be more conclusive than those observed for 
GABA, which shows considerable variability in its physiological response in 
hypertension.   Furthermore, studies examining the role of glutamatergic 
hyperactivity in the PVN of HF animals show striking similarities in the 
augmented responses observed between the two physiological states.  Taken 
together, these results suggest a significant role for glutamate in maintaining the 
sympathoexcitation observed in these two cardiovascular disease states. 
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XIV. Pregnancy and Neurosteroidal Modulation of GABAA 
Receptors 
Pregnancy is associated with an increase in blood volume (40% increase on 
pre-pregnancy levels), cardiac output (30-35% increase on pre-pregnancy 
levels) and sympathetic nerve activity in both animals and humans (Longo, 
1983; Heesch & Rogers, 1995; Greenwood et al., 2001; Jarvis et al., 2012).  
Coupled with these changes are increases in both plasma and brain 
concentrations of certain hormones, including oestrogen, progesterone and 
chorionic somatomammotropin (Figure 15; Longo, 1983; Concas et al., 1998). 
  
Figure 15 Increase in hormone levels, blood volume and cardiac output during the 
course of gestation in humans (Longo, 1983) 
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Of these hormones, experimental evidence has shown that progesterone, and 
more importantly metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-
20-one (3α-OH-DHP, allopregnanolone) and 5α-hydroxy-2α,21-diol-20-one 
(allotetrahydrodeoxycorticosterone), show potent positive modulatory action at 
GABAA receptors, particularly extrasynaptic GABAA receptors (Concas et al., 
1999; Maguire & Mody, 2009; Sanna et al., 2009). Furthermore, administration 
of progesterone or its metabolites into autonomic centres of the brains of virgin 
female rats (such as the RVLM) has been shown to produce cardiovascular 
effects that mimic those observed in pregnancy (Heesch & Rogers, 1995; 
Storey & Kaufman, 2004). 
 Systemic adminstration of progesterone or its metabolites has been 
shown to produce profound anxiolytic, hypnotic or anticonvulsant effects, a trait 
shared by the GABAA-receptor modulating benzodiazepine class of drugs 
(Concas et al., 1999). 
A seminal paper by Harrison and Simmonds (1984), showed that in rat brain 
slice preparations, application of alphaxalone, a synthetic, progesterone-based 
steroid anaesthetic, potentiated the depolarising effects of the GABAA receptor 
agonist muscimol.  Furthermore, muscimol binding to GABAA receptors was 
also increased in the presence of alphaxalone.  These effects were not 
repeatable when the inhibitory neurotransmitter glycine was added, suggesting 
a specificity for the GABAA receptor (Harrison & Simmonds, 1984).  Given the 
steroid nature of alphaxolone, the authors of this study concluded that 
endogenously synthesised steroids could also potentiate GABAergic inhibition 
in a similar manner. 
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Indeed this has been shown through various studies.  Callachan et al (1987), 
showed that in cultured bovine adrenomedullary chromaffin cells, application of 
100μM GABA in the presence of 300nM of the progesterone metabolites 5β-
pregnan-3α-ol-20-one (pregnanolone) or 5β-pregnane-3,20-dione 
(pregnanedione), had an augmented depolarising effect compared with 
application of 100μM GABA alone. An effect which was blocked by prior 
application of the GABAA receptor antagonist bicuculline (Callachan et al., 
1987).  In addition, application of high concentrations of both pregnanolone and 
pregnanedione activated GABAA receptor-mediated membrane depolarisations 
in the absence of GABA, suggesting that in addition to their modulatory role, 
progesterone metabolites have the ability to act as GABA-mimetics (Callachan 
et al., 1987).  However, given the high concentrations of steroids required to 
achieve this effect (>1μM), it is not clear whether endogenous progesterone 
metabolites would be able to achieve the same effects. 
In cultured hippocampal neurones, application of SKF 105111- 17β-17-[bis 
(1methylethyl) amino carbonyl] androstane-3,5-diene-3-carboxylic acid (SKF); a 
potent inhibitor of 5α-reductase, the enzyme involved in the breakdown of 
progesterone into allopregnanolone, amongst other metabolites - reduced the 
Cl- current intensity evoked from exogenously applied GABA. These results 
were reversed with dual application of allopregnanolone with either GABA or the 
GABAA receptor agonist muscimol (Puia et al., 2003). 
 
Modulation of GABAA receptors by progesterone metabolites has been 
shown to be dependent on their subunit conformation.  Recent evidence has 
shown that in Drosophila melanogaster RDL (resistant to dieldrin) GABAA 
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receptors, which lack neurosteroidal sensitivity, incorporation of the murine TM1 
and TM2 domains in the α1 and β2 subunits results in potentiated 
neurosteroidal sensitivity in α1 subunits, but not in β2 subunits (Hosie et al., 
2006).  Further dissection of the neurosteroidal binding site at this subunit 
reveals regions Q241 of the TM1 region, and N407 and Y410 of the TM2 region 
to be important, sites which are conserved amongst the α subunit family (Hosie 
et al., 2006; 2009). 
Multiple studies have shown that incorporation of a δ subunit into the GABAA 
receptor complex further potentiates neurosteroidal modulation of these 
receptors. 
Application of the progesterone metabolite tetrahydrodeoxycorticosterone 
(THDOC) on oocytes expressing either α1β2 or α1β2δ GABAA receptors 
significantly increased the depolarising effects of both receptor types by 
increasing the decay time constant and magnitude of the depolarisation.  
Application of 1μM GABA onto α1β2δ containing receptors did not induce 
membrane depolarisation.  However, in the presence of THDOC, 1μM GABA 
did produce a significant depolarisation.  In addition, application of 100μM 
GABA onto δ containing receptors did produce a modest depolarisation, which 
was significantly enhanced with the addition of THDOC (Figure 16, B/C).  The 
degree of depolarisation was enhanced, but to a much lesser degree in GABAA 
receptors which lacked the δ subunit (Figure 16, A/C, Zheleznova et al., 2008). 
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Figure 16 Effects of 1µM THDOC on GABA-induced inhibitory currents in oocytes 
expressing either α1β2 (A) or α1β2δ (B) GABAA-containing receptors.  THDOC 
significantly increased the decay time and depolarising magnitude in both receptor 
subtypes.  This effect was more profound in δ containing receptors (C).  Application of 
1μM GABA on δ containing receptors did not produce significant depolarising effects 
alone (B). Zheleznova et al, 2008. 
 
The results of this study suggest that in the absence of neurosteroidal 
modulation, GABAA receptors comprising the δ subunit appear to be silent, and 
thus contribute very little to inhibition.  However, in the presence of 
neurosteroids, their inhibitory potential is significantly enhanced.  Additionally, 
the potentiating effects of neurosteroids are not dependent on the presence of a 
δ subunit, since THDOC enhanced the inhibitory potential of GABAA receptors 
which lacked the δ subunit; however their presence does confer significant 
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increases in their modulatory potential.  This has been confirmed, since 
mutation of Q246 in the α4 subunit (analogous to Q241 in the α1 subunit) of 
α4β3δ-containing GABAA receptor blocked neurosteroid potentiation (Hosie et 
al., 2009), suggesting that δ subunits are not required for the binding or actions 
of neurosteroids, but do confer distinct physiological properties to receptors 
which incorporate the  subunit in the presence of neurosteroids.  
Pregnancy and the accompanying increases in progesterone levels have 
also been shown to modulate the subunit expression of GABAA receptors in the 
brain.  During late stage pregnancy in rats (P19), expression of the δ subunit in 
granule cells of the dentate gyrus (DGGC) significantly increases, as identified 
immunohistochemically (Sanna et al., 2009). Concomitantly, there is a 
significant decrease in expression of the γ subunit in these same cells.  These 
changes equate to an increase in the expression of extrasynaptic, and a 
decrease in the expression of synaptic GABAA receptors (Sanna et al., 2009).  
Coupled with these receptor subunit changes, application of GABA onto 
DGGCs from rats in oestrus, P15 and P19 show a significant increase in GABA-
mediated inhibitory currents in cells from rats at P19 compared with oestrus 
(Sanna et al., 2009).  These results suggest that in the presence of high levels 
of neurosteroids, GABAA receptors containing the δ subunit have greater 
inhibitory potentials than those containing the γ2 subunit.  Furthermore, the 
changes in δ and γ2 subunit expression in rats at P19 were reversed following 
antagonism of the enzyme 5α-reductase with finasteride, suggesting that the 
observed changes are as a result of increased progesterone levels observed 
during pregnancy (Sanna et al., 2009). 
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Conversely, in cultured hippocampal pyramidal cells from neonatal rats, 
exposure to 1μM progesterone for 6 days decreased mRNA and protein 
expression of the δ subunit by almost 50% compared with control levels.  This 
was reversed following withdrawal of progesterone (Mostallino et al., 2006).  
This effect was mimicked by application of allopregnanolone and blocked with 
finasteride, suggesting this effect was specific to progesterone application.  In 
correlation with a decrease in δ containing GABAA receptors, application of 
4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridine-3-ol (THIP), a GABAA receptor 
agonist with preference for δ-containing receptors over γ2-containing receptors, 
in conjunction with allopregnanolone resulted in a reduced potentiation of the Cl- 
current following 6 days of allopregnanolone treatment compared with control 
(Mostallino et al., 2006). 
The significance of these conflicting results is interesting. Given that both 
progesterone levels and levels of its metabolites increase in the brain during 
pregnancy, it would be likely that chronic application of progesterone or 
allopregnanolone onto cultured hippocampal cells would produce similar effects 
on δ-subunit expression than those seen during pregnancy; however the 
opposite appears to be the case.  It is possible to speculate that application of 
progesterone alone does not mimic pregnancy. Since many hormonal 
fluctuations occur during pregnancy, a convergence of these hormones may 
interact to produce complex changes, which ultimately manifest as those 
observed during de facto pregnancy.  Alternatively, the differences observed in 
these two studies could be due to the difference in ages between the animals.  
The study by Sanna et al (2009) utilised adult rats (60-90 days old), whereas 
Mostallino et al (2006), used cultured hippocampal neurones from neonatal rats.  
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It is known that GABAA receptors behave differently in the neonatal rat 
compared with adults (Taketo & Yoshioka, 2000), indeed acting as an excitatory 
receptor (Ben-Ari et al., 1994), and that endogenous neurosteroids produce 
differential responses in various populations of neurones (Lambert et al., 2009).  
It is therefore possible that the differential effects seen between these two 
studies are due to the age differences of animals.  Interestingly these two 
studies are the product of the same laboratory, yet the later study (Sanna et al., 
2009) does not correlate the results obtained in vivo with those obtained from 
the earlier in vitro study (Mostallino et al., 2006).  It is therefore possible to 
speculate that the authors also do not believe the in vitro methodology to be a 
reliable model for pregnancy. 
 In correlation with the observed decrease in γ2 expression in the 
hippocampus of late-stage pregnant rats (Sanna et al., 2009), both mRNA and 
protein expression of the long isoform of the γ2 subunit (γ2L) was found to be 
significantly reduced in both the hippocampus and cerebral cortex at day 10 of 
pregnancy, peaking at day 19 in rats.  Levels returned to control values at day 
21 of pregnancy, just prior to delivery (Follesa et al, 1998; Concas et al, 1998, 
1999).  The altered levels of γ2L expression in the hippocampus and cerebral 
cortex were abolished following treatment with finasteride from days 12-18 of 
pregnancy (Concas et al., 1999).  Levels of mRNA for the α5 subunit were also 
significantly reduced in the cerebral cortex during pregnancy, reaching maximal 
reduction at day 21 (~25% decrease compared to oestrus rats).  Levels of α5 
expression returned to normal following delivery (Follesa et al., 1998).  Coupled 
with these decreases in expression of the γ2L and α5 subunits, muscimol-
induced 36Cl- uptake in the cerebral cortex was significantly reduced at day 19 
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of pregnancy.  In addition, the potentiating effects of allopregnanolone was also 
reduced at day 19 of pregnancy, and only returned to control levels 2 days 
following delivery (Follesa et al., 1998). 
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XV. Neurosteroidal Modulation of Cardiovascular Homeostasis 
The numerous studies described previously show that neurosteroids, 
particularly progesterone and progesterone metabolites, have significant 
potential to modulate the activity of GABAA receptors in the brain.   
Synthesis of hormonal steroids typically takes place in peripheral tissues, 
such as the adrenal gland, liver, ovary, prostate and testis (Normington & 
Russell, 1992).  However, evidence has also shown the 5α-reductase enzyme 
to be present in the brain of humans, monkeys, rabbits, rats, dogs, ferrets, 
guinea pigs and mice; specifically in the hypothalamus, amygdala, midbrain, 
thalamus, hippocampus, cerebellum, cerebral cortex and olfactory tubercle 
(reviewed by Lephart, 1993), suggesting that the brain has the capacity to 
synthesise neuroactive steroids de novo. 
Of interest from this list are the hypothalamus and the midbrain, sites which play 
significant roles in modulating cardiovascular homeostasis through actions of 
the autonomic nervous system.  Given that pregnancy induces alterations in 
cardiovascular homeostasis, mediated in part through changes in autonomic 
control, it is possible to speculate that progesterone metabolite modulation of 
GABAA receptors in these nuclei could play a significant role. 
 Previous evidence has shown that in late term pregnant rats subjected to 
balloon inflation of the right atrium, the normal responses - increased urine 
volume, sodium excretion and potassium excretion - are abolished (Kaufman & 
Deng, 1993).  This is also accompanied by a reduction in the number of c-Fos 
positive neurones in the PVN, medial preoptic area and lateral septum (Deng & 
Kaufman, 1998), suggesting that pregnancy impairs the impact of 
 87 
 
cardiovascular afferents entering regions of the brain known to influence plasma 
volume.  From these experiments however, it was unclear whether the 
alterations were the result of central alterations to afferent input and/or 
alterations in the discharge properties of atrial volume receptors.  In addition, it 
was unclear whether these changes were mediated through progesterone or 
through alternative influences. 
Further experiments have demonstrated that the discharge properties of atrial 
volume receptors are indeed altered during pregnancy.  Two subtypes of 
unmyelinated atrial C-fibres exist, termed low-frequency (LF) and high-
frequency (HiF).  Low-frequency type fibres produce bursts of activity, which is 
independent of the magnitude of the stretch.  Conversely, HiF type fibres fire 
only when subjected to higher degrees of stretch than LF fibres (Hines & 
Hodgson, 2000; Storey & Kaufman, 2004).  Two independent studies have 
concluded that pregnancy impairs the functioning of the HiF type fibre, whist 
conserving LF fibre function (Hines & Hodgson, 2000; Storey & Kaufman, 
2004).  Furthermore, this effect was mimicked in virgin female rats following 
chronic administration (2 days) of pregnan (2-hydroxy-β-cyclodextrin), but not 
acute (10s atrial infusion) pregnan administration (Storey & Kaufman, 2004), 
implying that the pregnancy-induced changes in atrial receptor discharge 
properties are mediated through the chronic increased levels of progesterone. 
One of the main cardiovascular characteristics associated with 
pregnancy is an impairment of the arterial baroreflex.  During pregnancy, the 
baroreflex curve is lowered and the midpoint shifted to the left, meaning that the 
baroreflex operates at a lower set point.  Moreover, the sensitivity (gain) of the 
baroreflex curve at the most linear point is reduced, meaning that smaller 
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perturbations in blood pressure do not elicit as profound change in either heart 
rate or RSNA. Finally, maximal heart rate and RSNA are reduced, suggesting 
that the ability of the sympathetic nervous system to produce a 
sympathoexcitatory response in reaction to a hypotensive challenge is 
attenuated (Figure 17; Masilamani & Heesch, 1997; Brooks et al., 2010b). 
 
 
Figure 17 Pregnancy reduces baroreflex control of heart rate and RSNA in conscious 
rats. Blood pressure was increased and decreased with varying doses of phenylephrine 
and nitroprusside respectively.  Pregnancy resulting in attenuated heart rate and 
sympathoexcitatory responses during baroreceptor unloading (hypotensive) stimuli only.  
Pregnancy also decreased the maximal heart rate, heart rate range and baroreflex gain. 
(Brooks et al., 2010a) 
 
The consequences of the attenuated baroreflex control of blood pressure can 
be profound.  Pregnant women are prone to orthostatic hypotension and have a 
reduced ability to respond to haemorrhage, due to a depressed 
sympathoexcitatory response.  It is estimated that between 11-22% of all 
maternal deaths are due to peripartum haemorrhage (Brooks et al., 2010a).  It 
is not completely clear as to the need for a blunted baroreflex during pregnancy.  
It is possible that it could act as a protective mechanism, preventing 
vasoconstriction in the presence of high blood volume and cardiac output.  
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Moreover, a decreased baroreflex, and the resulting hypotensive condition 
which arises, could prevent blood from being shunted to more low-resistant 
vascular beds, such as the uterine circulation, thereby protecting the maternal-
foetal circulation barrier (Brooks et al, 2010a). 
 
 In the previous section (section 1.XIV), evidence was presented that 
neurosteroids, specifically metabolites of progesterone, have significant 
potential to modulate the physiological characteristics and subunit expression 
levels of GABAA receptors.  The studies examined in section 1.VI show that 
GABA acting at central sites known to regulate efferent sympathetic outflow to 
the cardiovascular system; such as the RVLM and PVN, has profound effects 
on the level of sympathetic output and cardiovascular homeostasis.  It is 
therefore possible to speculate that some of the cardiovascular characteristics 
observed in pregnancy are due to progesterone-mediated modulation of GABAA 
receptors in these brain areas. 
To this effect, autoradiographic analysis of [125I]Progestin and [3H]-oestrodiol 
binding has shown expression of both progesterone and oestrogen nuclear 
receptors in areas of the brain involved in cardiovascular regulation, such as the 
PVN, RVLM and NTS, suggesting these neuroactive hormones have the ability 
to act at the nuclear level, and thus alter gene transcription at these sites 
(Stumpf, 1990).  Furthermore, it has been previously shown that α1 containing 
GABAA receptors have a stronger capacity for modulation than α2 containing 
GABAA receptors (Orchinik et al., 1995).  Analysis of mRNA levels of the α1 and 
α2 subunits of the GABAA receptor in the RVLM of pregnant rats has shown that 
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their relative expression levels are unchanged in late-term pregnancy, 
suggesting that the RVLM retains the capacity for neurosteroidal modulation 
during pregnancy (Foley et al., 2003). 
This data suggests that the RVLM has the capacity for both genomic and non-
genomic modulation by progesterone.  To this effect, intravenous (i.v.) 
administration of allopregnanolone in virgin female rats produces a leftward shift 
in the baroreflex curve after just 15 minutes in SD rats, and 30 minutes in WKY 
rats (Heesch & Rogers, 1995).  Although this particular experiment does not 
conclusively demonstrate that these actions are centrally mediated it is clear 
that progesterone metabolites also have the capacity to perform non-genomic 
modulation of the cardiovascular system, most likely through GABAA receptor 
potentiation, as described earlier. 
To address the question regarding the cardiovascular effects of 
allopregnanolone administration being centrally mediated, Heesch (2011) 
microinjected the active isomer (3α-OH-DHP) into the RVLM of inactin-
anaesthetised virgin female rats.  Fifteen minutes following injection, RSNA had 
significantly decreased from baseline (82 ± 4.4% of control) with no effect on 
blood pressure.  In addition, sympathoexcitatory responses to a hypotensive 
stimulus were attenuated resulting in a downward shift and reduced gain of the 
baroreflex curve, with no alteration of the midpoint (pressure set point).  
Moreover, microinjection of the inactive isomer of allopregnanolone (3β-OH-
DHP) produced no significant effect, suggesting that the alterations observed 
were mediated through the active isomer of allopregnanolone and not a 
consequence of the surgical procedure or anaesthetic (Heesch, 2011). 
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In addition, the results of this experiment show that neurosteroidal hormones, 
which show a significant increase in circulating levels during pregnancy (Longo, 
1983), have the potential to alter cardiovascular parameters at a central level.  
However, the results from the study performed by Heesch (2011) show that 
neurosteroidal modulation of the RVLM does not produce a direct 
representation of the baroreflex curve observed in pregnancy, in which the 
curve is shifted down and to the left, allowing the hypotensive setting to prevail 
(Heesch & Rogers, 1995; Masilamani & Heesch, 1997; Brooks et al., 2010a). 
This therefore suggests that other factors must be important in resetting the 
baroreceptors to operate at a lower set point.  Given the myriad of hormonal 
changes that occur in pregnancy, it is not surprising that a single hormonal 
influence fails to confer all the necessary changes to mimic pregnancy in the 
virgin rat.  Furthermore, given the numerous brain nuclei which govern 
cardiovascular homeostasis, and the localisation of progesterone nuclear 
binding receptors (Stumpf, 1990), coupled with the physiological importance of 
GABAergic inhibition in these areas (discussed in 1.VI), it is also possible to 
suggest that pregnancy-induced modulation of these sites, for example the 
CVLM and PVN, could account for some of the cardiovascular alterations 
observed. 
An interesting observation when studying the baroreflex curve of the pregnant 
rat compared with virgin controls is that the alterations in sympathetic outflow 
are restricted to the hypotensive state, whereby reductions in blood pressure 
are met by an attenuated sympathoexcitation.  When challenged with a 
hypertensive stimulus, the sympathoinhibitory responses are not significantly 
different to virgin controls (Heesch & Rogers, 1995; Masilamani & Heesch, 
 92 
 
1997).  It is well established that the RVLM receives a substantial baroreceptor-
independent inhibition from the CVLM, since lesions of the rostral CVLM (known 
to receive baroreceptor inputs Cravo et al., 1991) in sinoaortically denervated 
rats still results in tonic sympathoinhibition (Cravo & Morrison, 1993).  Given 
that the attenuated sympathetically mediated responses to blood pressure 
fluctuations only manifest when baroreceptors are unloaded (i.e. during 
hypotension), it is possible that the RVLM is under increased baroreceptor-
independent GABAergic inhibition. 
This was acknowledged by Kvochina et al (2007), where the response to 
bilateral bicuculline injection into the RVLM of inactin anaesthetised, sinoaortic 
denervated late-term pregnant rats was measured.  It was observed that the 
sympathoexcitatory and pressor effects following RVLM disinhibition were 
significantly greater in the pregnant compared with non-pregnant controls 
(Kvochina et al., 2007). It is therefore possible that baroreceptor-independent 
inputs in late-term pregnant rats result in greater GABA release, increased 
GABAA receptor expression, GABAA receptor subunit alterations or increased 
GABAergic inputs, most likely originating from the caudal CVLM (Cravo et al., 
1991), which confer the observed increase in GABA-mediated inhibition. 
Of the central sites involved in cardiovascular control, the RVLM is by far 
the most studied in relation to pregnancy.  However, recent studies have also 
examined the role of the PVN in mediating the cardiovascular changes 
characteristic of pregnancy. 
It has long been established that the PVN has a critical role in regulating blood 
volume homeostasis in the rat and rabbit (Lovick & Coote, 1988b; Deering & 
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Coote, 2000; Pyner et al., 2002) and a contested role in blood pressure 
regulation (Kannan et al., 1988; Coote et al., 1998; Guyenet, 2006).  Since 
pregnancy is associated with a 40% increase in blood volume (Atherton et al., 
1982) and a mild reduction in blood pressure, it is sensible to suggest that 
alterations in PVN activity could contribute to these observed cardiovascular 
changes, and perhaps surprising that little work has been undertaken to 
examine the role of the PVN in manifesting these changes. 
Of the work that has examined the PVN in pregnancy; the main focus has been 
on alterations in GABAergic inhibition.  Following unilateral microinjection of 
bicuculline into the PVN, late-term pregnant rats (P21) showed a significant 
sympathoexcitation, pressor and tachycardic response.  However, this response 
was significantly attenuated compared with non-pregnant virgin controls 
(Kvochina et al., 2009; Page et al., 2011).   
Moreover, following unilateral microinjection of bicuculline into the PVN of 
urethane anaesthetised late-term pregnant rats (P20), the heart rate baroreflex 
gain is increased. However this increase is significantly attenuated compared 
with non-pregnant virgin controls (0.9 ± 0.3bpm/mmHg compared with 1.9 ± 
0.2bpm/mmHg; Page et al., 2011).  Furthermore, following blockade of GABAA 
receptors in the PVN of late-term pregnant rats, baroreflex function is only 
slightly elevated, while still remaining depressed compared with virgin controls 
(Figure 18).  This result suggests that during pregnancy, the PVN control of 
baroreflex function is under reduced GABAergic influence, a result which is 
consistent with those of Kvochina et al (2009). 
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Figure 18 Microinjection of bicuculline into the PVN of non-pregnant and pregnant rats 
increases the heart rate baroreflex function and gain.  This was significantly attenuated 
in the pregnant rat. Black lines represent control values. Dashed, grey lines represent 
bicuculline induced alterations in baroreflex (Page et al., 2011) 
 
This evidence for a decreased bicuculline-induced sympathoexcitation in the 
PVN of late-term pregnant rats correlates with the effects of bicuculline 
microinjection into the PVN of SHRs, however the results observed in the SHR 
following microinjection of comparable concentrations of bicuculline into the 
PVN (0.2nmol in Kvochina et al, 2009 compared with 0.15nmol in Li & Pan, 
2007b) were significantly greater.  For example, in the pregnant animal, 
microinjection of 2.0nmol bicuculline resulted in an increase in blood pressure 
by approximately 12mmHg, whereas in the SHR, microinjection of 1.5nmol 
bicuculline resulted in an increase of approximately 25mmHg (Li & Pan, 2007b).  
This discrepancy could be the result of differential methods for determining 
ABP.  Kvochina et al, (2009) used cannulation of the femoral artery, whereas Li 
& Pan (2007a) measured ABP using a non-invasive tail cuff 
sphygmomanometer. Furthermore, these two experiments utilised different 
anaesthetics (Inactin (Kvochina et al., 2009) and α-chloralose and urethane (Li 
& Pan, 2007b)), which could result in the differential response observed.  
Barbiturates, such as inactin, have previously been observed to decrease 
 95 
 
cardiovascular parameters, such as cardiac output and blood pressure in dogs 
(MacCannell, 1969), whereas α-chloralose produces a mild sympathoexcitation, 
but is often preferred due to its non-significant effects on cardiovascular 
parameters (Balis & Monroe, 1964).   This result could however be due to either 
a greater reduction in GABAergic inhibition in the pregnant rat compared with 
the SHR, or greater excitatory input to the PVN in the SHR. 
 
 The mechanisms involved in mediating the sympathoexcitation observed 
in pregnancy are poorly understood; especially given the potent modulatory 
action of neurosteroids on GABAA receptors it would be assumed that this 
would result in a decreased sympathetic drive. 
Indeed, in vitro electrophysiological experiments on PVN slices from 
normotensive, non-pregnant rats show that bath application of the neuroactive 
steroid THDOC significantly decreases the firing rate of PVN-RVLM projecting 
neurones through potentiation of GABAA receptors (Figure 19; Womack et al., 
2006).  This clearly shows that presympathetic neurones within the PVN have 
the capacity to be inhibited by neurosteroids associated with pregnancy, adding 
confusion to the emerging model of increased PVN activity during pregnancy. 
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Figure 19 Action currents recorded from PVN-RVLM projecting neurones following 
application of THDOC (100nM and 1μM indicated by bars).  Application of THDOC 
significantly reduced the firing activity of pre-autonomic neurones within the PVN of non-
pregnant, normotensive rats (Womack et al., 2006). 
 
The reason for the increased sympathetic nerve activity and PVN activity 
observed in late-term pregnant rats could be as a result of increased circulating 
levels of angiotensin II (AngII), which is characteristic of pregnancy (Hanssens 
et al., 1991).  In vitro application of AngII increases the firing rate of PVN-RVLM 
projecting neurones and significantly decreases the presynaptic release of 
GABA (Li & Pan, 2005).  Therefore the increased activity of PVN neurones 
observed in pregnancy could be a result of an AngII-mediated decrease in 
presynaptic GABA release, therefore negating any potentiating effects of 
pregnancy-associated neuroactive steroids on GABAA receptors.  What remains 
unclear is whether this is also associated with a decrease in the expression of 
GABAA receptors.  
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  This was further evidenced when in vivo microinjection of an AT1 
receptor antagonist into the PVN of non-pregnant and late-term pregnant rats 
significantly attenuated bicuculline-induced sympathoexcitation and pressor 
responses (Kvochina et al., 2009).  In the non-pregnant rat, further application 
of the excitatory amino acid antagonist Kyn further reduced the pressor 
response to bicuculline compared with AT1 receptor blockade, however this was 
unchanged in the late-term pregnant rat, such that Kyn application was not 
significantly different to AT1 receptor blockade (Kvochina et al., 2009).  The 
significance of this study is two-fold; firstly AngII, acting via AT1 receptors, 
contributes to the sympathoexcitatory effect of GABAA receptor blockade in the 
PVN of both normotensive and pregnant rats, and secondly; the 
sympathoexcitation observed in pregnancy appears not to be driven by 
excitatory amino acids (i.e. glutamate), but primarily via angiotensin.  This latter 
result is in contrast with the sympathoexcitation observed in hypertension, 
which is heavily governed by glutamatergic inputs in the PVN (Li & Pan, 2007a).  
However this does share a commonality with HF, where AT1 receptor 
expression in the PVN is increased and angiotensin administration into the PVN 
of HF rats produces a potentiated sympathoexcitation compared with sham 
operated controls (Zheng et al., 2009).  This could therefore be an important 
mechanism whereby sympathetic control of blood pressure and blood volume is 
controlled, since both HF and pregnancy are conditions of hypervolaemia 
(Longo, 1983; Remes, 1994) 
 Furthermore, in vitro electrophysiological studies have revealed 
that neurosteroidal application onto PVN-RVLM projecting neurones results in 
an attenuated potentiation of GABAergic inhibition in late-term pregnant rats 
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compared with non-pregnant controls (Heesch et al, unpublished).  This 
suggests that presympathetic neurones in the PVN of late-term pregnant rats 
either have a reduced sensitivity to neurosteroidal modulation, or the expression 
of GABAA receptors is reduced. 
 In conclusion, studies have shown that central control of the 
cardiovascular system plays a key role in mediating the cardiovascular changes 
that are vital to normal gestation in both humans and rodents.  Furthermore, 
many of these alterations are as a result of neurosteroidal modulation of GABAA 
receptors, predominantly mediated through progesterone and its neuroactive 
metabolites, which have been shown to have potent actions on the sympathetic 
nervous system when administered centrally.  The inhibitory role of GABA 
shows both an enhanced functioning; in relation to baroreceptor-insensitive 
neurones of the RVLM, and reduced functioning, in relation to the PVN.  
Furthermore, the sympathoexcitatory effects of GABAA receptor blockade within 
the PVN do not appear to be driven by glutamate; a result which is in contrast 
with the sympathoexcitation observed in hypertension, but do appear to be 
governed by angiotensin II; a trait which is shared with HF.  What remains 
unclear is the mechanism behind this reduced GABAA receptor-mediated 
inhibition in the PVN of pregnant rats. 
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XVI. Aims of Project 
The studies outlined indicate that both hypertension and pregnancy are 
conditions associated with significant increases in sympathetic nerve activity, 
and that the PVN has consistently been shown to contribute to this 
sympathoexcitation.  In addition, the PVN of hypertensive, but not pregnant rats 
has been shown to have increased glutamatergic excitation (Li & Pan, 2007a; Li 
et al., 2008a). However, both pregnancy and hypertension have a demonstrated 
decrease in GABAergic inhibition within the PVN (Li & Pan, 2006, 2007b; 
Kvochina et al., 2009; Page et al., 2011). 
Although this decrease in GABAergic inhibition and increase in 
glutamatergic excitation have been demonstrated electrophysiologically, no 
study has so far identified the molecular mechanism which underpins this 
alteration. 
 We aim to do this by addressing the hypothesis that altered GABA and 
NMDA receptor subunit configurations contribute to the sympathoexcitation 
observed in hypertension and pregnancy.  Given the electrophysiological 
experiments detailed above, we also hypothesise that these alterations will be 
different in nature, and that this may contribute to the chronicity of hypertension 
and the reversibility of the sympathoexcitation observed in pregnancy.  We will 
do this by combining quantitative immunoblotting with immunohistochemistry to 
identify if any of the subunits which comprise the GABAA receptor and NMDA 
receptor show alterations in expression in the PVN of both hypertensive and 
late-term pregnant rats compared with the normotensive, non-pregnant Wistar 
rat.  Furthermore, we aim to identify within which of the parvocellular subnuclei 
of the PVN any alteration occurs; so as to infer whether these alterations could 
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impact on sympathetic outflow. Finally we aim to identify whether any of the 
subunits for which we observe changes in expression are directly associated 
with spinally projecting, presympathetic neurones. 
Any similarities or differences in subunit expression between the three 
physiological states observed from this study will be important in our 
understanding of the molecular mechanisms underpinning the different 
longevities of these two sympathoexcitatory states. Moreover, these changes 
have the potential to become novel therapeutic targets for the treatment of 
hypertension and pregnancy-induced cardiovascular insufficiency. 
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Chapter 2. Methods 
Unless otherwise stated, all solutions used in this chapter are detailed in 
Appendix A 
 
I. Animals 
Experiments were carried out on age-matched (14 week) female Wistar (n=15) 
and spontaneously hypertensive rats (SHR n=15; Harlan Laboratories, Bicester, 
Oxon).  Pregnant Wistar rats (n=15) were mated either by Harlan Laboratories 
or by the Durham University Life Sciences Support Unit (LSSU).  The presence 
of a vaginal plug was deemed day 1 of pregnancy (Masilamani & Heesch, 1997; 
Kvochina et al., 2007, 2009) and animals were sacrificed on day 19.  All animals 
were given ad libitum access to food and water and housed on a 12 hour 
dark:light cycle (8am-8pm). All experiments were approved by the local ethics 
committee and conducted in accordance with the Animals (Scientific 
Procedures) Act 1986 under the PPL 40/3393 held by Dr Susan Pyner and the 
PIL 60/11867 held by the author. 
Wistars were chosen as the control animal due to their closer genetic 
relationship with the SHR than the more commonly used Wistar Kyoto rat 
(WKY).  This is evidenced through both transplant studies, where 
transplantation of skin from WKY to SHR and vice versa resulted in rejection 
(H'Doubler et al., 1991) and behavioural studies, where behaviour of the SHR 
was closer related to the Wistar and SD rat compared with WKY (Sagvolden et 
al., 1993). Furthermore, the incidence of spontaneous hypertension in the WKY 
strain limits their usefulness as a control for the SHR (Louis & Howes, 1990). 
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II. Antibody Production 
Antibodies to the GluN1, GluN2A and GluN2B subunits of the NMDA receptor 
and the 1 and 3 subunits of the GABAA
 receptor were produced in the 
laboratory of Dr Paul Chazot (Durham University), a detailed method of which 
has been previously published (Chazot et al., 1999).  The peptide for GluN1 
corresponded to regions 35-53 of the mouse GluN1 subunit 
(TRKHEQMFREAVNQANKRHC; Chazot et al., 1995), the GluN2A peptide 
corresponded to region 1381-1394 (RCPSDPYKHSLPSQ) of the mouse 
GluN2A N-terminal (Hawkins et al., 1999), the GluN2B peptide corresponded to 
regions 46-60 of the mouse C-domain (DEVAIKDAHEKDDKHC; Chazot & 
Stephenson, 1997a). The GABAAα1 peptide corresponded to region 1-14 of the 
mouse C-terminal (Ives et al, 2002). The GABAAβ3 peptide corresponded to 
regions 345-408 of the N-terminal (Sperk et al, 1997).  
Antibodies to the α2 (amino acids 416-424), α4 (amino acids 379-421), α5 
(amino acids 2-10), β1 (amino acids 350-404) β2 (amino acids 351-405) and δ 
(amino acids 1-44) subunits of the GABAA receptor were produced and kindly 
donated by Prof. Werner Sieghart (Uni. Vienna; Sperk et al, 1997). A detailed 
method of their production has previously been published (Sperk et al, 1997; 
Pirker et al, 2000).  
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III. Preparation of Brain Tissue for Immunohistochemistry 
Rats from each physiological state (i.e. normotensive, SHR and late-term 
pregnancy) were initially anaesthetised with Isoflurane (5% in 6L/min O2).  The 
level of anaesthesia was determined using absence of the pedal withdrawal 
reflex, with anaesthesia maintained at 2.5-3% Isoflurane in 6L/min O2.  An 
abdominal midline incision was made followed by isolation of the aorta from 
surrounding connective tissue.  A thread was placed around the aorta just 
above the iliac bifurcation and securely tied.  Anterior to this thread and just 
posterior to the left renal vasculature, an artery clip was placed on the aorta to 
occlude blood flow.  A further thread was positioned posterior to artery clip, 
which was loosely tied.  An incision was then made midway between the thread 
placed above the iliac bifurcation and artery clip, into which a cannula (Portex 
tubing 200/320/040), containing sodium pentobarbital (Dolethal, 60mg/kg, 
Vetoquinol, Buckingham, UK) was inserted (Figure 20).  This was secured in 
place using the previously placed thread anterior to the incision.  An incision just 
lateral to the midline was then made in the neck and the jugular vein was 
located and cut, as was the right renal vein, to allow the perfusate to flow freely.  
The animal was then perfused with 200ml ice-cold heparinised saline (0.9%) 
followed by 500ml 4% paraformaldehyde in 0.1M phosphate buffer (PB).  Once 
fixation was complete, the whole brain was removed from the skull and placed 
into 4% paraformaldehyde for 24 hours at 4ºC, followed by cryoprotection in 
10% and 20% sucrose. 
Hearts were also taken from each animal by removal from the thoracic cavity, 
weighed and expressed as a percentage of whole animal body weight. 
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Figure 20 Schematic representation of surgical protocol as described in section 2.III.  The 
descending aorta is removed from the surrounding tissue, around which a thread is tied 
dorsal to the iliac bifurcation.  Anterior to this thread and posterior to the renal 
vasculature, an artery clip is placed.  An incision is made midway between the thread and 
artery clip and a cannula inserted through which the perfusate flows. 
  
Arterial Clip 
Thread 
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IV. Measurement of Arterial Blood Pressure 
A subset of rats (Wistar, SHR and pregnant Wistar, n=3 for each) undergoing 
procedure 2.III were used for blood pressure measurements.  An aortic cannula 
was inserted as previously described and through this 1.5ml of anaesthetic 
(75mg/kg α-chloralose & 700mg/kg urethane) was administered.   At this point, 
isoflurane anaesthetic was withdrawn.  Animals were then connected to a blood 
pressure transducer (PowerLab 8/30; ADInstruments, Sydney, Aus.), and blood 
pressure recordings were obtained through LabChart software (version 7).  
Animals then underwent perfusion as detailed in section 2.III. 
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V. Immunohistochemistry of NMDA and GABAA Receptors 
a. Sectioning of Brain Tissue 
 
In order to access the PVN, the frontal lobe of the brain, rostral to the optic 
chiasm was removed using a razor blade, as was the hindbrain and cerebellum.  
Brains were then affixed to a freezing microtome on their coronal plane and 
allowed to fully freeze for around 10-15 minutes.  Once fully frozen, coronal 
sections of 40µm were taken and placed free floating into wells containing 0.1M 
PB.  Successive sections were taken and placed into a separate tray, which 
were then stained with 0.5% cresyl violet for neuroanatomical reference, as 
detailed later. 
 
b. Peroxidase Labelling of NMDA and GABAA Receptor 
Subunits in PVN 
 
After washing with PB, sections were incubated in 3% hydrogen peroxide 
(made in PB) for 5 minutes to quench any remaining endogenous peroxidise 
activity.  This was removed and followed by 5 minute incubation with antigen 
retrieval solution ‘Liberate Antibody Binding Solution’ (L.A.B. Polysciences Inc, 
Philadelphia, USA).  After removing the L.A.B. solution and washing in PB, 
sections were incubated in 0.4% Triton X-100 for 15 minutes, followed by 
blocking solution (0.4% Triton X-100, 10% normal goat serum) for 1 hour.  
Blocking solution was then removed and sections were incubated in primary 
antibody diluted in PB/1% normal serum over night at 4ºC (see Table I for 
concentrations). 
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After incubation, sections were allowed to reach room temperature before 
removal of the primary antibody and washing 3 times for 5 minutes each with 
PB-Tween (0.03% Tween-20 in PB).  Primary antibody was then removed and 
sections were incubated in 1:200 dilution of biotinylated secondary antibody 
(Vector Labs, Peterborough, UK) diluted in PB/1% normal serum for 2 hours at 
room temperature. 
Vectastain ABC Kit (Vector Labs, Peterborough, UK) was prepared following 
the manufacturers recommendations at least 30 minutes before use.  After 
removing the secondary antibody and washing 3x5 minutes in PB-Tween, 
sections were incubated in the ABC solution for 1 hour at room temperature. 
Sections were again washed for 3x5 minutes in PB-Tween before being 
incubated in 0.05% diaminobenzidine (DAB) and 0.0033% hydrogen peroxide 
diluted in PB until an adequate level of staining had been achieved, as 
determined by eye. 
After staining, sections were washed twice in distilled water (dH2O) before being 
mounted onto gelatinised slides and left to dry overnight. 
When dry, slides were dehydrated through increasing concentrations of ethanol 
(70, 95 and 2x 100%) for 4 minutes each, then cleared in xylene for 4 minutes 
before being coverslipped using DPX mountant and left to dry in a fume hood. 
 
c. Cresyl Violet Staining of Serial Sections 
 
Sections which were to be counterstained were mounted onto gelatinised slides 
and left to dry before being stained with Cresyl Violet (0.5% w/v) for 25 minutes, 
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followed by dehydration and clearing through ethanol and xylene (as above).  
Sections were then coverslipped using DPX mountant and left to dry. 
 
d. Table I. Concentration of Primary Antibodies used in 
Immunohistochemistry 
 
 
Antibody 
Concentration 
(μg/ml)/Source 
NMDA 
GluN1 1.0 (Chazot) 
GluN2A 1.0 (Chazot) 
GluN2B 1.5(Chazot) 
GABAA 
α1 1.0 (Chazot) 
α4 2.0 (Sieghart) 
α5 3.0 (Sieghart) 
β3 1.0 (Sieghart) 
Table 1. Only subunits for which a change in expression had been identified through 
Western blotting of whole PVN micropunches were analysed using 
Immunohistochemistry. GABAAα4 and GABAAβ3 were used as counting controls 
 
 
e. Antibody Specificity 
The specificity of GluN1, GluN2A, GluN2B, α1 and β3 antibodies was 
determined at the time of production as detailed in Chazot & Stephenson) 
(1997b).  Briefly, human embryonic kidney cells were transfected with the 
appropriate subunit to which the antibody had been made.  These were then 
 109 
 
subjected to SDS-PAGE.  The presence of a single band at the correct 
molecular weight was deemed specific. 
The specificity of α2, α4, α5, β1, β2 and δ antibodies was determined at the 
time of production as detailed in Pirker et al (2000). Briefly, antibodies were pre-
absorbed with their respective synthetic peptide for 24 hours before being 
subjected to immunohistochemical analysis.  Using this approach, no staining 
was evident. 
Furthermore, the pattern of expression that the antibodies produced when 
utilised for immunohistochemistry was compared with that expected from the 
literature (i.e. discrete staining pattern in the hippocampus and cortex).   
During the current experiments, sections underwent staining in which the 
primary or secondary antibodies had been omitted.  With this regimen, no 
staining was observed.  
 
f. Quantification of Immunohistochemically Stained 
GABAA and NMDA Receptor Subunits 
 
Immunohistochemically stained sections were examined using a Zeiss Axioskop 
2 microscope under bright field illumination for the presence of GABAA and 
NMDA receptor subunits within the PVN.  Digital images were captured using 
either a Hamamatsu Orca 285-CCD camera or Micropublisher 3.3 RTV camera 
controlled by Improvision Volocity software (v 6.0).  The on-screen axis was 
calibrated against a photomicrographed 1mm graticule.  Using this axis a 
150µm x 150μm square was drawn.  This was then placed indiscriminately 
within the anatomical boundaries of the PVN subnuclei, determined by analysis 
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of retrogradely traced CTB-labelled spinally projecting neurones (see Chapter 
2.VI and Chapter 4), corresponding counter stained sections, and the Paxinos 
and Watson (1998) brain atlas. Although selected areas were not completely 
random (i.e. area of interest was not chosen by computer), bias was kept to a 
minimum by not consciously choosing areas with high or low cell densities.  Cell 
counts were then performed using the on-screen counting tool with a numbered 
marker placed over each identified cell (Figure 21).  Cell counts were subjected 
to a one way analysis of variance (ANOVA) test, with Bonferroni post-hoc test 
and are expressed ± SEM. Values with a P value <0.05 were considered 
statistically significant.  No correction was made for double counting. Cells that 
expressed morphological characteristics of a neuron (soma or associated with 
identifiable projections) and were stained darker than background at x200 
magnification were counted.  A second individual, who was both independent 
from and ignorant of the conditions of the experiment counted a subset of 
sections.  Counts obtained from this independent analysis, which were within 
10% of the counts obtained by the original investigator, were deemed to be 
accurate.  Using this regimen, all second counted sections were within 10% of 
those counted by the original investigator. 
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Figure 21 Example of immunohistochemistry quantification.  A square measuring 150μm 
x 150µm was placed randomly on the image and the on-screen counting tool (red 
numbers) used to mark counted neurones within the boundaries of the box. Inset image 
shows a magnified view of the counting area. 
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VI. Identifying Areas of the PVN Containing Spinally Projecting 
Presympathetic Neurones in the PVN 
 
a. Injection of Retrograde Tracers in the IML Region of 
the Spinal Cord 
 
Normotensive female Wistar rats (n=7) were anaesthetised using an 
intraperitoneal injection of medetomindine (0.6mg/kg) and ketamine (30mg/kg) 
made up in 0.9% saline.  Depth of anaesthesia was tested using absence of 
pedal withdrawal reflex.  Once adequate anaesthesia was achieved, the 
animals were fixed into a stereotaxic frame (Stoelting, IL, USA); with heads 
fixed with ear bars for stability.  A midline incision was made between the dorsal 
scapula and the vertebral process of T2 was located.  Using this process as a 
guide, the musculature and soft tissue was dissected away to reveal the dorsal 
surface of the spinal column.  To allow easy access to the spinal cord, a thread 
was inserted through the musculature at T2 and secured to the front of the 
stereotaxic frame and the tail was stretched and secured to the operating table 
with surgical tape.  Using a hypodermic needle, an incision was made in the 
dura mater, and forceps were used to tease this away from the cord. A 33G 
nanofill syringe was then filled with 2µl of either 2% Fluorogold (Fluorochrome 
LLC, USA) or 0.5% Cholera Toxin-B (CTB; List Biologicals, USA) and mounted 
into the micromanipulator.  Fluorogold (n=5) or CTB (n=2) was then slowly 
pressure injected into the IML region of the left spinal cord (300μm lateral to the 
posterior median sulcus, 500μm ventral to the dorsal surface; Figure 22). 
The musculature and skin were then sutured and appropriate analgesic 
(buprenorphine; 0.01ml/100g intramuscular) was given.  To prevent 
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hypothermia, animals were placed into an incubator preheated to 29ºC for 
around 2 hours until the anaesthetic was reversed with atipamezole (Antisedin, 
0.2mg/kg i.p.).  Animals were then left to recover for either 7 days (for 
Fluorogold) or 14 days (for CTB) to allow retrograde transport of the tracer to 
the PVN, until the perfusion protocol detailed in section 2.III was implemented. 
 
 
Figure 22 Schematic representation of T2 region of spinal cord.  Nanofill syringe is 
represented as a line and shows the course through the spinal cord and site of injection 
into the IML region.  Drawing courtesy of Mr J.P. Cork. 
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b. Peroxidase Labelling of CTB-Labelled Presympathetic 
Neurones in the PVN 
 
Peroxidase labelling of CTB-labelled neurones was performed as previously 
published (Llewellyn-Smith et al, 2005). 
Animals that had been subjected to CTB injection in the T2 region of the IML 
were perfused with 4% paraformaldehyde via the descending aorta as 
described in section 2.III.  Whole brains were removed, post-fixed overnight in 
the same fixative and cryoprotected at 4°C in 20% sucrose. 
Brains were sectioned to 40μm on a freezing microtome as described in section 
2.Va; following which sections were placed in wells containing 0.1M PB (pH 
7.4).  Phosphate buffer was removed from the wells and sections were 
incubated in blocking buffer (0.4% Triton X-100, 10% normal horse serum) for 
60 minutes at room temperature.  Blocking buffer was removed and sections 
were incubated in goat anti-CTB (1:200,000 dilution; List Biologicals, USA) 
diluted in PB/1% normal serum for 48 hours at room temperature.  Following 
incubation, primary antibody solution was removed and sections were rinsed 3 x 
5 minutes in PB.  Sections were then incubated with biotinylated donkey anti-
goat secondary antibody (1:500 dilution; Vector Labs, Peterborough UK), 
diluted in PB/1% normal serum overnight at 4°C.  Secondary antibody solution 
was then removed and sections rinsed 3 x 5 minutes in PB, following which 
sections were incubated in ExtrAvidin-HRP (1:1500 dilution, Sigma, St Louis 
MO, USA) for 4 hours at room temperature. Sections were again washed for 
3x5 minutes in PB before being incubated in 0.05% diaminobenzidine (DAB) 
and 0.0033% hydrogen peroxide diluted in PB until an adequate level of 
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staining had been achieved, as determined by eye.  Sections were washed in 
dH2O and mounted onto gelatinised slides.  Once air dried, slides were 
dehydrated by placing through increasing concentrations of ethanol (70%, 95%, 
100%) before being cleared in xylene for 4 minutes.  Slides were then 
coverslipped with DPX mountant and left to dry in a fume hood. 
CTB-labelling was visualised using a Zeiss Axioskop 2 microscope under bright 
field illumination. Digital images were captured using a Micropublisher 3.3 RTV 
camera controlled by Improvision Volocity software (v 6.0).  Images were 
exported to Adobe Photoshop (version CS3), where brightness and contrast 
were adjusted. Neurones were measured using the on-screen measuring tool.  
The pixel size was calibrated using a 1mm graticule and the measuring tool was 
used to measured neurones at their greatest diameter.  
 
c. Identification of Fluorogold-labelled Spinally Projecting 
Neurones and their Co-localisation with GABAA/NMDA 
Receptor Subunits 
 
Animals which had been subjected to Fluorogold injection in the T2 region of 
the IML were perfused with 4% paraformaldehyde via the descending aorta as 
described in section 2.III.  Whole brains were removed, post-fixed overnight in 
the same fixative and cryoprotected at 4°C in 20% sucrose. 
Brains were sectioned to 40μm on a freezing microtome as described in section 
2.Va; following which sections were placed in wells containing 0.1M PB (pH 
7.4).  Phosphate buffer was removed from the wells and sections were 
incubated in blocking buffer (0.4% Triton X-100, 10% normal goat serum) for 60 
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minutes at room temperature.  Blocking buffer was then removed and sections 
were incubated in primary antibodies for either the α1 or α5 subunits of the 
GABAA receptor or the GluN2A subunit of the NMDA receptor (for antibody 
concentrations see Table 2.Vd), diluted in PB/1% normal serum overnight at 
4°C.  Following incubation, primary antibody solution was removed and sections 
were rinsed for 3 x 5 minutes in PB.  Sections were then incubated in a 
fluorescently labelled secondary antibody (Texas Red-labelled goat anti-rabbit; 
1:200 dilution; Jackson Immunoresearch Labs, USA) for 2 hours at room 
temperature.  Following staining, sections were mounted onto gelatinised slides 
and air dried; following which slides were dehydrated through increasing 
concentrations of alcohol (70%, 95% and 100%), before being cleared in 
xylene.  Slides were then coverslipped using DPX mountant and left to air dry in 
a fume hood. 
 
d. Visualisation and Quantification of Fluorescent 
Labelling and 3D rendering of Neurones 
Immunofluorescence was visualised using a Zeiss Axioskop 2 microscope 
equipped for epifluorescence with a motorised filter system. Fluorogold labelled 
neurones were readily detectible by illumination at 350nm. Texas-red labelled 
GABAAα1, GABAAα5 and GluN2A subunits were visualised by excitation at 
594nm. Digital images were captured using a Hamamatsu Orca 285-CCD 
camera controlled by Improvision Volocity software (v 6.0).  Images were 
exported to Adobe Photoshop (version CS3), where brightness and contrast 
were adjusted. 
 117 
 
 Acquisition of 3D rendered neurones was performed as previously 
described (Affleck et al, 2012).  Briefly, a series of z-stack images at 0.3µm 
intervals collected full section thickness images.  The acquired images were 
deconvolved using iterative restoration and the appropriate point spread 
function (PSF).  PSF’s model light behaviour and are based on Volocity 
specified parameters of widefield, numerical aperture, medium refractive index 
and emission wavelength, producing a confocal-like image.  A single neurone of 
interest was cropped from the image and displayed as an isosurface image.  
This generates an opaque image of the surface elements.  In this instance, this 
enables the relationship between Fluorogold and subunit immunoreactivity to be 
observed throughout the entirety of the neurone of interest in a single image. 
 In order to quantify the number of Fluorogold-labelled neurones 
expressing the subunit of interest, the number of Fluorogold-labelled neurones 
was counted per section, per PVN-subnuclei.  The number of Fluorogold-
labelled neurones which showed positive labelling for the subunit of interest was 
then counted in the same plane and expressed as a percentage of total 
Fluorogold-labelled neurones. Cell counts were then subjected to a one-way 
ANOVA test with Bonferroni post-hoc test and expressed ± SEM. Values with a 
P value <0.05 were considered statistically significant 
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VII. Acquisition of Brain Tissue for Western Blotting 
(Micropunches) 
Rats of all physiological states were deeply anaesthetised with isoflurane (5%, 
6L/min O2) before being terminally anaesthetised with an intracardiac injection 
of sodium pentobarbitone.  The dorsal surface of the skull was rapidly removed 
allowing for removal of the whole brain.  This was placed straight into cold 20% 
sucrose before being stored at 4ºC.  Brains were then frozen at between -20 
and -30ºC for 3 minutes in iso-pentane before being stored at -20ºC until 
required. 
 Removing the cerebellum and sectioning the frontal lobe rostral to the 
optic chiasm accessed the region of interest.  The caudal end of the 
remaining section was then mounted to a freezing microtome.  Using the 
Paxinos and Watson (1998) brain atlas, the area of the brain containing the 
PVN was located using the third ventricle and hippocampus as anatomical 
landmarks, and two 600µm sections were taken.  These were then stored at -
20°C until required. 
 Bilateral micropunches from individual animals were taken using a 1-
200µl pipette tip with an external diameter of 750µm and a dissecting 
microscope. Using the Paxinos & Watson (1998) brain atlas, the location of the 
PVN was lateral to the dorsal point of the third ventricle (Figures 23-24). 
Bilateral punches were then transferred to 70µl sample buffer containing 1:100 
dilution of protease inhibitor cocktail type III (Calbiochem, Germany), vigorously 
vortexed for 10 minutes to solubilise protein and then frozen at -20ºC. 
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Figure 23 Photomicrograph of coronal section through rat brain showing location of PVN 
micropunches.  The PVN was located using a brain atlas (Paxinos & Watson, 1998) and 
was determined to lie at the lateral aspect of the dorsal point of the 3rd ventricle (Shaded 
black in Figure 24). Scale = 3mm, 3V = 3rd ventricle 
 
 
  
3V 
PVN 
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VIII. Isolation of Cortex Tissue 
In order to ascertain whether any changes in NMDA or GABAA receptor subunit 
expression observed in the PVN were specific to this region, the level of protein 
expression for these subunits was analysed from cortex tissue from the same 
animals.   
Following removal of the PVN; as detailed in section 2.VII, the cortex was 
removed from the same brain sections using a razor blade to detach the cortex 
dorsal to the corpus callosum (Figure 24).  These were homogenised using a 
glass-glass dounce (VWR, PA USA) in homogenisation buffer (50mM Tris base, 
5mM EDTA, 5mM EGTA, 150μM protease inhibitor cocktail (Calbiochem, 
Nottingham UK), pH 7.4), following which a Lowry assay was performed to 
assess protein concentrations. 
 
Figure 24 Schematic of brain slice through the PVN region, showing the area removed 
from the cortex and PVN.  Unilateral regions are shown; however bilateral regions were 
removed from tissue. Schematic corresponds to the same level observed in Figure 23. 
Paxinos & Watson, 1998. 
Cortex 
PVN 
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IX. Lowry Assay 
A Lowry protein assay was performed on cortex samples as previously 
described (Lowry et al., 1951).  A protein standard was prepared using bovine 
serum albumin (BSA) from 0-100mg/ml diluted in dH2O. Furthermore 5μl and 
10μl aliquots of homogenised cortex sample were taken.  All samples (standard 
and cortex) were made up in triplicate.  Reagent D was prepared by combining 
100ml Reagent A (2% Na2CO3; 0.1M NaOH; 0.5% SDS) to 1ml Reagent B (2% 
Na K Tartrate) and 1ml Reagent C (1% CuSO4, 10% trichloroacetic acid).  0.5ml 
Reagent D was added to each sample, vortexed and left for 10 minutes.  
Following this, 50μl folin (1:1 dilution with dH2O) was added to each solution, 
vortexed and left for 30 minutes in dark.  0.5ml dH2O was then added to each 
sample, vortexed thoroughly and the absorbance read at 770nm using a 
Genova spectrophotometer (Jenway, Dunmow UK).  Absorbance readings from 
the protein standards were plotted on a standard curve, which was used to 
determine the protein concentrations of the cortex samples. 
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X. Quantitative Immunoblotting of PVN and Cortex 
Homogenates 
a. Sample Preparation 
 
PVN homogenates, as obtained in section 2.VII, were separated into 10µl 
aliquots.  Cortex homogenates were separated into 10μl aliquots.  Added to this 
was 2µl dithiothreitol (DTT) and 3µl dH2O to bring the total loading volume to 
15µl.  Samples were then briefly centrifuged (Microcentrifuge 5415R, 
Eppendorf, Germany) at 13000rpm and heated to 95°C for 5 minutes, before 
being centrifuged again at 13000rpm and vortexed thoroughly. 
 
b. Quantitative Immunoblotting of PVN and Cortex 
Homogenates for NMDA and GABAA Receptor Subunits 
PVN and cortex homogenates, as prepared in 2.VIIIa were subjected to SDS-
PAGE as previously described (Bradford et al., 2005). Briefly, loading wells 
were formed in a 6.5% SDS-PAGE stacking gel, which was set above a 10% 
acrylamide gel.  Gels were inserted into a Hoefer Mighty small II SE260 vertical 
slab gel electrophoresis tank (Hoefer, Germany) and filled with electrode buffer.  
Samples were loaded in nine out of ten wells; the final well was loaded with a 
pre-stained standard (10-250kDa; Sigma St Louis, MO USA). 
Electrophoresis was conducted at 180mV and 15mA until the sample buffer-
stained protein front was at the bottom of the gel.  The gel was removed from 
the tank and transferred to nitrocellulose (Fisher Scientific, Hampton UK) using 
a Hoefer TE series transfer unit (Hoefer, Germany), set to 50V, <200mA for 2-
2.5 hours in transfer buffer. 
 123 
 
The nitrocellulose was removed from the transfer tank and incubated in blocking 
buffer (5% (w/v) skimmed milk powder, 0.2% Tween-20, made up in tris-
buffered saline (TBS)) for at least 1 hour at room temperature, or overnight at 
4°C.  Primary antibodies were diluted in incubation solution (2.5% (w/v) 
skimmed milk powder, made up in TBS) and incubated at 4°C overnight (see 
Table II for concentrations). 
Nitrocellulose blots were moved back to room temperature and a series of 4 x 6 
minute washes was implemented using wash buffer (2.5% (w/v) skimmed milk 
powder, 0.2% Tween-20 made up in TBS), followed by secondary antibody 
incubation (1:2000 dilution in incubation buffer; Fisher Scientific, Hampton UK) 
for 1 hour at room temperature.  A further set of 4 x 6 minute washes was 
implemented after which the blot was stored in TBS to remove any excess wash 
buffer. 
The nitrocellulose was then incubated with luminol solution (Solution A:Solution 
B 1:1 (Solution A = 100mM Tris-base pH8.5, 25mM luminol, 396μM p-
Courmaric acid. Solution B = 100mM Tris-base pH8.5, 6.27mM H2O2)) for 1 
minute and exposed to ECF hyperfilm (Amersham) at differing exposure times.  
The hyperfilm was developed manually using Kodak GBX fixer and developer 
solutions. 
Nitrocellulose was then incubated again in blocking solution for 1 hour at room 
temperature, followed by overnight incubation in mouse anti-β-actin (1:3000; 
Sigma, St Louis MO) at 4°C.  This was then removed and 4x6 minute washes 
were implemented, followed by incubation in HRP linked anti-mouse secondary 
(1:2000; Fisher Scientific, Hampton UK) antibody for 1 hour at room 
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temperature.  This was then removed and further 4x6 minute washes were 
implemented.  Nitrocellulose blots were then developed as described above. 
 
c. Protein Expression Quantification 
 
Exposed hyperfilm were scanned (Dell, USA) into a desktop PC and analysed 
using ImageJ (NIH).  Optical density of each band was analysed and 
normalised against β-actin and background levels. Values were subjected to a 
one-way ANOVA with Bonferroni post-hoc test and expressed ± SEM. Values 
with a P value <0.05 were considered statistically significant. In blots where a 
second band appeared in addition to the band at the expected molecular 
weight, the density of the second band was also measured.  The density of both 
bands was then averaged to produce the final value.  These second bands 
were often believed to be the result of glycosylation or degradation of the 
original protein of interest. 
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d. Table II. Primary Antibody Concentrations Used in 
Quantitative Immunoblotting 
 
  
 Antibody Concentration (μg/ml) 
NMDA 
GluN1 1.0 
GluN2A 1.0 
GluN2B 1.5 
GABA 
α1 1.0 
α2 1.0 
α5 1.0 
β1 1.0 
β2 0.5 
β3 1.0 
δ 3.0 
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Chapter 3. Physiological Parameters of Animals Used 
 
I. Animal Weights 
A total of 50 animals were used in this study.  Female Wistar control rats (n = 
20) weighed 199 ± 2g (range 186 - 215g), female spontaneously hypertensive 
rats (SHR, n = 15) weighed 178 ± 2g (range 160 - 198g) and pregnant Wistars 
weighed 299 ± 7g (range 262 - 330g, n = 15). Pregnant rats had 10 ± 0.7 (range 
6 - 14) foetuses weighing 2.1 ± 0.15g (range 1.2 - 3.2g), placing them between 
P19 and P20 (Schneidereit, 1985). 
 
II. Blood Pressure 
Female SHR’s had a significantly higher blood pressure (150 ± 5mmHg; range 
140 – 160mmHg) than both Wistar control (72 ± 5mmHg; range 65 – 83mmHg) 
and late-term pregnant rats (90 ± 2mmHg; range 85 – 95mmHg).  Late term 
pregnant rats also had a slight but significantly higher mean arterial blood 
pressure than non-pregnant controls (P<0.05; Figure 25). 
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Figure 25 Mean arterial blood pressure of non-pregnant Wistar control, female SHR and 
late-term pregnant rats, measured by intra-aortic cannula.  SHRs had a significantly 
higher blood pressure than both Wistar (P<0.001) and Pregnant (P<0.001) rats.  Pregnant 
Wistars also had a slightly higher BP than non-pregnant (P<0.05). n = 3 for each 
biological group. 
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III. Heart Weights 
SHR’s had a significantly higher heart weight/body weight ratio (1.05 ± 0.06%; 
range 0.9 – 1.2%) than both normotensive (0.68 ± 0.05%; range 0.6 – 0.7%; 
P<0.01) and pregnant (0.57 ± 0.04%; range 0.5 – 0.6%; P<0.001) Wistars 
(Figure 26).  The heart weight/body weight ratio of the pregnant rat was not 
significantly different to that of the non-pregnant Wistar. 
 
 
Figure 26 Heart weights expressed as percentage of overall body weight. SHR had a 
significantly higher Heart weight/body weight than both normotensive (P<0.01) and 
pregnant (P<0.001) Wistars. N = 7 for each biological group.  
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Chapter 4. CTB Labelling of Spinally Projecting Neurones 
I. Introduction 
The distribution of spinally projecting neurones within the PVN has been 
extensively studied before (Swanson et al, 1980; Strack et al, 1989; Ranson et 
al, 1998; Pyner & Coote, 2000; Oldfield et al, 2001).  However, these studies 
have largely been carried out on male SD rats, with little or no information on 
the distribution of spinally projecting neurones in the female Wistar rat. 
This study aims to assess whether changes in the expression of specific 
GABAA and NMDA receptor subunits are associated with changes in the 
expression of immunoreactive cells in parvocellular subnuclei of the PVN.  It is 
therefore important to assess whether the anatomical boundaries of 
parvocellular subnuclei described previously in other species of rat match those 
observed in the female Wistar rat.  
The aim of this chapter was to map the distribution of spinally projecting 
neurones in the PVN of the female Wistar rat, and to identify subnuclei 
boundaries to assist in later cell count analysis. 
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II. Identification of spinally projecting neurones from the PVN of 
the female Wistar rat 
CTB injection into the T2 region of the spinal cord of two normotensive female 
Wistar rats labelled 1090 ± 92 (range 998 – 1182) neurones throughout the 
rostrocaudal extent of the PVN.  CTB injection into the spinal cord labelled 
neurones in five distinct nuclei in the ipsilateral PVN (Figure 27) with a small 
amount of labelling present in the contralateral PVN. 
Labelling was confined to the PVN, with no identifiable neurones present in 
other hypothalamic nuclei (Figure 27 Ai-Ci). 
Spinally projecting neurones were mainly located in the mid- to caudal levels of 
the PVN (Bregma -1.80mm to -2.12mm) and showed both somatic and 
projection labelling. 
PVN-IML projecting neurones were found in the anterior parvocellular (A), 
dorsal cap and ventral parvocellular (B), medial and posterior parvocellular 
subnuclei (C).  The somata of neurones in the anterior, medial, dorsal cap and 
ventral parvocellular regions were similar in size (23.33 ± 0.87μm; range 19.8 – 
26.9μm), but significantly smaller than those in the posterior parvocellular 
subnucleus (45.85 ± 3.02μm; range 40.5 – 54.5μm; P<0.0001) when measured 
at their greatest diameter.  Some labelled neurones were observed in 
magnocellular subnuclei, as has previously been reported (Pyner & Coote, 
2000; Oldfield et al, 2001). 
CTB-labelling was present in both soma (indicated by * on inset images of 
Figure 27 Ai-Ci) and projections (indicated by arrow head on inset images of 
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Figure 27) in all subnuclei.  Neurones in the posterior parvocellular subnuclei 
had a flattened appearance and were orientated such that the apical points of 
the soma were lying horizontal to the vertical midline (Figure 27 Ci plus inset).  
Neurones in the remaining parvocellular subnuclei had no such level of 
organisation (Figure 27 Ai/Bi).  
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Figure 27 Photomicrographs of CTB-labelled spinally projecting PVN neurones (Ai-Ci) 
and corresponding Cresyl violet stained countersections (Aii-Cii).  Inset images show 
magnified views of highlighted neurones. Arrowheads = labelled projections, * = labelled 
soma.  PaAP = Anterior Parvocellular; PaAM = Anterior Magnocellular PaDC = Dorsal 
Cap; PaVP = Ventral Parvocellular; PaLM = Lateral Magnocellular; PaMP = Medial 
Parvocellular; PaPO = Posterior Parvocellular; 3V = 3
rd
 Ventricle. Scale Bar = 200μm 
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Chapter 5. Localisation of NMDA Receptor Subunits in the 
PVN 
I. Introduction 
Electrophysiological studies in normotensive rats have shown that application of 
glutamate into the PVN consistently increases sympathetic outflow, heart rate 
and blood pressure (Li et al., 2006).  In addition, endogenous glutamate 
appears to be heavily inhibited by GABAergic inhibitory networks under 
normotensive conditions (Chen et al., 2003; Li et al., 2006). 
Studies examining the role of the PVN in the aetiology of hypertension have 
identified that glutamatergic activity appears to be increased.  To this effect, 
application of NMDA directly onto PVN-IML projecting neurones in vitro 
produces a greater inward current in SHR rats than in age matched WKY 
controls (Li et al., 2008a).  Furthermore, antagonism of NMDA receptors in the 
PVN of SHR significantly decreased LSNA, ABP and HR; a response, which 
was not observed in age matched WKY controls. 
In vitro electrophysiological studies have identified that the GluN2A subunit of 
the NMDA receptor appears to be up-regulated in the PVN of male SHR 
compared to age matched WKY controls (Ye et al., 2012b).  This up-regulation 
of the GluN2A subunit was also observed to contribute to the 
sympathoexcitation observed in these animals and normalisation of GluN2A 
levels returned NMDA receptor currents to control levels (Ye et al., 2012b). 
Pregnancy is a physiological condition that has also been shown to display 
increased sympathetic outflow controlled in part from the PVN (Kvochina et al., 
2009; Page et al., 2011).  However blockade of NMDA receptors in the PVN of 
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late-term pregnant rats did not significantly decrease the level of sympathetic 
outflow compared to when AT1 receptors alone were blocked, suggesting that 
NMDA receptors do not play a significant role in mediating the 
sympathoexcitation observed in pregnancy (Kvochina et al., 2009). 
The aim of this chapter was to identify whether the increase in GluN2A subunit 
expression observed in the PVN of the male SHR were also observed in the 
PVN of female SHRs, as well as identifying whether pregnancy was associated 
with any molecular changes in NMDA receptor subunit expression.  
Furthermore, this was combined with immunohistochemical identification of the 
distribution and quantification of cell immunoreactivity to assess within which 
subnuclei of the PVN any of the identified changes occurred. 
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II. Determination of NMDA Receptor Subunit Expression by 
Quantitative Immunoblotting 
 
a. PVN 
 
Expression levels of NMDA subunits in the PVN were analysed from PVN 
micropunches from non-pregnant normotensive Wistar rats, 14 week old SHR 
and late-term pregnant Wistar rats as described in section 2.X.  The level of 
GluN1 subunit expression was not significantly changed in either normotensive, 
SHR or pregnant rats (Figure 28). There was a slight, but non-significant 
decrease in expression of the GluN2A subunit in the late-term pregnant rat 
compared with Wistar controls (Figure 29); however there was an 85 ± 23% 
increase in expression in the SHR (Figure 29). There was also a significant 
increase in GluN2B expression in the PVN of late-term pregnant rats compared 
with normotensive and SHR (fig. 30), but no significant change observed in the 
SHR compared with normotensive controls. 
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Figure 28 Expression of the GluN1 subunit of the NMDA receptor in the PVN of 
normotensive, SHR and late-term pregnant rats, expressed as a percentage relative to 
the Wistar control value.  Analysis shows no significant change in expression between 
any of the physiological states. Whole brain homogenate from normotensive Wistar rats 
was probed to act as a positive control. WB = Whole brain, W = Wistar, H = SHR, P = 
Pregnant. N = 6 biological replicates. Molecular weight of GluN1 band = 120kDa. 
Molecular weight of β-actin band = 42kDa 
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Figure 29 Expression of the GluN2A subunit of the NMDA receptor in the PVN of 
normotensive controls, SHR and late-term pregnant Wistar rats, expressed as a 
percentage relative to Wistar. Analysis shows a significant increase in expression in the 
SHR compared to both normotensive (P<0.05) and late-term pregnant (P<0.05) rats. W = 
Wistar, H = SHR, P = Pregnant. N=7 biological replicates. Molecular weight of GluN2A 
band = 170kDa. Molecular weight of β-actin band = 42kDa. 
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Figure 30 Expression of the GluN2B subunit of the NMDA receptor in the PVN of 
normotensive controls, SHR and late-term pregnant rats, expressed as a percentage 
relative to Wistar. Analysis shows a significant increase in expression in the pregnant rat 
compared with normotensive, non-pregnant (P<0.05) and SHR (P<0.05). W = Wistar, H = 
SHR, P = Pregnant. N = 3 biological replicates. The lower band of the GluN2B subunit blot 
represents the expected molecular weight of the GluN2B subunit (166kDa). The higher 
band represents the expected molecular weight of the phosphorylated GluN2B subunit 
(180kDa). For this reason, the density of both bands was measured. The molecular 
weight of the β-actin band was 42kDa. 
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b. GluN2A Levels in Cortex 
To identify whether the increase in GluN2A subunit expression observed in the 
SHR was specific to the PVN, the level of GluN2A expression was measured 
from samples of cortex taken from the same animals.  The level of GluN2A 
subunit expression in the cortex of SHR and pregnant Wistars was significantly 
decreased compared with normotensive Wistars (37±0.5% and 47±6.5% 
decrease respectively; Figure 31). 
Western blotting of the GluN2A subunit in the cortex revealed a second, smaller 
band with a molecular weight of around 140kDa.  This band is believed to be a 
proteolytic fragment possibly caused by the serine protease plasmin (Yuan et 
al, 2009).  We hypothesise that this was not observed in the PVN due to the 
potentially lower protein expression observed. 
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Figure 31 Expression of GluN2A subunit expression in the cortex of normotensive 
controls, SHR and late-term pregnant rats; expressed as a percentage relative to 
normotensive controls.  Analysis shows a significant reduction in expression in both 
SHR (P<0.01) and late-term pregnant rats (P<0.01) relative to normotensive controls. W = 
Wistar, H = SHR, P = Pregnant. N = 3 biological replicates. The higher band on the 
GluN2A subunit blot represents the expected molecular weight of the GluN2A subunit 
(170kDa). The lower band is believed to be a proteolytic fragment with a molecular weight 
of around 140kDa. For this reason the density of both bands were measured. 
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III. NMDA Receptor Subunit Expression Revealed by 
Immunohistochemical Analysis 
Cells immunoreactive (IR) for the GluN1, -2A and -2B subunits of the NMDA 
receptor were found throughout the rostrocaudal extent of the PVN and within 
all five parvocellular subnuclei in normotensive (Figure 32), SHR (Figure 33) 
and late-term pregnant rats (Figure 34). 
 
a. GluN1 
GluN1 immunoreactivity was confined to the soma of neurones with no 
projections labelled (Figures 31-33 B,D,F).  Cells in the anterior (Figures 31-33 
A/B), medial, ventral and dorsal (Figures 32-34 C/D) subnuclei showed dark 
uniform staining (an example of which is identified by * in images B & D of 
Figure 32-34), whereas labelling in cells of the posterior subnucleus was 
confined to the lateral edges of each cell (an example of which is identified by 
an ‡ in image F of Figure 32-34). 
GluN1-IR cells within the posterior subnucleus have a flattened appearance and 
are orientated in the same plane, such that their apical points are lying 
horizontally to the vertical midline.  GluN1-IR cells within the subsequent four 
parvocellular subnuclei appear to have no such level of organised orientation. 
Semi-quantitative analysis of immunohistochemical staining of the GluN1 
subunit showed the highest density of GluN1-IR cells were located in the dorsal 
cap region in both normotensive (23 ± 1.8; range 20-26) and late-term pregnant 
rats (22 ± 2.6; range 17 – 26) Figure 35).  SHR showed a higher proportion of 
GluN1 staining in the ventral parvocellular subnuclei (24 ± 2; range 20 – 26; 
 142 
 
Figure 35), although there was no statistically significant difference between any 
of the subnuclei.  No significant change in expression was found in any 
subnuclei of the PVN between normotensive and SHR or late-term pregnant 
rats.  A small but significant reduction was observed between SHR and late-
term pregnant rats in the medial parvocellular subnuclei (SHR = 21.6 ± 0.8; 
range 20 – 24. Late-term pregnancy = 16 ± 1.8; range 14 – 18), but this was not 
significant when compared against normotensive controls (Figure 35). 
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Figure 32 Photomicrographs showing expression of the GluN1 subunit throughout the 
rostrocaudal extent of the PVN of normotensive rats. Neurones immunoreactive for 
GluN1 (GluN1-IR) were found in the anterior (A-B), medial, ventral, dorsal cap (C-D) and 
posterior (E-F) parvocellular subdivisions. Neurones show somatic labelling (arrows) 
with no identifiable projections observed. Somatic labelling was mainly observed around 
the periphery of each neurone in the posterior (F) subnuclei. Neurones in the anterior 
(A/B) medial, ventral and dorsal cap subnuclei (C/D) show full-somatic labelling with no 
apparent anatomical bias. Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. * = example of 
neurone showing uniform staining throughout soma. ‡ = example of neurone showing 
staining confined to lateral aspects of soma. Arrows = example of identified neurones 
  
* 
* 
‡ 
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Figure 33 Photomicrographs showing expression of the GluN1 subunit throughout the 
rostrocaudal extent of the PVN of SHR. Neurones immunoreactive for GluN1 (GluN1-IR) 
were found in the anterior (A-B), medial, ventral, dorsal cap (C-D) and posterior (E-F) 
parvocellular subdivisions. Neurones show somatic labelling (arrows) with no 
identifiable projections observed. Somatic labelling was mainly confined to the periphery 
of each neurone in all subnuclei. Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. * = example of 
neurone showing uniform staining throughout soma. ‡ = example of neurone showing 
staining confined to lateral aspects of soma. Arrows = example of identified neurones 
200μm 30μm 
* 
* 
‡ 
 145 
 
 
Figure 34 Photomicrographs showing expression of the GluN1 subunit throughout the 
rostrocaudal extent of the PVN of late-term pregnant rats. Neurones immunoreactive for 
GluN1 (GluN1-IR) were found in the anterior (A-B), medial, ventral, dorsal cap (C-D) and 
posterior (E-F) parvocellular subdivisions. Neurones show somatic labelling (arrows) 
with no identifiable projections observed. Somatic labelling was mainly confined to the 
periphery of each neurone in all subnuclei. Boxed regions in A, C & E represent images 
B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. * = 
example of neurone showing uniform staining throughout soma. ‡ = example of neurone 
showing staining confined to lateral aspects of soma. Arrows = example of identified 
neurones 
* 
* 
‡ 
 146 
 
  
 
Figure 35 Mean GluN1-IR cells per 150μm
 
x 150μm in the five-parvocellular subnuclei of 
the PVN in normotensive, SHR and late-term pregnant rats.  Analysis shows no 
significant change in GluN1 subunit expression in either hypertension or late-term 
pregnancy compared with normotensive controls.  A small, but significant decrease in 
expression was noted between SHR and late-term pregnancy in the PaMP.  The highest 
density of staining was observed in the dorsal cap in both non-pregnant and late-term 
pregnant rats and the ventral parvocellular subnuclei in the SHR. Abbr. = PaAP = Anterior 
Parvocellular, PaMP = Medial Parvocellular, PaVP = Ventral Parvocellular, PaDC = Dorsal  
Cap, PaPO = Posterior Parvocellular. Values are ± SEM. Significance Values: * = P<0.05. 
N=4 biological replicates for each subnucleus. 
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b. GluN2A 
Cells which were immunoreactive for the GluN2A subunit of the NMDA receptor 
were found throughout the rostrocaudal extent of the PVN and in all subnuclei 
for each physiological state (Figures 36-38).  Both somatic (indicated by * in 
Figures 36-38) and projection labelling (identified by arrowhead in Figures 36-
38) was identified throughout all five parvocellular subnuclei. 
Neurones in all parvocellular subnuclei had uniform staining throughout the 
soma, with no apparent anatomical bias observed (Figures 36-38 B/D/F).  
GluN2A-IR cells within the posterior subnucleus have a flattened appearance 
and are orientated in the same plane, such that their apical points are lying 
horizontally to the vertical midline (Figure 36-38 F).  GluN2A-IR cells within the 
subsequent four parvocellular subnuclei appear to have no such level of 
organised orientation (Figure 36-38 B/D). 
Semi-quantitative analysis of GluN2A-IR cells shows the highest proportion to 
be within the dorsal cap region of the normotensive animal (37 ± 1.3; range 35 – 
39), and the anterior and ventral parvocellular subnuclei of the late-term 
pregnant rat (AP = 35 ± 2.8; range 28 – 45. VP = 35 ± 2.8; range 32 – 41).  
There was no statistical significance in any of the parvocellular subnuclei 
between non-pregnant and pregnant rats.  Conversely however, GluN2A-IR 
staining was significantly increased in the medial (48 ± 2.8; range 45 – 54. 32 ± 
7.8% increase compared with control), dorsal cap (45 ± 1.7; range 42 – 48. 19 ± 
4% increase compared with control) and posterior (37.5 ± 2.5; range 35 – 40. 57 
± 10% increase compared with control) parvocellular regions in the SHR (Figure 
39). 
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Figure 36 Photomicrographs showing expression of the GluN2A subunit throughout the 
rostrocaudal extent of the PVN of normotensive rats. GluN2A-IR neurones were found in 
the anterior (A-B), medial, ventral, dorsal cap (C-D) and posterior (E-F) parvocellular 
subdivisions. Neurones show both somatic labelling (arrows) and projection labelling 
(arrowheads).  Somatic labelling was confined to the periphery in a subset of neurones in 
all subnuclei, however the majority of neurones in the medial, ventral and dorsal cap (D), 
as well as some in the anterior (A) and posterior (F) show uniform labelling with no 
apparent sub-cellular bias. Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F.  * = example of 
neurone showing uniform staining throughout soma. Arrows = example of identified 
neurones 
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Figure 37 Photomicrograph showing expression of the GluN2A subunit throughout the 
rostrocaudal extent of the PVN of the SHR. GluN2A-IR neurones were found in the 
anterior (A-B), medial, ventral, dorsal cap (C-D) and posterior (E-F) parvocellular 
subdivisions.  Neurones show predominantly somatic labelling (arrows) with a few 
labelled projections (arrowheads).  All subnuclei display neurones which show staining 
localised to the periphery of the cell as well as neurones that show uniform cell labelling 
throughout the soma. Boxed regions in A, C & E refer to the magnified areas in B, D & F 
respectively. 3V = 3
rd
 ventricle. Scale bar in A refers to C & E also. Scale bar in B refers to 
D & F also. * = example of neurone showing uniform staining throughout soma. Arrows = 
example of identified neurones 
* 
* 
* 
* 
* 
* 
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Figure 38 Photomicrographs showing expression of the GluN2A subunit throughout the 
rostrocaudal extent of the PVN of late-term pregnant rats. GluN2A-IR neurones were 
found in the anterior (A-B), medial, ventral, dorsal cap (C-D) and posterior (E-F) 
parvocellular subdivisions. Neurones show both somatic (arrows) and projection 
labelling (arrowheads). All subnuclei display neurones where labelling is confined to the 
periphery of the cell as well as neurones where labelling is uniform throughout. Boxed 
regions in A, C & E represent images B, D & F respectively. 3V = 3rd ventricle. Scale bar 
200μm A, C & E. 30μm B, D & F. * = example of neurone showing uniform staining 
throughout soma.  Arrows = example of identified neurones 
* 
* 
* 
 151 
 
 
 
Figure 39 Mean number of GluN2A-IR cells per 150μm
 
x 150μm in each subnuclei of the 
PVN in normotensive, SHR and late-term pregnant rats.  A significant increase in 
expression was observed in the PaMP, PaDC and PaPO in the SHR compared with both 
normotensive and late-term pregnant rats.. Abbr: PaAP = Anterior Parvocellular, PaMP = 
Medial Parvocellular, PaVP = Ventral Parvocellular, PaDC = Dorsal Cap, PaPO = Posterior 
Parvocellular. Values are ± SEM. Significance values: * = P<0.05, ** = P<0.01. N=4 
biological replicates for each subnucleus. 
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c. GluN2B 
GluN2B subunits were found throughout the rostrocaudal extent of the PVN and 
in each subnucleus (Figure 40-42 A-F). GluN2B subunits were present in 
parvocellular subdivisions of the PVN; however they appeared to be more 
prominent in the magnocellular subdivisions, where immunoreactive cells were 
larger and stained darker (Figure 42 C). A proportion of cells in the ventral 
parvocellular subnuclei appear to have magnocellular morphology.  However 
retrograde tracing methods (Chapter 4), have shown there to be the presence 
of spinally-projecting cells within this area.  For this reason, all immunoreactive 
cells within this region have been counted. 
GluN2B-IR stained cells were generally somatic in morphology (identified by * in 
Figures 40-42, with no projections observed.  Staining appeared uniform in the 
anterior, medial, ventral and dorsal cap (Figure 40-42 B/D), with staining 
appearing to be confined to the lateral edges of each cell in the posterior 
subnucleus (Figure 40-42 F). 
GluN2B-IR cells within the posterior subnucleus have a flattened appearance 
and are orientated in the same plane, such that their apical points are lying 
horizontally to the vertical midline (Figure 40-42 F).  GluN2B-IR cells within the 
subsequent four parvocellular subnuclei appear to have no such level of 
organised orientation (Figure 40-42 B/D). 
Semi-quantitative analysis of GluN2B-IR cells showed no significant change in 
expression amongst any of the parvocellular subnuclei in either normotensive 
non-pregnant, SHR or late-term pregnant rats (Figure 43).  Analysis shows that 
the highest degree of GluN2B-IR cells are located in the anterior (Wistar = 21 ± 
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1.7; range 18 – 24. SHR = 22 ± 1.3; range 17 – 24. Pregnant = 22 ± 1.7; range 
20 – 26) and ventral (Wistar = 27 ± 5; range 20 – 38. SHR = 22 ± 0.5; range 22 
– 23. Pregnant = 26 ± 0.5; range 26 – 27) parvocellular subnuclei in all three 
physiological states (Figure 43). 
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Figure 40 Photomicrographs showing expression of the GluN2B subunit throughout the 
rostrocaudal extent of the PVN of normotensive rats. GluN2B-IR neurones were found in 
the anterior (A-B), medial, ventral, dorsal cap (C-D) and posterior (E-F) parvocellular 
subdivisions. Neurones show somatic labelling only (arrows). In all subnuclei, staining 
was almost exclusively confined to the peripheral edge of the cell. Boxed regions in A, C 
& E represent images B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 
30μm B, D & F. 
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Figure 41 Photomicrographs showing expression of the GluN2B subunit throughout the 
rostrocaudal extent of the PVN of SHR. GluN2B-IR neurones were found in the anterior 
(A-B), medial, ventral, dorsal cap (C-D) and posterior (E-F) parvocellular subdivisions. 
Neurones show somatic labelling only (arrows). In all subnuclei, staining was almost 
exclusively confined to the peripheral edge of the cell. Boxed regions in A, C & E 
represent images B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 
30μm B, D & F. 
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Figure 42 Photomicrographs showing expression of the GluN2B subunit throughout the 
rostrocaudal extent of the PVN of late-term pregnant rats. GluN2B-IR neurones were 
found in the anterior (A-B), medial, ventral, dorsal cap (C-D) and posterior (E-F) 
parvocellular subdivisions. Neurones show both somatic labelling (arrows), with no 
projections observed. Labelling in neurones located in the posterior parvocellular 
subnuclei (E/F) was confined to the periphery of the cell. In all other subnuclei, staining 
was uniform throughout the soma. Staining in magnocellular subnuclei was darker and 
more dense than in parvocellular subnuclei. Boxed regions in A, C & E represent images 
B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. 
 
 157 
 
 
Figure 43 Mean number of GluN2B-IR cells per 150μm
 
x 150μm in each subnuclei of the 
PVN in normotensive, SHR and late-term pregnant rats.  No significant change in 
expression was observed across any of the subnuclei in either of the physiological 
states, in accordance with Western blot analysis. Abbr: PaAP = Anterior Parvocellular, 
PaMP = Medial Parvocellular, PaVP = Ventral Parvocellular, PaDC = Dorsal Cap, PaPO = 
Posterior Parvocellular. Values are ± SEM. N=4 biological replicates for each subnucleus. 
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Chapter 6. Localisation of GABAA Receptors in the PVN 
I. Introduction 
Around half of all synapses in the hypothalamus are GABAergic (Decavel & Van 
den Pol, 1990).  Multiple in vivo electrophysiological studies have shown that 
microinjection of GABA or GABAA receptor agonists into the PVN of 
normotensive rats produces profound depressor, bradycardic and 
sympathoinhibitory effects (Li & Pan, 2007b; Wang et al., 2009).  Furthermore, 
in vitro electrophysiological studies have shown that application of GABAA 
receptor antagonists dose dependently increases the firing activity of 
presympathetic neurones in the PVN (Li & Pan, 2006). 
Both in vivo and in vitro electrophysiological studies have been utilised to 
explore the role of GABA and GABAA receptors in the PVN in the aetiology of 
sympathoexcitation in hypertension and pregnancy. 
Studies in the SHR have revealed that microinjection of GABA or GABAA 
receptor agonists produce a blunted (Li & Pan, 2007b) or exaggerated (Allen, 
2002; Akine et al., 2003) sympathoinhibitory, depressor and bradycardic effect.  
In vitro electrophysiological studies however have shown that application of 
GABA onto PVN-RVLM projecting neurones produced a significantly blunted 
peak amplitude of GABA current compared with normotensive WKY and SD 
controls (Li & Pan, 2006). 
Seldom work has been carried out to explore the role of the PVN in contributing 
to the sympathoexcitation observed in late-term pregnant rats.  However of the 
work performed, blockade of GABAA receptors with the antagonist bicuculline 
produced significantly attenuated sympathoexcitatory, pressor and tachycardic 
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effects compared with non-pregnant controls (Kvochina et al., 2009; Page et al., 
2011). 
Given that both hypertension and late-term pregnancy appear to be associated 
with decreased GABAergic inhibition in the PVN, the purpose of this chapter 
was to examine whether these electrophysiological changes were associated 
with changes in the expression of specific GABAA receptor subunits.  
Furthermore, this was combined with immunohistochemical identification of 
GABAA receptor subunits to assess within which subnuclei of the PVN these 
changes occurred. 
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II. Determination of GABAA Receptor Subunit Expression by 
Quantitative Immunoblotting 
 
a. PVN 
 
Expression levels of the GABAA α1, α2, α5, β1, β2 and β3 subunits were 
analysed from bilateral whole PVN micropunches acquired from normotensive 
Wistar, SHR and late-term pregnant rats, as described in 2.X. 
Expression of the α1 subunit was significantly reduced in both SHR (48 ± 6.5%; 
P<0.01) and late-term pregnant rats (43 ± 1.2%; P<0.01) compared with 
normotensive Wistars (Figure 44). 
Expression of the α5 subunit was significantly reduced in both SHR (97 ± 2% 
decrease; P<0.001) and late-term pregnant rats (38 ± 8% decrease; P<0.05) 
compared to normotensive Wistar controls (Figure 46). 
The expression of the α2 (Figure 45), β1 (Figure 47), β2 (Figure 48) and β3 
(Figure 49) subunits was not significantly altered in the PVN of SHR or late-term 
pregnant rats compared with Wistar controls (P>0.05).   
Quantitative immunoblotting failed to reveal any expression of the δ-subunit in 
normotensive, SHR and late-term pregnant rats (results not shown). 
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Figure 44 Expression of the GABAA α1 subunit in the PVN of normotensive, SHR and 
late-term pregnant rats expressed as a percentage relative to Wistar.  Expression is 48 ± 
6.5% lower in the SHR than Wistar controls (P<0.01). Expression is 43 ± 1.2% lower in the 
late-term pregnant rat compared with Wistar control (P<0.01). W = Wistar, H = SHR, P = 
Pregnant. n =3 biological replicates 
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Figure 45 Expression of the GABAA α2 subunit in the PVN of normotensive, SHR and 
late-term pregnant rats expressed as a percentage relative to Wistar.  Probing of PVN 
tissue with anti-α2 antibody produced two bands; only the top band was analysed.  
Analysis shows no significant change in expression between either SHR or late-term 
pregnant rats and Wistar controls (P>0.05). W = Wistar, H = SHR, P = Pregnant. n = 3 
biological replicates. In the GABAAα2 blot, the higher band represents the expected 
molecular weight of the GABAAα2 subunit (51kDa). The identity of the lower band, with a 
molecular weight of around 45kDa was unknown, and for this reason was not analysed. 
  
W H P 
α2 
β-actin 
58kDa 
48kDa 
48kDa 
36kDa 
 163 
 
 
 
 
 
Figure 46 Expression of the GABAA α5 subunit in the PVN of normotensive, SHR and 
late-term pregnant rats expressed as a percentage relative to Wistar.  Expression was 97 
± 2% lower in SHR compared with Wistar controls (P<0.001).  Expression in the late-term 
pregnant rat was 38 ± 8% compared with Wistar controls (P<0.05). W = Wistar, H = SHR, P 
= Pregnant. n = 6 biological replicates 
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Figure 47 Expression of the GABAA β1 subunit in the PVN of normotensive, SHR and 
late-term pregnant rats expressed as a percentage relative to Wistar.  Analysis shows no 
significant change in expression between either SHR or late-term pregnant rats 
compared with Wistar controls (P>0.05). W = Wistar, H = SHR, P = Pregnant. n = 3 
biological replicates 
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Figure 48 Expression of the GABAA β2 subunit in the PVN of normotensive, SHR and 
late-term pregnant rats expressed as a percentage relative to Wistar.  Analysis shows no 
significant change in expression between either SHR or late-term pregnant rats 
compared with Wistar controls (P>0.05). W = Wistar, H = SHR, P = Pregnant. n = 3 
biological replicates 
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Figure 49 Expression of the GABAA β3 subunit in the PVN of normotensive, SHR and 
late-term pregnant rats expressed as a percentage relative to Wistar.  Analysis shows no 
significant change in expression between either SHR or late-term pregnant rats 
compared with Wistar controls (P>0.05). W = Wistar, H = SHR, P = Pregnant. n = 3 
biological replicates 
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b. Cortex 
Expression of the α1 subunit in the cortex was not significantly different 
between SHR and late-term pregnant rats compared with Wistar controls 
(Figure 50).  Expression of the α5 subunit was significantly reduced in the 
cortex of SHR (65 ± 10% decrease; P<0.01) and late-term pregnant rat (71 ± 
3.5% decrease; P<0.01) compared with Wistar control (Figure 51).  The 
percentage decrease in α5 expression observed in the cortex of the SHR was 
significant compared to the PVN (P<0.05).  There was no significant difference 
between the decrease in expression observed in the cortex and PVN of the late-
term pregnant rat (P>0.05). 
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Figure 50 GABAA α1 expression in the cortex of Wistar, SHR and late-term pregnant rats 
expressed as a percentage of Wistar control.  Analysis shows no significant change in 
expression between any state (P>0.05). W = Wistar, H = SHR, P = Pregnant. n = 3 
biological replicates 
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Figure 51 GABAA α5 expression in the cortex of Wistar, SHR and late-term pregnant rats, 
expressed as a relative percentage of Wistar.  Analysis shows a significant decrease in 
expression in the cortex of SHR (P<0.01) and late-term pregnant rats (P<0.01). W = 
Wistar, H = SHR, P = Pregnant. n = 3 biological replicates 
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III. GABAA Receptor Subunit Expression Revealed by 
Immunohistochemical Analysis 
Cells immunoreactive for α1 (Figures 52, 54, 55), α4 (Figures 56, 58, 59), α5 
(Figures 60, 62, 63) and β3 (Figures 64, 66, 67) were found throughout the 
rostrocaudal extent of the PVN of normotensive and late-term pregnant rats.  
Expression of the α1 (Figures 53, 55), α4 (Figures 57, 59) and β3 (Figures 65, 
67) subunit was observed throughout the rostrocaudal extent of the SHR, but 
there was no evidence of staining for the α5 subunit (Figure 61, 63). 
 
a. GABAAα1 
GABAAα1 immunoreactivity had a somatic morphology (identified by arrows in 
Figures 52-54), with no observable projections (Figure 54-55).  Neurones 
appeared round and uniform in staining with little variation in morphology or size 
(16.19 ± 0.8µm).  It is possible that this is labelling of the cell nucleus, since no 
nucleus can be identified in these neurones.  However, previous studies using 
this antibody have proven its specificity by subjecting HEK cells both positive 
and negative for the GABAAα1 subunit to SDS-PAGE. Using this regimen, no 
staining appeared in HEK-ve cells and a single band with the expected 
molecular weight was observed in HEK+ve cells (Chazot & Stephenson, 
1997b). 
Semi-quantitative analysis of α1-immunoreactive cells showed the 
highest density of staining to be in the anterior parvocellular subnucleus of the 
normotensive (98 ± 2.5; range 93 – 106) and SHR (117 ± 10.5; range 107 – 
128) and ventral parvocellular subnucleus of the late-term pregnant rat (70 ± 2; 
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range 65 – 74). However, there was no significant change in expression in any 
parvocellular subnuclei of the SHR compared with normotensive controls 
(Figure 55).  However α1-IR was significantly decreased in the anterior (66 ± 
2.3; range 59 – 70. 34 ± 2% decrease compared with non-pregnant controls), 
medial (72 ± 3; range 67 – 80. 19 ± 3% decrease compared with non-pregnant 
controls), ventral (70 ± 2; range 65 – 74. 26 ± 5% decrease compared to 
normotensive Wistar) and posterior (44 ± 5; range 36 – 55. 39 ± 7% decrease 
compared with non-pregnant controls) parvocellular subdivisions of the late-
term pregnant rat compared with non-pregnant controls (Figure 55). 
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Figure 52 Photomicrographs showing expression of the α1 subunit throughout the 
rostrocaudal extent of the PVN of normotensive Wistar rats. Neurones immunoreactive 
for α1 (α1-IR) were found in the anterior (A-B), ventral, dorsal cap (C-D), medial and 
posterior (E-F) parvocellular subdivisions. Neurones show somatic labelling (arrows) 
with no identifiable projections observed. Somatic labelling was uniform throughout 
each neurone in all subnuclei. Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. 
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Figure 53 Photomicrographs showing expression of the α1 subunit throughout the 
rostrocaudal extent of the PVN of SHR. Neurones immunoreactive for α1 (α1-IR) were 
found in the anterior (A-B), ventral, dorsal cap (C-D), medial and posterior (E-F) 
parvocellular subdivisions. Neurones show somatic labelling (arrows) with no 
identifiable projections observed. Somatic labelling was uniform throughout each 
neurone in all subnuclei. No significant difference in cell number was observed in any 
parvocellular subnuclei compared with normotensive Wistars. Boxed regions in A, C & E 
represent images B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 
30μm B, D & F. 
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Figure 54 Photomicrographs showing expression of the α1 subunit throughout the 
rostrocaudal extent of the PVN of late-term pregnant Wistar rats. Neurones 
immunoreactive for α1 (α1-IR) were found in the anterior (A-B), ventral, dorsal cap (C-D), 
medial and posterior (E-F) parvocellular subdivisions. Neurones show somatic labelling 
(arrows) with no identifiable projections observed. Somatic labelling was uniform 
throughout each neurone in all subnuclei. A significant decrease in cell number was 
observed in the anterior, medial, ventral, dorsal cap and posterior parvocellular 
subnuclei compared with non-pregnant Wistars. Boxed regions in A, C & E represent 
images B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & 
F. 
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Figure 55 Mean number of α1-IR cells per 150μm
 
x 150μm in each subnucleus of the PVN 
in normotensive, SHR and late-term pregnant rats. No significant change in cell number 
was observed between SHR and normotensive Wistar in any parvocellular subnuclei.  A 
significant decrease in expression was observed in the anterior, medial, ventral and 
posterior parvocellular subnuclei of the late-term pregnant rat compared with non-
pregnant Wistar and SHR. Abbr: PaAP = Anterior Parvocellular, PaMP = Medial 
Parvocellular, PaVP = Ventral Parvocellular, PaDC = Dorsal Cap, PaPO = Posterior 
Parvocellular. Values are ± SEM. * = P<0.05; ** = P<0.01. N=4 biological replicates for 
each subnucleus. 
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b. GABAAα4 
Cells immunoreactive for the α4 subunit of the GABAA receptor were found 
throughout the rostrocaudal extent of the PVN and in all parvocellular subnuclei 
of Wistar (Figure 56), SHR (Figure 57) and late-term pregnant (Figure 58) rats. 
Staining was confined to the soma (identified with arrows in Figures 56-58), with 
no projections observed.  Qualitative analysis shows that in late-term pregnant 
rats, the density of staining was increased in the periventricular area of the 
anterior parvocellular subnucleus (Figure 58 A). 
The somata of neurones immunoreactive for the α4 subunit were significantly 
larger than those stained for the α1, α5 and β3 subunit, measured at their 
longest axis (α1 = 16.19 ± 0.8μm; α4 = 24.13 ± 2.4μm; α5 = 16.51 ± 0.6μm; β3 = 
15.56 ± 1.1μm). 
In all physiological states, α4-IR neurones in the posterior parvocellular 
subnucleus had a flattened appearance and were orientated in the same plane, 
such that their apical points were lying horizontal to the vertical midline (Figure 
56-58 F).  Cells in the subsequent four parvocellular subnuclei had no such 
level of orientation (Figure 56-58 B/D).  Furthermore, in the non-pregnant, 
normotensive Wistar rat staining within cells of the posterior parvocellular 
subnucleus was confined to the lateral edges (identified by ‡ in Figure 56F); 
whereas staining in other parvocellular subnuclei was more uniform throughout 
the cell (identified by arrows in Figure 56 B/D).  No such pattern of staining was 
observed in the posterior subnucleus of the SHR or late-term pregnant rat 
(Figure 57-58 F).  The highest degree of staining was observed in the medial 
parvocellular subnucleus for the normotensive Wistar (26 ± 4; range 19 – 38) 
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and late-term pregnant rat (20 ± 2.6; range 14 – 27) and the ventral 
parvocellular subnucleus for the SHR (24 ± 4.3; range 17 – 32).  However there 
was no significant difference between any parvocellular subnuclei between any 
of the different physiological states (Figure 59). 
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Figure 56 Photomicrographs showing expression of the α4 subunit throughout the 
rostrocaudal extent of the PVN of Wistar rats. Neurones immunoreactive for α4 (α4-IR) 
were found in the anterior (A-B), ventral, dorsal cap (C-D), medial and posterior (E-F) 
parvocellular subdivisions. Neurones show somatic labelling (arrows) with few 
identifiable projections observed. Somatic labelling was uniform throughout each 
neurone in the mid- to rostral levels. In the posterior parvocellular subnuclei, staining 
was somatic with few projections; however the somatic staining was confined to the 
periphery of each neurone. Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. ‡ = example of 
neurone were staining is confined to lateral edges. Darker stained patches on Figure A-B 
are non-specific artefacts and were not considered when acquiring data. 
‡ ‡ 
A B 
C D 
F G 
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Figure 57 Photomicrographs showing expression of the α4 subunit throughout the 
rostrocaudal extent of the PVN of SHR. Neurones immunoreactive for α4 (α4-IR) were 
found in the anterior (A-B), ventral, dorsal cap (C-D), medial and posterior (E-F) 
parvocellular subdivisions. Neurones show somatic labelling (arrows) with no 
identifiable projections observed. Somatic labelling was uniform throughout each 
neurone in the mid- to rostral levels. In the posterior parvocellular subnuclei, staining 
was somatic with few projections; however the somatic staining was confined to the 
periphery of each neurone. No significant change in expression was observed between 
SHR and normotensive Wistar. Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. Arrows 
represent examples of immunoreactive neurones. 
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Figure 58 Photomicrographs showing expression of the α4 subunit throughout the 
rostrocaudal extent of the PVN of late-term pregnant Wistar rats. Neurones 
immunoreactive for α4 (α4-IR) were found in the anterior (A-B), ventral, dorsal cap (C-D), 
medial and posterior (E-F) parvocellular subdivisions. Neurones show somatic labelling 
(arrows) with few identifiable projections observed. Somatic labelling was uniform 
throughout each neurone in all subnuclei. Qualitative analysis suggests α4-IR neurones 
showed a higher level of expression in the periventricular area.  Boxed regions in A, C & 
E represent images B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 
30μm B, D & F.  Arrows represent examples of immunoreactive neurones. 
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Figure 59 Mean number of α4-IR cells per 150μm x 150µm in each subnucleus of the PVN 
in normotensive, SHR and late-term pregnant rats. No significant change in cell number 
was observed between any physiological state. Abbr: PaAP = Anterior Parvocellular, 
PaMP = Medial Parvocellular, PaVP = Ventral Parvocellular, PaDC = Dorsal Cap, PaPO = 
Posterior Parvocellular. Values are ± SEM. N=4 biological replicates for each subnucleus. 
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c. GABAAα5 
Cells immunoreactive for the α5 subunit of the GABAA receptor were found 
throughout the rostrocaudal extent of the PVN of normotensive and late-term 
pregnant rats (Figure 60 & 62).  No expression was observed in any 
parvocellular subnuclei of the SHR PVN (Figure 61).  Furthermore, late-term 
pregnancy was associated with a significant decrease in α5-IR neurones in the 
medial (12 ± 1.2; range 11 – 15. 56 ± 4% decrease compared to non-pregnant 
controls), ventral (12 ± 0.6; range 11 – 13. 60 ± 2% decrease compared to non-
pregnant controls) and dorsal cap (12 ± 1.4; range 10 – 15. 52 ± 6% decrease 
compared to non-pregnant controls) parvocellular regions of the PVN (Figure 
63).  There was a slight but non-significant decrease in the number of α5-IR 
neurones in the anterior subnucleus (14 ± 2.3; range 10 – 18. 30 ± 12% 
decrease) compared with non-pregnant Wistars (Figure 63). There was no 
significant difference in the number of α5-IR neurones in the posterior 
parvocellular subnucleus in the late-term pregnant rat compared with 
normotensive controls (31 ± 1.5 α5-IR neurones/150μm2 (range 29 – 34) vs. 
29.5 ± 0.5 α5-IR neurones/150μm2 (range 29 – 30) respectively; Figure 63).   
Qualitative analysis of α5-IR neurones in the PVN of late-term pregnant rat’s 
shows that the density of staining is reduced compared with non-pregnant 
Wistars (Figure 60 & 62).  This appears more prominent in mid- to rostral levels 
of the PVN (Figure 60 & 62 D/F). 
Cells immunoreactive for the α5 subunit in non-pregnant, normotensive and 
late-term pregnant rats showed somatic labelling with no obvious projections 
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observed.  Staining was uniform in density in all parvocellular subnuclei 
(illustrated by arrows in Figure 60 & 62 B/D/F). 
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Figure 60 Photomicrographs showing expression of the α5 subunit throughout the 
rostrocaudal extent of the PVN of Wistar rats. Neurones immunoreactive for α5 (α5-IR) 
were found in the anterior (A-B), ventral, dorsal cap (C-D), medial and posterior (E-F) 
parvocellular subdivisions. Neurones show somatic labelling (arrows) with no 
identifiable projections observed. Somatic labelling was uniform throughout each 
neurone in all subnuclei.  Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. Darker stained 
patches on Figure A-D are non-specific artefacts and were not considered when 
acquiring data. 
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Figure 61 Photomicrographs showing expression of the α5 subunit throughout the 
rostrocaudal extent of the PVN of SHR. No identifiable neurones were observed in any of 
the parvocellular subnuclei.  Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. 
 
 
3V 
3V 
3V 
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Figure 62 Photomicrographs showing expression of the α5 subunit throughout the 
rostrocaudal extent of the PVN of late-term pregnant Wistar rats. Neurones 
immunoreactive for α5 (α5-IR) were found in the anterior (A-B), ventral, dorsal cap (C-D), 
medial and posterior (E-F) parvocellular subdivisions. Neurones show somatic labelling 
(arrows) with no identifiable projections observed. Somatic labelling was uniform 
throughout each neurone in all subnuclei. Qualitative analysis suggests that the staining 
density was reduced in α5-IR neurones compared with non-pregnant Wistar rats.  Boxed 
regions in A, C & E represent images B, D & F respectively. 3V = 3rd ventricle. Scale bar 
200μm A, C & E. 30μm B, D & F. 
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Figure 63 Mean number of α5-IR cells per 150μm x 150µm in each subnucleus of the PVN 
in normotensive, SHR and late-term pregnant rats. A significant decrease in the number 
of α5-IR neurones was observed in all parvocellular subnuclei of the PVN.  Furthermore, 
a significant decrease in the number of α5-IR neurones was observed in the medial, 
ventral, dorsal cap and posterior parvocellular subnuclei of the PVN in the late-term 
pregnant rat.  A slight but non-significant decrease was observed in the anterior 
parvocellular subnucleus of the late-term pregnant rat.  Interestingly, there was no 
change in the number of α5-IR neurones in the posterior subnucleus in the late-term 
pregnant rat. Abbr: PaAP = Anterior Parvocellular, PaMP = Medial Parvocellular, PaVP = 
Ventral Parvocellular, PaDC = Dorsal Cap, PaPO = Posterior Parvocellular. Values are ± 
SEM. N=4 biological replicates for each subnucleus. 
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d. GABAAβ3 
Cells immunoreactive for the β3 subunit of the GABAA receptor were found 
throughout the rostrocaudal extent of the PVN and in all parvocellular subnuclei 
in the Wistar (Figure 64), SHR (Figure 65) and late-term pregnant rat (Figure 
66). 
GABAAβ3-IR neurones had a somatic morphology with no evidence of 
projection labelling.  Staining density appeared uniform throughout the neurone 
(illustrated by arrows in Figures 64-66 B/D/F). Neurones appeared round and 
uniform in staining with little variation in morphology or size (16.19 ± 0.8µm).  It 
is possible that this is labelling of the cell nucleus, since no nucleus can be 
identified in these neurones.  However, previous studies using this antibody 
have proven its specificity by subjecting HEK cells both positive and negative 
for the GABAAα1 subunit to SDS-PAGE. Using this regimen, no staining 
appeared in HEK-ve cells and a single band with the expected molecular weight 
was observed in HEK+ve cells (Chazot & Stephenson, 1997b). 
In all physiological states, neurones within the posterior subnucleus had a 
flattened appearance and were orientated in the same plane; such that their 
apical points were lying horizontal to the vertical midline (Figures 64-66 F).  
Neurones in the remaining four parvocellular subnuclei had no such level of 
orientation (Figures 64-66 B/D). 
Semi-quantitative analysis shows the highest density of staining to be in the 
anterior parvocellular subnucleus of the normotensive Wistar (91 ± 3.3; range 
85 – 104); medial parvocellular subnucleus of the SHR (100 ± 0.5; range 100 – 
101) and ventral parvocellular subnucleus of the late-term pregnant rat (89 ± 
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2.9; range 81 – 94).  However, no significant change in the number of β3-IR 
neurones was observed in any parvocellular subnuclei between any of the 
physiological states (Figure 67).  
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Figure 64 Photomicrographs showing expression of the β3 subunit throughout the 
rostrocaudal extent of the PVN of Wistar rats. Neurones immunoreactive for β3 (β3-IR) 
were found in the anterior (A-B), ventral, dorsal cap (C-D), medial and posterior (E-F) 
parvocellular subdivisions. Neurones show somatic labelling (arrows) with no 
identifiable projections observed. Somatic labelling was uniform throughout each 
neurone in all subnuclei.  Boxed regions in A, C & E represent images B, D & F 
respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. 
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Figure 65 Photomicrographs showing expression of the β3 subunit throughout the 
rostrocaudal extent of the PVN of SHR. Neurones immunoreactive for β3 (β3-IR) were 
found in the anterior (A-B), ventral, dorsal cap (C-D), medial and posterior (E-F) 
parvocellular subdivisions. Neurones show somatic labelling (arrows) with no 
identifiable projections observed. Somatic labelling was uniform throughout each 
neurone in all subnuclei.  No significant change in β3-IR neurones was observed 
between SHR and normotensive Wistar.  Boxed regions in A, C & E represent images B, 
D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 30μm B, D & F. 
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Figure 66 Photomicrographs showing expression of the β3 subunit throughout the 
rostrocaudal extent of the PVN of late-term pregnant Wistar. Neurones immunoreactive 
for β3 (β3-IR) were found in the anterior (A-B), ventral, dorsal cap (C-D), medial and 
posterior (E-F) parvocellular subdivisions. Neurones show somatic labelling (arrows) 
with no identifiable projections observed. Somatic labelling was uniform throughout 
each neurone in all subnuclei.  No significant change in β3-IR neurones was observed 
between late-term pregnant rat and non-pregnant Wistar.  Boxed regions in A, C & E 
represent images B, D & F respectively. 3V = 3rd ventricle. Scale bar 200μm A, C & E. 
30μm B, D & F. 
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Figure 67 Mean number of β3-IR cells per 150μm x 150µm in each subnucleus of the PVN 
in normotensive, SHR and late-term pregnant rats. No significant change in cell number 
was observed between any state. Abbr: PaAP = Anterior Parvocellular, PaMP = Medial 
Parvocellular, PaVP = Ventral Parvocellular, PaDC = Dorsal Cap, PaPO = Posterior 
Parvocellular. Values are ± SEM. N=4 biological replicates for each subnucleus. 
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IV. Summary of Changes Observed in the Number of 
Immunoreactive Cells in the PVN of Hypertensive and 
Pregnant Rats 
The results presented in the previous two chapters detail the changes in 
expression of specific GABAA and NMDA receptor subunits in the PVN of 
hypertensive and late-term pregnant rats. 
Hypertension was associated with a significant decrease in the number of α5-IR 
neurones in all five parvocellular subnuclei (Figure 68; black circles) as well as 
a significant increase in the number of GluN2A-IR neurones in the dorsal cap, 
medial and posterior parvocellular subnuclei of the PVN (Figure 68; red 
squares).  Concomitant changes were also observed in the dorsal cap, medial 
and posterior subnuclei of the PVN (Figure 68). 
Late-term pregnancy was associated with a significant decrease in the number 
of α1-IR neurones in the anterior, ventral, medial and posterior parvocellular 
subnuclei (Figure 69; red triangles) as well as a significant decrease in the 
number of α5-IR neurones in the dorsal cap, ventral and medial parvocellular 
subnuclei (Figure 69; black circles).  Concomitant decreases were therefore 
observed in the ventral and medial parvocellular subnuclei of the PVN (Figure 
69). 
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Chapter 7. Co-localisation of GABAA and NMDA Receptors 
with Presympathetic Spinally Projecting PVN  
Neurones 
 
I. Introduction 
It is reasonable to suggest that the most direct way for GABA and glutamate to 
exert their effects on sympathetic outflow from the PVN is to synapse directly 
onto presympathetic neurones.  A significant population of presympathetic 
neurones emanating from the PVN and known to influence cardiovascular 
homeostasis project to the IML region of the spinal cord (Pyner & Coote, 2000), 
and are one of the final sites for modulation of sympathetic outflows (Ranson et 
al., 1998). 
 Electron microscopic analysis has revealed that glutamate makes direct 
synaptic contact onto parvocellular neurones of the PVN (van den Pol, 1991). 
However this study did not ascertain the nature of these parvocellular neurones 
(i.e. whether they were interneurone or presympathetic neurone).  Furthermore, 
glutamate was used to identify the synapse, and so the identity of the 
postsynaptic receptor to which glutamate in these synapses targets remains 
unclear. 
Electrophysiological studies have revealed that PVN-IML projecting neurones 
are responsive to pharmacological modulation of GABAA and NMDA receptors 
(Li et al., 2008a; Han et al., 2010).  Interestingly blockade of GABAA receptors 
with bicuculline failed to significantly alter the firing rate of the majority of PVN-
IML neurones; suggesting that most of these neurones are unresponsive to 
GABA acting through GABAA receptors (Han et al., 2010). 
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 What remains unclear from these studies is the identity of the subunits, 
which compose the GABAA and NMDA receptors that this population of 
neurones express.  The purpose of this chapter was to assess whether the 
subunits for which changes have been observed in this thesis (Chapters 5 & 6) 
were directly associated with PVN-IML projecting neurones in the normotensive 
rat.  
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II. Results 
a. GABAAα1 
Fluorogold (FG) labelling was present in the somata of the spinally projecting 
neurones as well as projections arising from the somata (Figure 70 A & A’). An 
isosurface view (indirect rendering) selected from a 3D opacity image, revealed 
GABAAα1 immunofluorescence to be encapsulating cytoplasmic labelled FG 
fluorescence.  This suggests that GABAAα1 immunofluorescence is potentially 
membrane bound. 
Cells immunoreactive for the GABAAα1 subunit were found throughout the 
rostrocaudal extent of the PVN with an identical pattern of staining to that 
described in Chapter 6.III.a. 
Quantitative analysis of the number of FG positive (FG+ve) neurones 
expressing the GABAAα1 subunit revealed 55.15 ± 2.5% (range 41 - 74%) of the 
FG+ve neurones were also positive for the GABAAα1 subunit.  The highest 
proportion of double labelled neurones were observed in the posterior 
parvocellular subnuclei (59.5 ± 7.2%; range 43 – 74%) and the lowest 
proportion found in the anterior parvocellular subnuclei (50.25 ± 4.2%; range 41 
– 58%; Figure 71).   Fluorogold positive neurones that were not immunoreactive 
for the GABAAα1 subunit were often lying in close apposition to GABAAα1+ve 
neurones (Figure 70 C’ inset).   
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Figure 70 Photomicrographs showing relationship between spinally projecting PVN 
neurones and the GABAAα1 subunit in the normotensive, non-pregnant Wistar.  
Neurones labelled with FG (FG+ve) were found throughout the rostrocaudal extent of the 
PVN (A).  The pattern of GABAAα1 (GABAAα1+ve) staining was as described previously 
(Chapter 6.III.a) for the PVN.  Quantitative analysis shows 55.15 ± 2.5% of FG neurones 
express the GABAAα1 subunit (large arrows A’-C’). FG+ve neurones that did not express 
the GABAAα1 subunit lay in close apposition to FG-ve/GABAAα1+ve neurones (inset 
image C’). Isosurface rendering view revealed the GABAAα1 subunit to surround the FG 
labelled spinally projecting neurones (A’’-C’’). Scale bars: A-C = 100μm, A’-C’ = 30μm, A’’-
C’’ = 2.7μm
2
. 3V = 3
rd
 ventricle. PaDC = Dorsal Cap, PaMP = Medial Parvocellular, PaVP = 
Ventral Parvocellular, PaPM = Posterior Magnocellular. Orientation Marker for 3D 
rendered image - D = Dorsal, V = Ventral, L = Lateral. n = 5 biological replicates 
 
 
 
 
 
Figure 71 Quantitative analysis of the relationship between FG+ve neurones and 
GABAAα1+ve neurones in the five parvocellular subnuclei of the PVN, expressed as a 
percentage of total FG neurones immunoreactive for GABAAα1.  Analysis reveals a mean 
total of 55.15 ± 2.5% of FG+ve neurones to be immunopositive for GABAAα1, with no 
statistical difference observed between individual subnuclei. n = 5 biological replicates 
for each subnuclei 
  
Percentage of Cells Immunoreactive for FG and GABAAα1 
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b. GABAAα5 
Cells immunoreactive for the GABAAα5 subunit were found throughout the 
rostrocaudal extent of the PVN with an identical pattern of staining to that 
described in Chapter 6.III.c. 
Immunoreactivity for the GABAAα5 subunit was confined to the somata (Figure 
72 B – B’), in contrast to FG labelling which was observed in both soma and 
projections (Figure 72 A – A’).  An isosurface view (indirect rendering) selected 
from a 3D opacity image, revealed GABAAα5 immunofluorescence to be 
encapsulating cytoplasmic labelled FG fluorescence.  This suggests that 
GABAAα5 immunofluorescence is potentially membrane bound. (Figure 72 A’’-
C’’). 
Quantitative analysis of the number of FG+ve neurones which were also 
immunopositive for the GABAAα5 subunit revealed an average of 73.29 ± 3.2% 
(range 44 - 89%) of FG+ve neurones expressed the GABAAα5 subunit, with the 
highest proportion observed in the ventral parvocellular subnuclei (81 ± 4%; 
range 77 – 85%) and the lowest observed in the posterior parvocellular 
subnuclei (61 ± 9.2%; range 44 – 76%; Figure 73). 
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Figure 72 Photomicrographs showing relationship between spinally projecting PVN 
neurones and the GABAAα5 subunit in the normotensive, non-pregnant Wistar.  
Neurones labelled with FG (FG+ve) were found throughout the rostrocaudal extent of the 
PVN (A).  The pattern of GABAAα5 (GABAAα5+ve) staining was as described previously 
(Chapter 6.III.c) for the PVN.  Quantitative analysis shows 73.29 ± 3.2% of FG neurones 
express the GABAAα5 subunit (large arrows A’-C’).  Isosurface rendering view revealed 
the GABAAα5 subunit to surround the FG labelled spinally projecting neurones (A’’-C’’). 
Scale bars: A-C = 100μm, A’-C’ = 30μm, A’’-C’’ = 2.6μm
2
. 3V = 3
rd
 ventricle, PaDC = Dorsal 
Cap, PaMP = Medial Parvocellular, PaVP = Ventral Parvocellular, PaPM = Posterior 
Magnocellular. Orientation Marker for 3D rendered image - D = Dorsal, V = Ventral, L = 
Lateral. n = 5 biological replicates. 
 
 
 
 
Figure 73 Quantitative analysis of the relationship between FG+ve neurones and 
GABAAα5+ve neurones in the five parvocellular subnuclei of the PVN, expressed as a 
percentage of total FG neurones immunoreactive for GABAAα5.  Analysis reveals a mean 
total of 73.29 ± 3.2% of FG+ve neurones to be immunopositive for GABAAα5, with no 
statistical difference observed between individual subnuclei. n = 5 biological replicates 
for each subnuclei 
  
Percentage of Cells Immunoreactive for FG and GABAAα5 
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c. GluN2A 
Expression of the GluN2A subunit of the NMDA receptor was found throughout 
the rostrocaudal extent of the PVN, with a pattern of expression as described 
previously (Chapter 5.III.b). 
Staining for the GluN2A subunit was found in both soma and projections (Figure 
74 B – B’). Although FG labelling was found in both soma and projections 
(Figure 74 A – A’), double labelling of FG/GluN2A was predominantly localised 
to the soma (Figure 74 C – C’).  Isosurface rendered viewing of an 
FG+ve/GluN2A+ve neurone revealed GluN2A subunit immunoreactivity 
surrounds FG labelled spinally projecting neurone (Figure 74 A’’- C’’). 
Quantitative analysis of the number of FG+ve neurones which express the 
GluN2A subunit of the NMDA receptor revealed 54.95 ± 2.8% (range 40 – 88%) 
of FG+ve neurones to express the GluN2A subunit, with the highest proportion 
of double labelled neurones in the posterior parvocellular subnuclei (69.75 ± 
7.1%; range 53 – 88%) and the lowest proportion observed in the ventral 
parvocellular subnuclei (43.75 ± 1.9%; range 40 – 49%; Figure 75).  Fluorogold 
positive neurones which were not immunoreactive for the GluN2A subunit were 
often lying in close apposition to GluN2A+ve neurones (Figure 74 C’ inset). 
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Figure 74 Photomicrographs showing relationship between spinally projecting PVN 
neurones and the GluN2A subunit of the NMDA receptor in the normotensive, non-
pregnant Wistar.  Neurones labelled with FG (FG+ve) were found throughout the 
rostrocaudal extent of the PVN (A).  The pattern of GluN2A (GluN2A+ve) staining was as 
described previously (Chapter 5.III.b) for the PVN.  Quantitative analysis shows 54.95 ± 
2.8% of FG neurones express the GluN2A subunit (large arrows A’-C’). FG+ve neurones 
that did not express the GluN2A subunit lay in close opposition to FG-ve/GluN2A+ve 
neurones (inset image C’). Isosurface rendering view revealed the GluN2A subunit to 
surround the FG labelled spinally projecting neurones (A’’-C’’). Scale bars: A-C = 100μm, 
A’-C’ = 30μm, A’’-C’’ = 1.5μm
2
. 3V = 3
rd
 ventricle, PaDC = Dorsal Cap, PaMP = Medial 
Parvocellular, PaVP = Ventral Parvocellular, PaPM = Posterior Magnocellular. Orientation 
Marker for 3D rendered image - D = Dorsal, V = Ventral, L = Lateral.. n = 5 biological 
replicates 
 
 
 
 
Figure 75 Quantitative analysis of the relationship between FG+ve neurones and 
GluN2A+ve neurones in the five parvocellular subnuclei of the PVN, expressed as a 
percentage of total FG neurones immunoreactive for GluN2A.  Analysis reveals a mean 
total of 54 ± 2.8% of FG+ve neurones to be immunopositive for GluN2A.  Significantly 
more double labelled neurones were observed in the PaPO compared with the PaVP 
(P<0.05), however no other statistically significant differences were observed. n = 5 
biological replicates for each subnuclei. * = P<0.05 
 
 
 
  
* 
Percentage of Cells Immunoreactive for FG and GluN2A 
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Chapter 8. Discussion 
I. Overview of Results 
This study aims to address whether hypertension and pregnancy are associated 
with changes in the subunit expression of the GABAA and NMDA receptors in 
the hypothalamic paraventricular nucleus (PVN).  These changes may underpin 
the sympathoexcitation which is characteristic of these two physiological states. 
A decrease in the expression of the α1 and α5 subunit of the GABAA receptor 
was found in the PVN of both hypertensive and late-term pregnant rats.  In the 
late-term pregnant rat, the decrease in α1 expression was also associated with 
a significant decrease in the number of immunoreactive cells in parvocellular 
subnuclei of the PVN.  However, a decrease in immunoreactive cells was not 
observed in the PVN of the hypertensive rat. 
Conversely, both hypertension and pregnancy were associated with significant 
decreases in the number of α5-IR neurones in parvocellular subnuclei of the 
PVN. 
Hypertension was associated with a significant increase in the expression of the 
GluN2A subunit of the NMDA receptor, which was associated with significant 
increases in the number of immunoreactive cells in parvocellular subnuclei of 
the PVN.  Late-term pregnancy on the other hand was associated with a 
significant increase in the GluN2B subunit of the NMDA receptor, although this 
was not associated with any increase in cell immunoreactivity. 
Furthermore, spinally projecting neurones in the PVN of normotensive rats were 
associated with the GABAAα1, GABAAα5 and GluN2A subunit of the NMDA 
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receptor, suggesting that any changes observed in these subunits is likely to 
influence the discharge properties of these neurones. 
Both hypertension and late-term pregnancy were not associated with significant 
changes in the expression of the α2, α4, β1, β2 or β3 subunit of the GABAA 
receptor or the GluN1 subunit of the NMDA receptor. 
These results would therefore suggest that normal cardiovascular control 
requires the contribution of the α1 and α5 subunits of the GABAA receptor as 
well as a balance of GluN2A and GluN2B subunits, whereas hypertension and 
pregnancy exhibiting sympathoexcitation possess different receptor 
confirmations from the normal state. Furthermore, the changes observed in late-
term pregnancy differ from that which is observed in hypertension and may 
reflect the plasticity of this state such that sympathetic nerve activity can revert 
to normal post-partum. 
Sympathoexcitation is a characteristic feature of both hypertension and 
pregnancy.  This sympathoexcitation is critically involved in the pathogenesis of 
hypertension, chronically elevating blood pressure by directly increasing 
vascular resistance and myocardial contractility (Esler, 2000).  Conversely the 
sympathoexcitation observed in pregnancy is a necessity for normal foetal 
development.  Pregnancy-induced sympathoexcitation results in a significant 
increase in blood volume and cardiac output (40% and 30% increases 
respectively; Longo, 1983; Jarvis et al., 2012) and a positive correlation exists 
between maternal blood volume and foetal birth weight (Salas et al., 1993). 
Crucially, as mentioned above, the sympathoexcitation apparent in late-term 
pregnancy refers to normal post-partum; therefore the neurochemical changes 
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which underpin this sympathoexcitation maintains plasticity within the system; in 
contrast to that which is observed in hypertension. 
Interestingly, previous studies have shown that pregnancy in rats is associated 
with a slight but significant reduction in MAP (Kvochina et al, 2009; Page et al, 
2011).  However in this study, late-term pregnancy was associated with a slight 
but significant increase in blood pressure.  The reasons for this are unclear, but 
could be due to differences in measurement protocol.  For example, in this 
study MAP was measured by catheterisation of the aorta, whereas previous 
studies (Kvochina et al, 2009; Page et al, 2011) measured MAP from the 
femoral artery.  It is possible that given the increase in plasma volume and 
cardiac output observed in pregnancy (Longo et al, 1983) that this is manifested 
as a slight increase in aortic pressure. 
Previous studies have provided compelling evidence that the PVN is a key 
central nucleus involved in the aetiology of sympathoexcitation observed in both 
of these physiological states (Guyenet, 2006; Page et al, 2011). In vivo 
electrophysiological studies have shown that both hypertension and pregnancy 
appear to be associated with a decrease in the activity of the GABAergic 
system within the PVN (Li & Pan, 2006; Kvochina et al., 2009; Page et al., 
2011; Ye et al., 2012a).  However, the molecular mechanisms that govern this 
increased sympathetic nerve activity are not fully understood. 
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II. Changes in GABAA Receptor Subunit Expression Observed in 
the PVN of Hypertensive and Late-Term Pregnant Rats 
In hypertension, bilateral microinjection of the GABAA receptor agonist 
muscimol into the PVN produced an attenuated depressor, bradycardic and 
sympathoinhibitory response in the SHR compared to age matched WKY 
controls (Li & Pan, 2007b).  Furthermore, blockade of the GABAergic system, 
with bilateral microinjections of the GABAA receptor antagonist bicuculline 
produced attenuated pressor, tachycardic and sympathoexcitatory effects in 
SHR compared with WKY controls (Li & Pan, 2007b).  In vitro analysis of PVN 
neurones from both SHR and WKY rats showed that PVN-RVLM projecting 
neurones in the SHR had a significantly higher baseline firing rate than those in 
age-matched WKY controls (Li & Pan, 2006).  Direct application of bicuculline 
increased the firing rate of all rhodamine-labelled neurones in 6 week SHR and 
13 week old WKY rats, but only increased the firing rate of 48.9% of these 
neurones in 13 week old SHR (Li & Pan, 2006).  Furthermore, the concentration 
of endogenous GABA in the hypothalamus has also been shown to be reduced 
in 10- and 17-week old SHR compared with age matched WKY controls 
(Hambley et al., 1984).  Taken together, these results suggest that the 
GABAergic inhibition in the PVN of the SHR is attenuated compared with 
normotensive rats.   
This study has shown that hypertension is accompanied by a 48 ± 6.5% 
decrease in expression of the α1 subunit as well as a 97 ± 2% decrease in 
expression of the α5 subunit of the GABAA receptor compared with 
normotensive Wistar controls.  Furthermore, this is accompanied by a complete 
reduction in α5-IR neurones in all parvocellular subdivisions of the PVN in the 
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SHR (Figure 63).  This is the first demonstration that the PVN of hypertensive 
animals are associated with decreases in specific GABAA receptor subunits. 
Furthermore, this is the first study to show that the PVN of the hypertensive rat 
is associated with a highly significant decrease in expression of the α5 subunit 
of the GABAA receptor.  The α5 knockout mice (gabra5
-/-) shows that removal of 
this subunit from the GABAA receptor results in significant increases in the basal 
firing rate of hippocampal neurones (Glykys et al, 2008).  Therefore it is highly 
likely that the complete decrease in expression observed in the PVN of the 
hypertensive rat will significantly increase the basal firing rate of these 
neurones, as well as contributing to the decreased GABAergic influence 
observed in this state.  We also have evidence that there is decreased α5 
expression in the spinal cord of the SHR; albeit to a lesser extent (unpublished 
results). 
Interestingly, the reduction in α1 subunit expression observed in the SHR 
is not accompanied by a reduction in the number of immunoreactive cells in any 
of the parvocellular subnuclei of the PVN.  Possible explanations for this are 
twofold.  First, the cell counts were confined to the parvocellular subdivisions 
only, whereas the quantitative immunoblotting was performed on PVN 
micropunches incorporating both the parvocellular and magnocellular 
subdivisions.  Since GABAAα1 subunits were expressed in both magno- and 
parvocellular subnuclei of the PVN, it is possible that the decrease in α1 
expression is confined to the magnocellular subdivisions and not associated 
with any parvocellular subnuclei.  Secondly, a decrease in cell immunoreactivity 
suggests that neurones which would have previously expressed the α1 subunit 
of the GABAA receptor now lack this subunit.  It is possible that no neurone fully 
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loses expression of the α1 subunit, but may express it at a decreased level.  
The methodological approach taken in this study did not allow for quantification 
of cell staining density; which could have alluded to the relative expression of 
subunits within individual cells. 
A reduced GABAergic inhibition has also been observed in the PVN of 
late-term pregnant rats.  To this effect, unilateral microinjection of bicuculline 
into the PVN of late-term pregnant rats (P21) produced an attenuated pressor, 
tachycardic and sympathoexcitatory effect compared with non-pregnant animals 
(Kvochina et al., 2009; Page et al., 2011).  At present, little work has been 
undertaken to further examine the contribution the PVN makes to 
sympathoexcitation observed in pregnancy.  However the studies detailed 
above, suggest that overall GABAergic inhibition is reduced in the PVN of late-
term pregnant rats. 
Here we show that late-term pregnancy (P19) is associated with a decrease in 
the expression of the α1 and α5 subunits in the PVN.  The decrease in α1 
subunit expression is similar in degree to that observed in the SHR (43 ± 1.2% 
vs. 48 ± 6.5% respectively).  However, the decrease in expression for the α5 
subunit was not as pronounced in the late-term pregnant rat as for the SHR (38 
± 8% vs. 97 ± 2% respectively).  Furthermore, the decrease in α1 expression 
was associated with a significant decrease in the number of α1-IR neurones in 
the anterior (34 ± 2%), medial (19 ± 3%), ventral (26 ± 5%) and posterior (39 ± 
7%) parvocellular subdivisions compared with non-pregnant controls (Figure 
55).  The decrease in α5 expression was also associated with a significant 
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decrease in the number of α5-IR neurones in the medial (56 ± 4%), ventral (60 ± 
2%) and dorsal cap (52 ± 6%) regions (Figure 63). 
Cell counts of α1-IR neurones in the PVN show a differential response 
between SHR and late-term pregnant rats, despite showing similar decreases in 
overall expression.  Late-term pregnancy is associated with a 29.5 ± 4% 
decrease in the number of α1-IR neurones across all parvocellular subnuclei 
compared with normotensive controls, whereas the SHR shows no significant 
difference.  This suggests that while the expression of the α1 subunit within 
individual neurones in the PVN of SHR may be reduced, in late-term pregnant 
rats, this is associated with a total loss of immunoreactivity in almost 30% of 
neurones. 
Furthermore, both hypertension and late-term pregnancy are associated with a 
significant reduction in the expression of the α5 subunit of the GABAA receptor, 
which in both physiological states is associated with a decrease in the number 
of α5-IR neurones within the PVN.  In agreement with the Western blot analysis, 
the number of α5-IR neurones in the SHR is significantly less than is observed 
in the late-term pregnant rat.  Indeed, no α5-IR neurone was identified in any 
parvocellular subnuclei in the PVN of the SHR, whereas late-term pregnancy 
was associated with an averaged 56 ± 2% decrease across all parvocellular 
subnuclei compared with non-pregnant controls. 
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III. Changes in NMDA Receptor Subunit Expression Observed in 
the PVN of Hypertensive and Late-Term Pregnant Rats 
The PVN of hypertensive rats has been found to be associated with 
increased activity of NMDA receptors, such that blockade of NMDA receptors in 
the PVN of the SHR produces a significantly greater decrease in LSNA, HR and 
ABP than in normotensive controls (Li & Pan, 2007a).  Furthermore, application 
of NMDA onto PVN-IML projecting neurones produced a significantly 
augmented inward current compared with normotensive controls (Li et al., 
2008a). 
This study also presents data to show that the decrease in GABAA 
receptors observed in the hypertensive rat is also accompanied by an increase 
in expression of the GluN2A subunit of the NMDA receptor.  Analysis of whole 
PVN micropunches shows an 85 ± 23% increase in GluN2A expression in the 
PVN of the SHR compared with normotensive controls.  Furthermore, this is 
accompanied by an increase in the number of GluN2A-IR neurones in the 
medial (32 ± 7.8%), dorsal cap (19 ± 4%) and posterior (57 ± 10%) parvocellular 
subnuclei of the PVN compared with normotensive controls (Figure 39).  
Hypertension was not associated with a significant increase in expression of the 
GluN1 or GluN2B subunits from either whole PVN micropunches or analysis of 
immunoreactive cells.  This is in contrast to results obtained by Ye et al (2012b), 
who observed that the PVN of the SHR was associated with an increase in 
GluN2B subunit expression, although this was not associated with an increase 
at the level of the synapse. 
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Results from in vivo electrophysiological studies in late-term pregnant 
rats suggest that the sympathoexcitation observed in this state is not mediated 
by glutamatergic inputs, but is instead dependent upon AngII inputs (Kvochina 
et al., 2009). 
In this study, we show that late-term pregnancy was associated with a 
98.5 ± 40% increase in GluN2B expression in whole-PVN micropunches.  This 
was not associated with any increase in the number of immunoreactive cells in 
any of the parvocellular subnuclei.  However, qualitative analysis of 
immunohistochemical staining for this subunit showed that staining density was 
more pronounced in the magnocellular subnuclei of the PVN, suggesting that 
this increased expression may contribute to the increased neurohumoral 
component associated with pregnancy.  Further evidence that this increase is 
not associated with autonomic controlling parvocellular neurones was presented 
in a study by Kvochina et al (2009) where blockade of NMDA receptors in the 
PVN of late-term pregnant rats did not significantly attenuate the 
sympathoexcitatory or pressor effects of prior bicuculline microinjection 
(Kvochina et al., 2009). 
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IV. Distribution of Presympathetic Spinally Projecting Neurone 
from the PVN and their Subunit Immunoreactivity 
To our knowledge, this is the first study to examine the distribution of 
presympathetic spinally projecting neurones in the PVN of the female Wistar rat.  
Previous neuroanatomical studies have focussed their studies on the male 
Wistar (Portillo et al., 1998) or Sprague Dawley rat (Shafton et al., 1998; Pyner 
& Coote, 2000; Hallbeck et al., 2001). 
 The pattern of distribution observed in this study labelled with both CTB 
(Chapter 4) and FG (Chapter 7) was similar to that previously reported (Portillo 
et al., 1998; Shafton et al., 1998), with labelling observed in the five 
parvocellular subnuclei as described by Paxinos and Watson (1998). 
Results from this study also show that presympathetic neurones in the PVN of 
normotensive female Wistar rats express subunits of the GABAA and NMDA 
receptor.  In the normotensive female Wistar rat, quantitative analysis of the 
number of FG labelled presympathetic neurones show that 55.15 ± 2.5% 
express the α1 subunit of the GABAA receptor, whereas 73.29 ± 3.2% express 
the α5 subunit of the GABAA receptor.  Furthermore, 54.95 ± 2.8% of 
presympathetic spinally projecting neurones express the GluN2A subunit of the 
NMDA receptor. 
These results suggest that at least a proportion of spinally projecting neurones 
in the PVN of the normotensive female Wistar rat have the potential to be 
directly influenced by the decrease in GABAA α1 and α5 subunit expression, a 
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characteristic of both hypertension and late-term pregnancy and previously 
reported in this study. 
 The observation that 54.95 ± 2.8% of PVN-IML projecting presympathetic 
neurones express the GluN2A subunit of the NMDA receptor in the 
normotensive Wistar reveals that there is a significant proportion of this 
population which are not directly influenced by GluN2A-containing NMDA 
receptor activity.  Given that the increase in GluN2A subunit expression 
observed in the SHR was associated with significant increases in the number of 
GluN2A-IR neurones in the medial, dorsal cap and posterior parvocellular 
subnuclei; areas which contain the majority of PVN-IML presympathetic 
neurones (Pyner & Coote, 2000), it is possible to speculate that at least part of 
this increase in GluN2A-IR is attributable to this population of presympathetic 
neurones.  
A number of neurones expressed the α1 or α5 subunit of the GABAA 
receptor or the GluN2A subunit of the NMDA receptor and are putatively 
identified as non-spinally projecting given their absence of FG; however it is 
feasible that not all spinally-projecting neurones were labelled in this study.  
This suggests that populations of neurones other than PVN-IML projecting 
presympathetic neurones have the capacity to respond to the changes in 
expression that these subunits show in both hypertension and pregnancy.  The 
identity of these neurones remains unclear, but given the high level of 
interneurones and neurones projecting to other central nuclei within the PVN 
(i.e. RVLM, NTS; Oldfield et al., 2001), it is possible that these populations of 
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neurones may also be susceptible to fluctuations in the expression of these 
subunits. 
Interestingly, in the case of the GABAAα1 and GluN2A subunits, those FG+ve 
neurones which did not express either of these subunits were often found to be 
lying in close apposition to GABAAα1 or GluN2A positive neurones.  This 
suggests a potential indirect mechanism; possibly through an interneurone, by 
which these neurones respond to receptors containing these subunits.  This 
also provides another mechanism by which these presympathetic neurones 
may be able to respond to fluctuations in the expression of these subunits 
observed during hypertension and pregnancy. 
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V. Physiological Implications of Results  
a. Implications of the Decrease in GABAA Receptor 
Expression on Neuronal Excitability in the PVN 
GABAA receptors containing either the α1 or the α5 subunits display 
distinct physiological characteristics as well as subcellular localisation.  GABAA 
receptors containing the α1 subunit comprise the most common GABAA 
receptor subunit conformation, together with the β2 and γ2 subunits, and 
confirms a synaptic localisation (Somogyi et al., 1996).  As such, these 
receptors play an important role in mediating phasic inhibition (Prenosil et al., 
2006).  Although a reduction in the expression of the α1 subunit was observed, 
there was no alteration observed in β2 expression, suggesting that this subunit 
may complex with other subunits to form receptors with physiologically distinct 
characteristics. 
Conversely, the presence of the α5 subunit within GABAA receptors (most often 
in combination with the β3 and γ2 subunits) overrides the ability of the γ2 
subunit to promote synaptic localisation and targets the receptor to the 
extrasynaptic membrane (Farrant & Nusser, 2005; Serwanski et al., 2006).   
GABAA receptors comprising the α5 subunit have a higher sensitivity to GABA 
and are able to respond to lower concentrations that are constantly present in 
the extrasynaptic space, thereby mediating a constant tonic form of inhibition 
(Farrant & Nusser, 2005).  This allows extrasynaptic receptors to act as a brake, 
preventing over excitation of neuronal membranes. 
Hippocampal neurones from α5 knock-out mice show an increased basal firing 
rate compared with wild type controls.  This level of baseline activity is of a 
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similar magnitude to wild type neurones subjected to the α5 inverse agonist 
L655,708 (Glykys et al., 2008).  Furthermore, PVN-RVLM projecting neurones 
from normotensive rats have been found to be under a heavy tonic inhibitory 
influence from extrasynaptic receptors (Park et al., 2007).  To this effect, 
blockade of extrasynaptic receptors significantly increased the basal firing rate 
of these neurones when compared with control or when synaptic receptors only 
were blocked (Park et al., 2007), suggesting that tonic inhibition is critical in 
controlling the level of firing of these PVN neurones. Furthermore, results 
described in this thesis have shown that an average of 73.6 ± 5.9% of PVN-IML 
projecting neurones express the α5 subunit, suggesting that this population of 
neurones has the potential to be influenced by activity of α5-containing GABAA 
receptors. 
Although tonic inhibition is largely believed to be controlled by δ-containing 
GABAA receptors, due to its high sensitivity for GABA (Zheleznova et al., 2009), 
recent in vitro studies on magnocellular neurosecretory neurones of the 
supraoptic nucleus (SON) have shown that tonic inhibition in this population of 
neurones is governed by α5 containing GABAA receptors more-so than δ-
containing GABAA receptors (Jo et al., 2011).  Moreover, the expression of α5-
subunit mRNA in the SON was 400% greater than the δ subunit (Jo et al., 
2011).  Given that the PVN and SON are similar in their neurochemistry and 
function (Swanson & Sawchenko, 1983), it is reasonable to suggest that tonic 
inhibition in the PVN is controlled by a similar manner, and could explain the 
relative difficulty in probing for the δ subunit in the PVN in this study.  This 
suggestion is further evidenced in this study by the high number of PVN-IML 
projecting presympathetic neurones which express the α5 subunit.  
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Given the results obtained, and in conjunction with the electrophysiological 
studies described above, it is possible to speculate that both the complete loss 
of expression of the α5 subunit observed in hypertension and the partial 
reduction in expression in late-term pregnancy would significantly increase the 
basal firing rate of neurones within the PVN.  Furthermore, given that α1 
containing receptors are concentrated at synapses (Somogyi et al., 1996), it is 
possible to speculate that the similar reduction in expression observed in both 
hypertension and late-term pregnancy would also reduce the capacity for phasic 
inhibition.  
Physiologically, this reduction in both phasic and tonic inhibition would be 
important in mediating the sympathoexcitation observed in both hypertension 
and pregnancy.  The causes of this decrease in inhibition are not clear; however 
multiple previous studies give some indication. 
First, the PVN of both hypertensive and pregnant rats has been found to have 
an increased sensitivity to angiotensin administration (Kvochina et al., 2009; 
Gabor & Leenen, 2012).  To this effect blockade of angiotensin receptors by the 
angiotensin receptor antagonist candesartan into the PVN of hypertensive rats 
significantly decreased arterial blood pressure in Dahl salt sensitive rats fed a 
high salt diet, but not those fed a low salt diet (Gabor & Leenen, 2012).  
Furthermore, infusion of the AT1 receptor antagonist L158, 809 into the PVN of 
late-term pregnant rats significantly attenuated the sympathoexcitatory and 
pressor effects of bicuculline injection (Kvochina et al., 2009).  Previous studies 
have shown that the sympathoexcitatory effects of angiotensin II within the PVN 
are achieved through inhibition of presynaptic GABA release (Li & Pan, 2005).  
Taken together, the sympathoexcitation in both hypertension and pregnancy 
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may be mediated; at least in part, through an AngII mediated disinhibition 
through attenuation of GABA release.  Since reduced GABA activity in cell 
culture lines has been shown to decrease the cell surface expression of GABAA 
receptors (Saliba et al., 2009), it is possible that reduced presynaptic GABA 
release in the PVN could reduce the number of postsynaptic GABAA receptors.  
This would be true for both synaptic and extrasynaptic GABAA receptors, since 
it has been shown that the activity of extrasynaptic GABAA
 receptors within the 
PVN is dependent upon presynaptic GABA release (Park et al., 2007) 
 Angiotensin may not be the only candidate for the loss of presynaptic 
GABA release.  Studies have shown that both hypertension and pregnancy are 
associated with a reduced baroreceptor input.  In hypertension, this is believed 
to be due to either arterial stiffening, reducing the capacity for arterial distension 
and therefore baroreceptor activation, and/or “resetting” of baroreceptors to 
operate at a higher set point (Head, 1995; Kougias et al., 2010).  In pregnancy, 
progesterone has been shown to reduce the activity of high frequency atrial 
volume receptors (Hines & Hodgson, 2000; Storey & Kaufman, 2004).  In rats, 
baroreceptor inputs synapse onto second order neurones in the NTS (Andresen 
& Kunze, 1994; Kougias et al., 2010).  A recent neuroanatomical study from our 
laboratory has provided evidence that a subpopulation of these second order 
neurones project to and make a putative glutamatergic synapse with GABAergic 
interneurones surrounding the PVN (Affleck et al., 2012); which previous 
evidence has shown to synapse with spinally projecting presympathetic 
neurones (Watkins et al., 2009).  Since hypertension and pregnancy are 
associated with reduced baroreceptor input, this would likely reduce 
glutamatergic input on GABAergic neurones in the PVN; in turn reducing 
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presynaptic GABA release, and therefore reducing the density of postsynaptic 
GABAA receptors. 
Thirdly, electrophysiological data has shown that NMDA receptor activation can 
suppress GABAA receptor function.  Electrical stimulation of CA1 neurones in a 
hippocampal slice preparation from adult guinea pigs produces an NMDA 
receptor dependent excitation.  Continued stimulation of these neurones results 
in an increased sensitivity to applied NMDA, and a reduced sensitivity to GABA 
(Stelzer et al., 1987).  This was also observed in isolated CA1 neurones from 
adult guinea pigs, in which continued application of NMDA reduced the peak 
amplitude of evoked GABA currents to around 15% of control levels (Figure 76; 
Stelzer & Shi, 1994).  Furthermore, the decreased sensitivity to GABA and 
increased NMDA sensitivity were blocked by prior application of the NMDA 
receptor antagonist AP5.  Moreover, application of NMDA to cultured mouse 
cortical neurones reduced the expression of GAD65/67 as well as reducing 
dendrite growth (Monnerie & Le Roux, 2007); an effect, which was blocked by 
prior antagonism of GluN1/2A/2B containing receptors, but not GluN1/2B 
containing receptors (Monnerie et al., 2010).  This suggests that GluN2A 
containing receptors may be important in mediating the NMDA-mediated 
decrease in GAD expression.  Indeed a decrease in GAD activity has been 
previously observed in the hypothalamus of SHR (Czyzewska-Szafran & 
Wutkiewicz, 1986).  This decrease in GAD activity and the resulting decrease in 
presynaptic GABA release could ultimately drive a decrease in postsynaptic 
GABAA receptor density. 
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Figure 76 Normalised GABAA receptor responses following NMDA receptor activation.  
NMDA receptor activation reduces GABAA receptor activity in a time-dependent fashion 
(right), culminating in a response which is 75% lower than control levels.  Application of 
NMDA in the presence of the NMDA receptor antagonist AP5 fails to significantly alter 
peak responses (centre), suggesting a NMDA-specific mechanism (Stelzer & Shi, 1994). 
 
Previous studies have shown that activation of NMDA receptors maintains 
sympathetic tone in hypertension (Li & Pan, 2007a; Li et al., 2008a), and that 
this is coupled with a decrease in GABAA receptor activity (Li & Pan, 2006, 
2007b).  Furthermore, results from this study and from a recently published 
study by another group (Ye et al., 2012b) show that hypertension is associated 
with a significant up-regulation of the GluN2A subunit of the NMDA receptor in 
the PVN.  Taken together, it is possible to speculate that NMDA receptor 
activation in the PVN of hypertensive rats results in GABAA receptor 
endocytosis, thereby reducing the activity of GABAA receptors and resulting in 
the reduced expression of the α1 and α5 subunits observed in this study.  
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However this is unlikely since pregnancy has been shown to be associated with 
a decrease in GABAergic inhibition of autonomic neurones (Kvochina et al., 
2009; Page et al., 2011) independent of an increase in both NMDA receptor 
activity (Kvochina et al., 2009) and increase in NMDA receptor subunit 
expression in parvocellular subnuclei. 
It is more likely that since NMDA receptors are under heavy GABAA 
receptor mediated inhibition in the PVN of normotensive rats (Chen et al., 
2003); that the down regulation of the α1 and α5 subunits of the GABAA 
receptor in hypertensive and pregnant rats precedes the up-regulation of NMDA 
receptor activity.  This is evidenced by studies showing that the 
sympathoinhibitory actions of NMDA receptor blockade in the PVN of 
normotensive rats requires the prior removal of GABAA receptor mediated 
inhibition (Chen et al., 2003).  Furthermore, GluN2A subunit trafficking to the 
synapse is dependent on activation of synaptic NMDA receptors (Barria & 
Malinow, 2002; Storey et al., 2011).  Therefore, the removal of GABAA 
receptors in the PVN of hypertensive rats would allow for an increase in the 
activity of glutamatergic synapses, thereby increasing GluN2A subunit 
expression. 
Irrespective of whether the decrease in GABAA receptor expression precedes 
the increase in NMDA receptor expression or vice versa; it is possible that the 
two are self-perpetuating; such that the reduction in GABAergic inhibition 
resulting from the decreased GABAA receptor expression allows for NMDA-
mediated excitation to dominate. This in turn may further propagate the 
decrease in GABAergic inhibition, either through decreasing GABAA receptor 
expression and/or decreasing GAD67 expression. 
 227 
 
b. Implications of the Increase in NMDA Receptor 
Expression on Neuronal Excitability in the PVN 
Although we show an increase in GluN2B subunit expression in the whole PVN 
of late-term pregnant rats, it is unclear what physiological effect this has, since 
this was not associated with changes in immunoreactivity in parvocellular 
subnuclei.  In a previous study examining the role of NMDA receptors in 
maintaining sympathetic tone in late-term pregnancy, blockade of NMDA 
receptors with kynurenic acid failed to significantly blunt the sympathoexcitatory 
and pressor effects of bicuculline microinjection when compared to blockade of 
angiotensin receptors (Kvochina et al., 2009).  This suggests that NMDA 
receptors do not play a significant role in controlling the sympathoexcitation 
observed in pregnancy.  Furthermore, given the activity-dependent nature of 
GluN2A subunit entry into synapses, it would be expected that any increase in 
glutamatergic activity would result in an increase in GluN2A subunit expression, 
since these are activity-dependent (Gambrill et al., 2011).  However, it was 
noted that expression of the GluN2B subunit was more prominent in 
magnocellular subnuclei.  It is therefore possible that the increase in GluN2B 
subunit expression mediates an increase in the neurohumoral component of 
pregnancy and has little effect on autonomic control. 
This is consistent with previous experiments examining plasma osmolality.  
Non-pregnant rats that consumed a 2% saline solution for 4-10 days showed a 
significant increase in plasma osmolality as well as a decrease in GluN2B 
subunit expression in both the PVN and SON (Curras-Collazo & Dao, 1999).  
Since pregnancy is associated with a decrease in plasma osmolality of around 
10mOsm/kg (Heesch et al., 2009), it is possible to speculate that this may 
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cause an increase in GluN2B subunit expression, opposing that observed 
following an increase in osmolality.  This is further supported by a study from 
Davison et al (1989) showing that vasopressin secretion is increased in late 
term pregnancy, consistent with an increase in excitatory input to hypothalamic 
neurosecretory cells (although metabolic clearance of vasopressin is increased, 
resulting in normalised serum levels). 
Analysis of GluN1 subunit expression in whole PVN micropunches as well as 
immunohistochemistry revealed no significant increase in expression in either 
SHR or late-term pregnant rats.  This is in contrast to results obtained from HF 
rats; where GluN1 subunit expression was found to increase in the PVN (Li et 
al., 2003). 
Since the GluN1 subunit is an obligatory subunit, required for binding of the co-
agonist glycine (Kohr, 2006), it would be expected that any increase in GluN2 
subunit expression should be met with a concomitant increase in GluN1 
immunoreactivity.  Furthermore, a recent electrophysiological study has 
demonstrated that the increase in GluN2A subunit expression in the PVN of 
SHR confers physiologically relevant properties to PVN neurones (Ye et al., 
2012b); suggesting that the increase in GluN2A subunit expression is 
contributing to an increase in functional receptors. 
We hypothesise that this discrepancy may be the result of intracellular pools of 
unassembled GluN1 subunits, located within the endoplasmic reticulum (Chazot 
& Stephenson, 1997b).  Expression of GluN1 subunits alone in cultured cells 
results in the accumulation of intracellular GluN1 subunits, with no cell surface 
expression (McIlhinney et al., 1998).  This pool of unassembled intracellular 
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GluN1 subunits has also been identified in the brain of mice (Chazot & 
Stephenson, 1997b).  Co-expression of the GluN1 subunit in cell cultures with 
the GluN2A subunit promotes cell surface trafficking of these receptors 
(McIlhinney et al., 1998), suggesting that the intracellular GluN1 subunits 
require a GluN2 subunit for surface trafficking.  In the PVN of hypertensive or 
late-term pregnant rats, the increase in GluN2A and GluN2B which are seen 
respectively in the absence of any GluN1 subunits could be due to cell surface 
promotion of intracellular GluN1 subunits by the increased level of GluN2 
subunits observed in both of these physiological states (Figure 77).  The 
methodology used in this study to investigate whole PVN protein expression as 
well as immunohistochemistry incorporated both intracellular and extracellular 
populations of GluN1 receptor subunits. 
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Figure 77 Schematic representation of possible mechanism mediating the increase in 
GluN2 subunit expression without increasing overall GluN1 subunit expression.  
Increased GluN2 expression (1); as observed in the PVN of SHR and late-term pregnant 
rats, recruits unassembled intracellular GluN1 (2) subunits for cell surface trafficking (3). 
 
Alternatively, the GluN1 subunit undergoes alternative splicing to produce eight 
variants; GluN1-1a/b-GluN1-4a/b (Stephenson, 2001).  The antibody used in 
this study encompassed all GluN1 isoforms.  It was therefore not possible to 
assess whether an increase in one isoform resulted in the decrease of another, 
thereby creating the impression of no change. 
 
 
1. 
2. 
3. 
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c. Effect of Decreased GABAA and Increased NMDA 
Receptor Expression on Sympathetic Outflow and 
Pathophysiology 
Both hypertension and pregnancy show marked elevations in sympathetic nerve 
activity (Greenwood et al., 1999; Greenwood et al., 2001); however in 
pregnancy this is known to return to pre-pregnancy levels post-partum 
(Greenwood et al., 2001).  Moreover, the level of sympathetic activation 
observed in pregnancy is significantly lower than in hypertension.  Single-unit 
muscle sympathetic nerve activity (s-MSNA) in 35 week-pregnant humans, as 
measured through microneurographic measurement of the right peroneal nerve, 
was 30 ± 2.0 impulses per 100 cardiac beats, reducing to 21 ± 1.1 impulses per 
100 cardiac beats post-partum (Greenwood et al., 2001).  In contrast, 
measurement of s-MSNA in established hypertensive humans by the same 
research group utilising the same methodology showed s-MSNA to be 63 ± 5.6 
impulses per 100 cardiac beats (Greenwood et al., 1999).  Collectively, this 
suggests that the sympathoexcitation observed in hypertension and pregnancy 
is likely to be differentially controlled, such that pregnancy-induced 
sympathoexcitation is not as pronounced as hypertension, and is also reversible 
post-partum. 
The results presented indicate that both hypertension and pregnancy 
show similar decreases in expression of the α1 subunit of the GABAA receptor 
(48 ± 6.5% vs. 43 ± 1.2% respectively).  Similarly, both hypertension and 
pregnancy also show a reduction in expression of the α5 subunit, however to a 
much greater extent in the SHR than in the pregnant rat (97 ± 2% vs. 38 ± 8% 
respectively).  Neither hypertension nor late-term pregnancy was associated 
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with any alterations in the expression of the α2, β1, β2 or β3 subunit.  This 
suggests that the α1 and α5 subunits could be critically involved in contributing 
to the sympathoexcitation observed in both of these physiological states.  The 
greater decrease observed in α5 subunit expression in the SHR compared with 
late-term pregnancy could contribute to the greater sympathoexcitation 
observed in this state by removal of tonic inhibition. 
Furthermore, hypertension was associated with an 85 ± 23% increase in whole-
PVN GluN2A subunit expression; as well as an average 36 ± 7.2% increase in 
GluN2A-IR cells in parvocellular subnuclei of the PVN.  This increase in GluN2A 
subunit expression was not observed in the PVN of late-term pregnant rats.  
Moreover, in vivo electrophysiological studies have demonstrated that 
antagonism of NMDA receptors in the PVN of late-term pregnant rats does not 
significantly reduce renal sympathetic nerve activity or blood pressure 
(Kvochina et al., 2009).  It is therefore possible that coupled with the more 
pronounced decrease in α5 subunit expression, the increase in GluN2A subunit 
expression also contributes to maintaining an increased sympathetic tone in 
hypertension.  Late-term pregnancy was associated with a significant increase 
in GluN2B subunit immunoreactivity; however this was not associated with an 
increase in cell immunoreactivity in any of the parvocellular subnuclei.  Given 
that expression of the GluN2B subunit was more pronounced in magnocellular 
subnuclei, coupled with previous studies showing plasma osmolality influences 
GluN2B subunit expression in hypothalamic magnocellular subnuclei (Curras-
Collazo & Dao, 1999), it is possible that this increase modulates the increased 
neurohumoral aspect of pregnancy and is more associated with altered plasma 
osmolality than the increased sympathetic nerve activity. 
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Immunohistochemical analysis allowed us to assess whether the 
changes observed from whole-PVN micropunches were associated with 
changes in the number of immunoreactive cells.  This also allowed us to assess 
within which parvocellular subnuclei any changes occur, and from this speculate 
which neuronal pathways this could potentially influence. 
The increase in GluN2A subunit expression in the PVN of the SHR was 
associated with a significant increase in immunoreactive cells in the medial, 
dorsal cap and posterior parvocellular subnuclei.  Neuronal tract tracing of PVN-
IML projecting neurones presented in this thesis and previously (Swanson et al., 
1980; Portillo et al., 1998; Ranson et al., 1998; Shafton et al., 1998; Pyner & 
Coote, 2000; Oldfield et al., 2001; Watkins et al., 2009) have shown that all of 
these subnuclei contain neurones projecting to SPN in the spinal cord.  
Moreover, these subnuclei of the PVN also send projections to the NTS 
(Oldfield et al., 2001), as well as containing high densities of RVLM projecting 
neurones (Shafton et al., 1998; Pyner & Coote, 1999, 2000; Oldfield et al., 
2001; Stocker et al., 2006; Chen & Toney, 2010) and branching projections to 
both the RVLM and IML (Shafton et al., 1998; Pyner & Coote, 2000; Chen & 
Toney, 2010).  Moreover, we have shown that around 54% of PVN-IML 
projecting neurones in the normotensive rat express the GluN2A subunit.   This 
suggests that any alteration in excitatory transmission occurring in these 
subnuclei, as a result of the increased GluN2A subunit expression, is likely to 
increase the firing activity of neurones projecting to both the IML and RVLM; 
both sites of cardiovascular control.  Furthermore, hypertension was also 
associated with a significant decrease in expression of the α5 subunit of the 
GABAA receptor in the same regions; as well as the anterior and ventral 
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parvocellular subnuclei.  A reduction in α5 subunit expression in the absence of 
increased NMDA receptor expression has been shown to significantly increase 
the spontaneous firing activity of neurones (Glykys et al., 2008). Therefore the 
concomitant increase in GluN2A expression and decrease in α5 expression in 
the same subnuclei is likely to significantly increase the firing rate of these 
neurones. 
Furthermore, we have preliminary evidence that α5 expression is also reduced 
in whole spinal cord homogenate from SHR compared with normotensive 
controls (unpublished data).  Moreover, this was associated with a significant 
reduction in α5-IR neurones in the IML region of the spinal cord (unpublished 
data).  Sympathetic preganglionic neurones in the IML region of the spinal cord 
have been found to be under heavy α5-mediated tonic inhibition (Wang et al., 
2008).  We have also provided evidence for a decrease in the expression of the 
α5 subunit in the cortex of the SHR.  This decrease in α5 expression in the 
three central areas studied here suggests that this decrease may not only be a 
significantly important mechanism behind the increased sympathetic outflow, 
but may be a characteristic feature of this animal. 
Pregnancy was associated with a significant decrease in expression of 
the α1 subunit in the anterior, medial, ventral and posterior parvocellular 
subnuclei; as well as a significant decrease in α5 cell immunoreactivity in the 
medial, ventral and dorsal cap subnuclei.  A reduction in expression of these 
GABAA receptor subunits is likely to increase the spontaneous activity of 
neurones within these regions, however given the absence of any increase in 
NMDA receptor subunit expression in any of the parvocellular subdivisions, this 
is likely to be to a lesser extent than is observed in hypertension, and could 
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contribute to the lower level of sympathoexcitation observed in pregnancy 
compared with hypertension (Greenwood et al., 1999; Greenwood et al., 2001). 
Given that the decrease in α5 subunit expression observed in the SHR occurred 
in subnuclei which did not show a significant increase in GluN2A expression 
(i.e. anterior and ventral parvocellular subnuclei), this suggests that the 
reduction in GABAA receptor expression may not be a consequence of 
increased NMDA receptor activation.  However we cannot conclusively rule out 
the possibility that GluN2A expression has increased in these regions in the 
absence of de novo cell expression. 
This is further evidenced in pregnancy, where the α1 and α5 subunits of the 
GABAA receptor show decreased cell immunoreactivity in the absence of 
increased NMDA receptor expression in any parvocellular subnuclei, again 
suggesting that GABAA receptor decreases may precede NMDA receptor 
activation. 
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VI. Methodological Considerations 
The micropunch method of tissue isolation allows for the measurement of 
protein levels accurately and consistently in the PVN of animals from all three 
physiological states.  However, it is possible that anatomical variation could 
result in regions other than the PVN from being acquired.  Since there was not a 
substantial difference in weight between both normotensive and SHR animals 
and pre-pregnant Wistars, it is unlikely that differences in brain sizes would be a 
confounding factor in identifying the PVN region.  The use of the third ventricle 
as an anatomical landmark to identify the region containing the PVN was also a 
factor reducing this risk. 
Combining results obtained from quantitative immunoblotting with cells 
immunohistochemically stained for the respective subunits means that results 
obtained from the whole PVN micropunches can be determined at a subnuclear 
level.  Based on neuroanatomical studies described in this thesis and 
previously, changes observed in discrete parvocellular subnuclei can then be 
translated into a possible physiological role.  Identification of subnuclei was 
based on five parvocellular subnuclei identified through retrograde labelling of 
PVN-IML projecting neurones (Chapter 4), coupled with the Paxinos & Watson 
(1998) brain atlas. 
Although retrograde labelled PVN-IML projecting neurones labelled five discrete 
parvocellular subnuclei (Swanson et al., 1980), immunohistochemical staining 
for subunits of the GABAA or NMDA receptor in the absence of retrogradely 
labelled PVN-IML neurones produced more diffuse staining patterns, with no 
anatomical bias of parvocellular subnuclei.  This was more pronounced at 
rostral-mid levels of the PVN, where absolute identification of the boundaries of 
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the anterior, dorsal cap and ventral parvocellular regions were often difficult to 
fully discern.  The chance of misidentifying a subnucleus was minimised 
through the use of serial counter-stained sections, which in conjunction with the 
Paxinos and Watson brain atlas allowed for the identification of the specific 
parvocellular subnuclei. 
 The use of antibodies in scientific research provides a potential area of 
error, given the possibility of non-specific labelling.  In this study, the specificity 
of all antibodies used had been tested at the point of production (as detailed in 
Chapter 2Ve). However the “gold standard” in the checking of antibody 
specificity is through the use of knock-out mice, whereby the protein of interest 
is removed from the genome and therefore not expressed.  Since this has not 
been done with the antibodies used in this study, the possibility that the 
antibodies labelled non-specific proteins is possible.  
In this study, semi-quantitative analysis of immunohistochemically 
stained brain sections was achieved by counting the number of stained 
neurones in a given area.  Although the area selected to count was not chosen 
based on any criteria other than it lie within the subnuclear boundaries, the 
possibility of bias arises from the fact that the area was not chosen by random 
generation, and could be considered a limitation to the study. 
Previous studies have shown that certain subunits of the GABAA 
receptor, specifically the α4, β1, γ2 and δ subunits, show fluctuating expression 
levels manifested by hormones related to the oestrous cycle (Griffiths & Lovick, 
2005; Lovick, 2008).  Studies in the periaqueductal grey region (PAG) have 
found that the number of α4, β1 and δ immunoreactive cells almost double in 
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number at the late diestrus stage compared with proestrus (Griffiths & Lovick, 
2005).  Furthermore, expression of the γ2 and δ subunits are shown to fluctuate 
in an opposing manner, such that high levels of δ during the diestrus phase are 
accompanied by low levels of γ2, and vice versa in oestrus (Maguire et al., 
2005).  A possible methodological limitation to this study is that the stage of 
oestrous for the normotensive and SHR rats was not taken into consideration.  
Although fluctuations in the oestrous cycle of the normotensive and SHR 
animals may have masked alterations in some GABAA receptor subunits from 
being identified, multiple arguments can be made which validate the results 
obtained for the α1 and the α5 subunit. 
First, there is no evidence in the literature to show that the oestrous cycle has 
any effect on the expression of the α5 subunit.  Studies examining oestrous-
related changes in tonic activity concentrate on expression of the δ subunit.  
Incorporation of a δ subunit into a GABAA receptor significantly increases its 
sensitivity to neurosteroids (Hosie et al., 2009; Zheleznova et al., 2009) and 
studies have shown that expression of the δ subunit is directly related to the 
stage of oestrus (Griffiths & Lovick, 2005; Lovick, 2008).  Although accurate 
analysis of δ subunit expression could not be made in this study (due to the 
stage of oestrus cycle not being taken into account), attempts were made to 
determine δ subunit levels from PVN micropunches, but failed to detect the 
subunit.  This is in accordance with results from the SON, where δ subunit 
mRNA expression was 400% lower than α5 subunit mRNA expression, and was 
barely detectable (Jo et al., 2011). 
A study by Follesa et al (1998) examined pregnancy-induced changes in 
expression of multiple GABAA receptor subunits in the cortex and hippocampus 
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of rats.  This study observed that pregnancy was associated with a significant 
decrease in the expression of the α5 but not α1 subunit in the cortex, reaching a 
minimum around 25% lower than pre-pregnant levels at day 21 of pregnancy.  
Based on this study, it is apparent that the expression of GABAA α5 subunits 
may be susceptible to neurosteroidal modulation.  If so, then given the 
substantially higher concentrations of progesterone observed in pregnancy 
compared with those observed during the oestrus cycle (263.7±12.1 nmol/L vs. 
53.1±5.4 nmol/L respectively; Kobayashi et al., 1999), we would expect to see 
substantially greater changes in α5 expression in the PVN of late-term pregnant 
rats compared with SHR.  The results from this study show that expression of 
the α5 subunit in the SHR is 59% lower than that observed in the late-term 
pregnant rat (97.2±2% vs. 38 ± 8% respectively). 
There is also no evidence in the literature that the α1 subunit of the 
GABAA receptor is susceptible to fluctuations in hormones associated with the 
oestrous cycle.  Although studies have shown that the γ2 subunit of the GABAA 
receptor, which frequently complexes with the α1 subunit at synapses (Somogyi 
et al., 1996), has an expression pattern which fluctuates in accordance with the 
stage of oestrous, no study has examined whether this is associated with a 
down-regulation of the α1 subunit.  Indeed a recent paper by Maguire et al 
(2005) suggest that the oestrus cycle affects only the expression of the γ2 and δ 
subunits, since the kinetics or frequency of spontaneous IPSCs in hippocampal 
neurones were not altered during the cycle. 
Further evidence that the changes we observed in expression of the α1 
and α5 subunits in the SHR were independent of oestrous come from our own 
study.  We performed semi-quantitative analysis of expression levels of the α4 
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subunit, which previous studies have found to be susceptible to fluctuations in 
oestrous-related hormone levels in regions of cardiovascular control (Griffiths & 
Lovick, 2005; Lovick, 2008).  In this, we observed greater variation within the 
data observed for both normotensive and SHR than was observed for the other 
GABAA receptor subunits examined, suggesting changing expression levels 
amongst the different animals sampled, possibly associated with oestrous 
cycling.  Furthermore, the results displaying a significant decrease in α1 and α5 
subunit expression are consistent across normotensive and SHR animals taken 
from random periods of the oestrous cycle. 
If the changes that we have observed in the expression of the α1 and α5 
subunits were caused by an oestrous-related hormonal influence, we would 
expect the effect to be widespread throughout the brain.  In this study, we 
measured the expression of the α1 and α5 subunits in the cortex of the same 
animals.  From this, we observed that the level of α1 subunit expression was 
not significantly different between SHR or late-term pregnant rats compared 
with normotensive controls.  Expression of the α5 subunit was significantly 
decreased in the cortex of the SHR and late-term pregnant rat; however the 
levels observed in the cortex were different from those observed in the PVN of 
the same animals.  Expression of the α5 subunit in the cortex of SHR was 75% 
lower than control; significantly higher than the 97% observed in the PVN 
(P<0.05).  Furthermore, expression of the α5 subunit was 72% lower in the 
cortex of late-term pregnant rats compared with control, significantly lower than 
the 38% decrease observed in the PVN.  Changes in α5 expression in the 
cortex of pregnant rats have previously been observed in Sprague Dawley rats, 
where the decrease in α5 expression peaked at 25% on day 21 of pregnancy 
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(Follesa et al., 1998).  The larger decrease observed in this study could be the 
result of species variation. 
It is not surprising that levels of the α5 subunit are decreased in the 
cortex of the SHR compared with normotensive controls.  Studies have shown 
that GABAergic inhibition in the hippocampus of SHR is significantly reduced 
compared with normotensive controls (Ichida et al., 1996) and may be related to 
its behavioural characteristics of attention deficit hyperactivity disorder (ADHD), 
where these animals show hyperkinesic and hyperactive tendencies compared 
with multiple control animals (Sagvolden et al., 1993).  Since there are dense 
reciprocal connections between the cortex and the hippocampus (Irle & 
Markowitsch, 1982; Rolls, 2000), it is possible that the down-regulation of 
GABAergic inhibition in the hippocampus results in altered neurotransmission of 
the cortex. Furthermore, the increased level of motor activity associated with the 
SHR (Sagvolden et al., 1993) may be the result of decreased inhibition of 
cortical motor centres.  Since results presented here show decreased α5 levels 
in the PVN, cortex and spinal cord of the SHR, a lower α5 subunit expression 
may be a characteristic feature of this animal. 
Irrespective of the decreased cortical levels of α5, the evidence presented here 
showing the substantial difference in expression levels between the cortex and 
PVN of the SHR and late-term pregnant rat, coupled with the number of 
biological replicates within which the almost complete absence of α5 in the PVN 
of the SHR has been observed; strongly suggest that the decrease in α5 
observed in the PVN of the SHR is specific to the PVN and could ultimately play 
a significant role in mediating the sympathoexcitation observed in this animal. 
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VII. Therapeutic Potential 
The number of confirmed hypertensive cases in the Western world is rising year 
on year (Carretero & Oparil, 2000).  Furthermore, two-thirds of patients who are 
prescribed anti-hypertensive medication fail to reach adequate blood pressure 
levels of lower than 140/90mmHg (Chobanian et al., 2003).  Pregnant women 
are at a higher risk of postural hypotension resulting in syncope, as well as a 
decreased ability to respond to haemorrhage; responsible for around 22% of all 
maternal deaths (Brooks et al., 2010a).  The need for novel treatments for both 
hypertension as well as for emergency obstetrics is therefore of a high priority 
for governments and health systems. 
 Current therapies aimed at reducing sympathetic nerve activity in various 
cardiovascular diseases, whether through pharmacological or mechanical 
means, have produced conflicting results. 
Prolonged activation of the carotid sinus has been shown to reduce mean 
arterial blood pressure through reduction of sympathetic nerve activity in dogs 
(Lohmeier et al., 2009; Lohmeier et al., 2010). However results show that once 
stimulation ceases, ABP rose back to control levels, suggesting that the effects 
are not long lasting (Lohmeier et al., 2009). 
Renal denervation has provided an exciting prospect for reducing renal nerve 
activity in hypertensive patients. Clinical studies have found that patients who 
have undergone bilateral renal denervation observed a decrease in systolic 
blood pressure of 33mmHg and a decrease in diastolic blood pressure of 
11mmHg at 6 months post-operative, compared with control groups (Esler et 
al., 2010). In addition, blood pressure continued to decrease at 24 months post-
operative (Schlaich et al., 2012).  Promising as these results may be, renal 
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denervation is an invasive and irreversible procedure, and is not applicable to 
all patients. 
Pharmacological reduction of sympathetic nerve activity has been 
attempted in patients with heart failure. Treatment with the imidazoline receptor 
antagonist monoxidine significantly reduced plasma noradrenaline levels by 
18.8% compared with pre-treatment levels (Cohn et al., 2003).  However a 
significantly higher mortality rate in the treatment compared with placebo group 
resulted in this trial being halted.  This suggests that although a 
pharmacological reduction in sympathetic nerve activity in cardiovascular 
disease states is possible, much is still unknown about its effectiveness and 
tolerability. 
The results presented in this thesis provide novel therapeutic targets for 
the treatment of hypertension, as well as targets for potential manipulation of 
the cardiovascular system during pregnancy. 
Many clinically used neuroactive drugs act by targeting either the 
glutamatergic or GABAergic systems within the brain.  Benzodiazepines are a 
classic example and have been widely used for the treatment of insomnia and 
anxiety disorders (Lader, 2008).  Benzodiazepines are modulators of GABAA 
receptor function, and act either to potentiate (positive modulators) or attenuate 
(negative modulators) GABAergic transmission (Johnston, 1996; Rudolph & 
Knoflach, 2011).  Furthermore, many of the drugs which come under the 
umbrella of benzodiazepines are subunit specific.  It is therefore possible to 
speculate that, based on the results presented in this thesis, therapies which act 
as positive modulators specifically targeted at either the α1 or α5 subtype of the 
 244 
 
GABAA receptor may be useful in the treatment of essential hypertension and 
pregnancy-induced baroreflex suppression.  Indeed clinically available drugs, 
which act at GABAA receptors comprising either the α1 or the α5 subunit, do 
exist (Rudolph & Mohler, 2006). 
Currently however, these drugs have significant undesirable side effects.  
Zolpidem is a benzodiazepine that preferentially binds to α1 containing GABAA 
receptors.  Its primary therapeutic role is in the treatment of insomnia, since 
potentiation of α1 containing GABAA receptors results in sedation (Rudolph & 
Knoflach, 2011).  Given its high degree of sedation, α1 based therapies pose 
significant side effects using currently available drugs. 
Pharmacological modulation of α5 containing GABAA receptors has 
recently attracted a great deal of attention.  Studies have shown that mice 
lacking the α5 subunit show greater hippocampus-dependent learning than 
wild-type mice (Martin et al., 2009).  Furthermore, wild-type mice administered 
with an inverse agonist to α5 containing GABAA receptors also show greater 
hippocampus-dependent learning (Chambers et al., 2003; Martin et al., 2009).  
The α5 subunit therefore provides an enticing therapeutic target for cognitive 
enhancement.  However, the results presented here suggest that a removal or 
down-regulation of the α5 subunit in the PVN may contribute to the 
sympathoexcitation observed in hypertension and pregnancy.  At present, none 
of the studies employing inverse agonists to the α5 subunit have measured 
sympathetic nerve activity or blood pressure to assess whether positive inverse 
modulation of these receptors has a sympathoexcitatory or pressor effect. 
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Currently, no drug that specifically and positively modulates α5 containing 
GABAA receptors exists.  L-838417 is a partial agonist of GABAA receptors, 
which contain α2, α3 or α5 subunits, but is an antagonist to α1 containing 
receptors (Rudolph & Knoflach, 2011). Since it does not positively modulate α1 
containing receptors, this drug does not display the sedative properties 
associated with zolpidem, but does have unfavourable pharmacokinetic 
properties, such as variable absorption and bioavailability that limit its clinical 
use (Scott-Stevens et al., 2005; Rudolph & Knoflach, 2011).  Given its more 
restricted expression compared with the α1 subunit, as well as its non-sedative 
properties and significant reduction in expression in the PVN of hypertensive 
and pregnant rats, positive pharmacological modulation of the α5 subunit may 
prove an important therapeutic target that offers fewer side effects. 
Pharmacological antagonism of the NMDA receptor with the 
uncompetitive antagonist memantine has proved an important therapeutic target 
in the treatment of Alzheimer’s disease, where it is prescribed for its cognitive 
enhancement properties (Tricco et al., 2012).  The efficacy of this drug in the 
treatment of hypertension has not yet been established; however memantine 
appears to be generally well tolerated with few side effects (Areosa et al., 
2005), suggesting its use as a therapeutic may be beneficial over the 
benzodiazepines described previously.  The actions of memantine are not 
dependent upon the subunit conformation of the NMDA receptor therefore its 
actions would not be a specific antagonism of GluN2A containing receptors, for 
which we observed an increase in the PVN of SHR.  However given that NMDA 
receptor activity is increased in the PVN of SHR, antagonism of NMDA 
receptors with non-selective drugs provides a possible therapeutic target for the 
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treatment of hypertension.  Future pharmaceutical advances may provide 
clinically relevant drugs, which would allow for the specific antagonism of 
GluN2A-containing NMDA receptors. 
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VIII. Future Perspectives 
The results from this study provide a potential molecular basis to explain the 
sympathoexcitation observed in hypertensive and late-term pregnant rats.  
However this needs to be confirmed by combining relevant pharmacological 
tools with in vivo and in vitro electrophysiology to assess the contribution these 
receptor subunit changes make to both PVN neuronal excitability and 
cardiovascular physiology. 
The results described here have also shown that the alterations 
observed in expression of the α1 and α5 subunit of the GABAA receptor and 
GluN2A subunit of the NMDA receptor is specific to the PVN.  However what 
remains unclear is the order in which these subunit changes occur.  The 
hypertensive animals used in this study were at a stage of established 
hypertension; what these results fail to answer is whether the alterations indeed 
precede the onset of hypertension; i.e. are these alterations in GABAA and 
NMDA expression a cause or result of hypertension.  Assessing when these 
changes occur in pre- and/or early hypertensive animals could have profound 
implications for future drug therapy regimens. 
Moreover, oestrus-related changes in the expression of certain GABAA receptor 
subunits has prevented us from being able to assess the expression levels of all 
components of the GABAA receptor; specifically the γ2 and δ subunits.  These 
two subunits are known to mediate profound effects on both phasic and tonic 
inhibition within the CNS respectively, and potential alterations in these subunits 
would allow for a more complete assessment of all potential mechanisms 
underlying reduced GABAergic control in the PVN. 
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IX. General Discussion 
The results presented in this thesis provide evidence that the PVN of both 
hypertensive and late-term pregnant rats are associated with changes in 
specific subunits of the GABAA and NMDA receptor.  Furthermore, both 
hypertension and late-term pregnancy were associated with changes in the 
same subunits of the GABAA receptors, suggesting that these may be crucial in 
mediating the sympathoexcitation observed in these two states.  Whereas 
hypertension was associated with an increase in the expression of the GluN2A 
subunit of the NMDA receptor, this was not observed in the PVN of late-term 
pregnant animals and this may be a critical component underpinning the 
chronicity of hypertension. 
What remains unclear from this study is the nature of these changes throughout 
the course of hypertension or pregnancy.  In the case of hypertension, 
assessing when the decrease in α1 and α5 subunit expression occurs could be 
crucial for the implementation of future therapeutic regimens.  Determining 
whether these changes occur prior to the increase in GluN2A subunit 
expression may also be critical in maintaining reversibility in the neurochemical 
imbalance observed in the PVN of these animals. 
Therefore, we have provided some insight into the neurochemical changes that 
could underpin the sympathoexcitation observed in both hypertension and 
pregnancy; however this is by no means a complete picture.  Future work will 
determine whether these changes can be exploited therapeutically. 
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Appendix 1 - Recipes 
 
0.1M Phosphate Buffer (PB): 0.05M sodium dihydrogen orthophosphate, 
0.05M disodium hydrogen orthophosphate, made up in distilled water (dH2O). 
pH 7.4 
4% Paraformaldehyde (PFA): 1 litre 0.1M PB, heated to 60ºC (not exceeding).  
40g paraformaldehyde added and left until dissolved.  Once cooled, pH 
adjusted to 7.4 and then stored at 4ºC. 
Transfer Buffer: 0.025M Tris, 0.4M glycine, 20% (v/v) methanol, made to final 
volume with dH2O 
Electrode Buffer: 5mM Tris, 0.38mM glycine, 2mM EDTA, pH 8.8.  Made to 
final volume with dH2O. 
Blocking buffer for immunoblotting: 5% (w/v) skimmed milk powder, 0.2% 
Tween-20, made up in TBS 
Incubation buffer for immunoblotting: 2.5% (w/v) skimmed milk powder, 
made up in TBS 
Wash buffer for immunoblotting: 2.5% (w/v) skimmed milk powder, 0.2% 
Tween-20 made up in TBS 
Tris-buffered Saline (TBS): 50mM Tris, 0.9% (w/v) sodium chloride, pH 7.4.  
Made up in dH2O 
Sucrose for Cryoprotection: 10% or 20% (w/v) sucrose made up in 0.1M PB  
Sample Buffer: 30mM NaH2PO4, 30% (v/v) glycerol, 0.05% (w/v) Bromophenol 
blue, 7.5% (w/v) sodium dodecyl sulphate (SDS) made up in dH2O 
SDS-PAGE Stacking Gel: 56.9% (v/v) dH2O, 24.7% (v/v) stacking gel buffer 
(1M Tris, 1% (w/v) SDS), 16.1% (v/v) acrylamide (40%), 2% ammonium 
persulphate (APS, 1mM stock) and 0.25% TEMED 
SDS-PAGE Running Gel (10%): 47.6% (v/v) dH2O, 23.8% (v/v) acrylamide 
(40% stock), 23.8% running gel buffer (0.5M Tris, 8mM EDTA, pH6.8, 0.4% 
SDS (w/v), pH8.8), 4.8% APS, and 0.8% TEMED 
Luminol: Solution A:Solution B 1:1 (Solution A = 100mM Tris-base pH8.5, 
25mM luminol, 396μM p-Courmaric acid. Solution B = 100mM Tris-base pH8.5, 
6.27mM H2O2) 
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